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ABSTRACT OF DISSERTATION

MODULATION OF THE ALPHA-7 NICOTINIC ACETYLCHOLINE
RECEPTOR FOLLOWING EXPERIMENTAL RAT BRAIN INJURY
IMPROVES CELLULAR AND BEHAVIORAL OUTCOMES
Traumatic brain injury (TBI) is a leading cause of death and long-term
disability worldwide, and survivors are often left with cognitive deficits and
significant problems with day to day tasks. To date, therapeutic pharmacological
treatments of TBI remain elusive despite numerous clinical trials. An improved
understanding of the molecular and cellular response to injury may help guide
future treatment strategies. One promising marker for brain injury is the
translocator protein (TSPO), which is normally expressed at a low level, but is
highly expressed following brain damage and is associated with
neuroinflammation. The isoquinoline carboxamide PK11195 binds selectively to
the TSPO in many species, and has therefore become the most-studied TSPO
ligand. To characterize the time-course of TSPO expression in the controlled
cortical injury (CCI) model of TBI we subjected Sprague-Dawley rats to CCI and
euthanatized them after 30 minutes, 12 hours, 1, 2, 4, or 6 days.
Autoradiography with radiolabelled PK11195 was used to assess the time-course
of TSPO binding following CCI. Autoradiographs were compared to adjacent
tissue slices stained with the microglia/macrophage marker ED-1, with which a
moderate positive correlation was discovered. PK11195 autoradiography was
used as a tool with which to assess neuroinflammation following CCI and the
administration of an α7 nAChR antagonist, methyllycaconitine (MLA). We
hypothesized that blocking the calcium permeable α7 nAChR after brain injury
would have a neuroprotective effect by attenuating excitotoxicity in the shortterm.
Our study revealed clear dose-dependent tissue sparing in rats
administered MLA after trauma and a modest improvement in functional
outcome. The relatively modest recovery of function with MLA, which could be
due to prolonged α7 nAChR blockade or downregulation lead us to explore the
potential of α7 nAChR partial agonists in treating TBI. The α7 nAChR partial
agonists tropisetron, ondansetron, and DMXB-A produced a moderate
attenuation of cognitive deficits, but did not have a neuroprotective effect on
tissue sparing. These studies show that following TBI, α7 nAChR modulation

can have neuroprotective effects and attenuate cognitive deficits. Whether this
modulation is best achieved through partial agonist treatment alone or a
combination antagonist/agonist treatment remains to be determined.
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1. CHAPTER 1
Introduction & Background
1.1

An overview of traumatic brain injury
Traumatic brain injury (TBI) is one of the leading causes of death and

long-term disability worldwide.

At least 10 million people sustain a TBI that

results in death or hospitalization every year (Langlois et al., 2006), a
conservative estimate since many TBIs go unreported.

Survivors of TBI are

frequently left with long-term or life-long cognitive impairments that have a
significant impact on quality of life (Pagulayan et al., 2006; Strandberg, 2009). In
addition to these cognitive impairments, people who have sustained a TBI are at
significantly higher risk of developing other health problems. Compared to the
general population, TBI victims are twice as likely to binge drink (Horner et al.,
2005), several times more likely to develop epilepsy (Frey, 2003), and 7.5 times
as likely to die 1-3 years after the initial injury (Selassie et al., 2005).
Furthermore, moderate and severe TBI increases the probability of developing
depression and Alzheimer’s disease (AD) in later life (Plassman et al., 2000).
In the United States civilian population TBI is responsible for about 1.5
million new hospital visits every year (Rutland-Brown et al., 2006), and it has
been estimated that there are currently over 5.3 million TBI patients (Langlois et
al., 2006). The most frequent causes of moderate to severe TBIs are road traffic
accidents, followed by falls and assaults. The incidence of TBI is highest in
people between 15 and 24 years of age, and those persons over the age of 75
(Kraus et al., 1984). The direct cost of care associated with TBI is estimated to
be greater than $30 billion, and additional lifetime costs associated with TBI are
estimated to be another $30 billion. Despite the huge amount of money spent on
treating TBI, a recent study found that as many as 40% of those hospitalized
experienced significant unmet needs one year later (Corrigan et al., 2004).
Needs most often cited were improvement in memory and problem solving,
managing stress and emotional upset, controlling one’s temper, and improving
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one’s job skills. It is also important to note that the true number of people who
sustain a TBI is difficult to determine, since large numbers of victims of mild TBI’s
may not visit the emergency room.
1.1.1 Epidemiology and financial burden of TBI in the United States
An increased awareness of TBI has been brought about in the United
States of America by various reports from warzones in Afghanistan and Iraq.
Those in military service have always had a higher incidence of TBI than the
general population, and while penetrating injuries are common, the incidence of
closed head injury is known to be much higher (Galarneau et al., 2008). Most of
these injuries are the result of an explosion (e.g. an improvised explosive
device), and the term ‘blast injuries’ is used to describe them. The injury is
caused by large and sudden changes in air pressure as a direct result of an
explosion (Taylor and Ford, 2009; Wolf et al., 2009). However, brain injuries can
also be sustained from impact of objects put in motion by the blast, or by impact
of the head against another object. Because of the nature of blast injuries the
incidence of TBI in military personnel fighting in the “War on Terror” is difficult to
estimate as they can often go unrecognized.

A recent survey of military

personnel returning from the theatre of war revealed a 12% incidence of mild
TBI, a condition that can significantly affect quality of life (Schneiderman et al.,
2008). The increased awareness of TBI has lead to the Department of Defense
and the Department of Veterans Affairs instituting routine screening of veterans
for TBI (Affairs, 2007), and medical professionals are now being trained to
recognize and treat these brain injuries (Martin et al., 2008).
1.1.2 Classification of TBI: closed versus penetrating head injuries
There are many different ways in which a person can sustain a TBI,
including, but not limited to, motor vehicle collisions, falls, and gun-shots. In
order to develop treatment strategies for TBI it is important to understand how
these injuries vary, and therefore, it is necessary to categorize these injuries
based on similarities. The easiest way of classifying injuries is to determine
whether they are skull penetrating brain injuries, or closed skull injuries.
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Penetrating brain injuries are most often caused by gunshots associated with
combat or other acts of violence (e.g. stab wounds). Closed head injuries are
significantly more common (Styrke et al., 2007), and are caused when static or
dynamic forces are applied to the head. The rapid acceleration, deceleration,
and rotational forces involved in vehicular collisions are the most common cause
of this injury (Denny-Brown and Russell, 1941; Ivancevic, 2008; Krave et al.,
2005). Injuries caused by dynamic forces can be further sub-divided into injuries
involving an impact, and those that do not (impulsive). In many instances injuries
will be the result of both inertial forces and of an impact. Obviously, the amount
of force acting on the brain is an important factor in influencing the severity of the
TBI.
1.1.3 Classification of TBI: primary and secondary injuries
It is clear that there is significant variation in the types and severity of TBIs
and it is easy to presume that following the initial insult, the brain healing process
begins. Unfortunately this is not the case, and it is widely recognized that brain
injuries can become more severe with time (Anderson et al., 2005; Himanen et
al., 2006; Sato et al., 2001; Shiozaki et al., 2001). This is due to the evolution of
a secondary injury that occurs in the minutes, hours, days, and even months
after the initial (primary) injury. The primary injury causes a disruption in the
homeostasis of the brain; axons are damaged or sheared, cells are ruptured,
blood vessels are damaged, and tissue may be lost (Gaetz, 2004; Gennarelli,
1993; Gennarelli and Graham, 1998; Hammoud and Wasserman, 2002; Strich,
1961; Strich, 1956). An immediate and significant effect of this damage is often
ischemia, which contributes significantly to secondary damage (Bramlett and
Dietrich, 2004; Graham et al., 1978; Graham et al., 1988; Nortje and Gupta,
2006; Zauner et al., 2002). Damaged or ruptured cells release a multitude of
different messenger molecules, including pro-inflammatory cytokines and the
excitatory neurotransmitters glutamate and acetylcholine (ACh). Increased levels
of these molecules lead to activation of their respective ionotrophic receptors and
an influx of calcium (Ca2+) and sodium (Na+) into neurons.

Under normal

conditions ACh and glutamate are released in precisely controlled areas, and are
3

then rapidly degraded (ACh) or taken up into presynaptic neurons or astrocytes
via energy dependant transporters (glutamate). However, following an injury the
haphazard nature of neurotransmitter release combined with the amount
released leads to the activation of many cellular pathways and damaging
enzymes.

The end result of this is cellular dysfunction and cell death via

apoptosis or necrosis.
1.1.4 Classification of TBI: injury severity
TBI patients can be categorized as having a severe, moderate, or mild TBI
when admitted to the hospital. The most widely used tool for assessment of the
severity of injury is the Glasgow Coma Score (GCS). The GCS consists of a
battery of tests for eye response (1-4 points), verbal response (1-5 points), and
motor response (1-6 points). The test therefore rates patients on a scale of 3-15,
3 being deep coma/death, and 15 being fully awake (Teasdale and Jennett,
1974).

It is generally accepted that a score of ≥13 is a mild injury, 9-12 is

moderate, and a score ≤8 is classed as a severe injury (Jennett, 1998; Parikh et
al., 2007). In addition to the GCS, doctors may take into account measures such
as the duration of post-traumatic amnesia and loss of consciousness to make a
final assessment of injury severity. While this scale has been shown to be of
prognostic value (Narayan et al., 2002), a recent workshop convened by the
Veterans Brain Injury Center and the National Institute of Disability and
Rehabilitation criticized its use in recruiting for clinical trials because of the lack of
assessment of factors such as age, extra-cranial injury, and pre-existing
neurological impairment that may override treatment effects (Saatman et al.,
2008). Furthermore, the GCS does not discriminate well in less severely injured
patients, which comprise the majority of cases.
Since these clinical assessments are clearly not applicable in animal
models of TBI the injury severity is frequently defined by the parameters of the
injury-producing device (Cernak, 2005; Morales et al., 2005). Because of this
discrepancy, it is important to realize that while a mild/moderate/severe injury in a
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rodent paradigm models some aspects of the human condition it is not
necessarily fully equivalent (see below for a more detailed discussion).
1.1.5 The secondary injury cascade
Excitotoxicity is the term used to describe the process by which excitatory
neurotransmitters can adversely affect the survival of neurons by over-stimulating
their respective ionotrophic receptors. T. Hayashi is credited with being the first
to report the excitotoxic effects of glutamate in 1954, when he observed that
glutamate applied directly to the cortex induced convulsions (Hayashi, 1954).
But it was not until 1969 that J. Olney coined the term excitotoxicity when he
noticed that monosodium glutamate fed to mice or monkeys produced lesions in
the brain (Olney, 1969; Olney and Sharpe, 1969). Since these early studies the
mechanisms by which glutamate causes neuronal death have been thoroughly
elucidated.
Once released into the synaptic cleft, glutamate can bind to and activate a
family of glutamate receptors.

Activation of ionotrophic receptors leads to

depolarization of the post-synaptic membrane by facilitation of cation flow into the
neuronal cytoplasm. In total there are 11 types of glutamate receptor, 8 are
metabotrophic and 3 are ionotrophic. The three types of ionotrophic glutamate
receptors

are

the

kainite

receptor,

the

α-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid (AMPA) receptor, and the

N-methyl-D-aspartic

acid

(NMDA) receptor (Dingledine et al., 1999; Liu and Zhang, 2000; Paoletti and
Neyton, 2007). AMPA and NMDA receptors are found on post-synaptic neurons
in intimate proximity to presynaptic nerve terminals (Antal et al., 2008; Kharazia
et al., 1996).

Whereas activation of AMPA receptors is dependant only on

glutamate binding, NMDA receptors require the binding of co-agonist glycine
(Kleckner and Dingledine, 1988), depolarization-induced removal of magnesium
ion blockade of the ion channel (Nowak et al., 1984; Ruppersberg et al., 1994)
and binding of glutamate. The initial activation of AMPA receptors by glutamate
leads to sodium influx and membrane depolarization, which facilitates the
removal of the magnesium block in nearby NMDA receptors and allows for
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NMDA receptor activation by glutamate when the co-agonist glycine is present.
Once activated NMDA receptors are selectively permeable to calcium ions (Jahr
and Stevens, 1993; MacDermott et al., 1986), further depolarizing the postsynaptic membrane and leading to activation of intracellular signaling pathways.
However, sustained high levels of glutamate can lead to prolonged activation of
excitatory glutamate receptors. It is the NMDA receptor that is believed to be the
major contributor to the toxic effects of glutamate due to its relatively high
permeability to calcium.
Calcium is an important secondary messenger that has various
physiological actions inside a cell (Berridge et al., 2003; Petersen et al., 2005).
Under normal physiological conditions the extracellular calcium concentration is
10,000 fold higher than the intracellular concentration (approximately 1 mM
versus 100 nM, respectively). This high degree of control is maintained by the
elimination of calcium from the cell via the sodium/calcium exchanger (Yu and
Choi, 1997), calcium ATPase (Jensen et al., 2004), or by sequestration in
calcium ‘sinks’ such as the endoplasmic reticulum and the mitochondria (Pizzo
and Pozzan, 2007).

However, when there is an excess of extracellular

glutamate, prolonged activation of NMDA receptors may lead to the accumulation
of calcium in the cell (Dubinsky, 1993). The mitochondria can take up a lot of
calcium via the mitochondrial calcium uniporter (Kirichok et al., 2004), which has
a much higher activity than the extrusion pathway via 2Na+/Ca2+ exchange. In
this way the mitochondria play a role in maintaining cellular calcium homeostasis
(Carafoli, 2003), but when too much calcium is present adenosine-5'-triphosphate
(ATP) synthesis is inhibited and reactive oxygen species (ROS) including
superoxide and peroxonitrite are produced (Brookes et al., 2004; Hall et al.,
2004). Peroxidation of lipids by ROS is damaging to the cell and could result in
cell death. Furthermore, the lack of ATP will have many detrimental effects in the
cell; including failure of energy-dependent glutamate transporters.

Normally,

glutamate is cleared from the extracellular space by active transport across the
plasma membrane; therefore a failure of these transporters will lead to a reduced
clearance of glutamate and exacerbated NMDA receptor stimulation. Calcium
6

overload can lead to the formation of the permeability transition pore (Crompton,
1999) and subsequent release of cytochrome c (Luetjens et al., 2000). In the
cytoplasm, cytochrome c can activate the intrinsic apoptosis pathway via
activation of caspase 9, which then activates caspases 3 and 7 (Cohen, 1997).
The excess calcium produced by over-stimulation of NMDA receptors is very
different from normal physiological circumstances where the effects of calcium on
the cell are regulated by discrete, localized increases. These large-magnitude
global increases in calcium concentration within the cell activate numerous
signaling cascades and enzymes, including phospholipases, proteases, and
endonucleases. Once activated, these enzymes lead to membrane damage,
loss of membrane potential, cytoskeletal damage, and deoxyribonucleic acid
(DNA) damage. The disruption of cellular homeostasis in a disease state can
lead to programmed cell death via apoptosis, or to a disorderly cell death via
necrosis. Taken together this demonstrates the damage that excitotoxicity can
cause and the integral role of the mitochondria in secondary injury and neuronal
dysfunction. Studies in rodent models of TBI have demonstrated the early onset
of mitochondrial dysfunction and lipid peroxidation (Singh et al., 2006).
Although many studies focus on the role of glutamate it is important to
realize that several other excitatory neurotransmitters could potentially contribute
to calcium-related excitotoxicity. Acetylcholine is one such neurotransmitter best
known for its prominent role at the neuromuscular junction (NMJ) in the
peripheral nervous system (PNS). It is now well established that ACh also has a
critical role in the CNS, where it acts at G-protein coupled muscarinic
acetylcholine receptors (mAChR) as well as a number of ionotrophic receptors.
Of particular interest with regard to excitotoxicity is the α7 nicotinic acetylcholine
receptor (nAChR); a ligand-gated ion channel with high permeability to calcium
(Delbono et al., 1997; Sands et al., 1993). Also of note is the serotonin receptor
5-HT3 (5-hydroxytryptamine), since unlike other serotonin receptors it is a
sodium-permeable ion-channel rather than a G-protein coupled receptor. While
the 5-HT3 receptor is not selectively permeable to calcium like the NMDA and α7
nAChR (Mochizuki et al., 1999), it is of interest because it is unique among
7

serotonin receptors, sharing a great deal of homology with the α7 nAChR
receptor, and is found in areas of the brain known to be especially vulnerable to
injury such as the hippocampus (Fletcher and Barnes, 1999; Ge et al., 1997;
Parker et al., 1996).
In addition to excitotoxicity, the contribution of inflammation to secondary
injury is an important consideration. In the periphery, the inflammatory response
has numerous roles including phagocytosis of dead cells and invading
pathogens, and the promotion of recovery.

However, in the brain an

inflammatory response could contribute to post-injury damage and loss of
function.

The brain has long been considered to be an immunologically

privileged organ (Murphy and Strum, 1923; Shirai, 1921), able to tolerate
introduction of antigen without eliciting an immune response. However, it is now
becoming apparent that immune cells play a central role in the pathogenesis of
secondary injury (for a review see Galea et al., 2007). Microglia are the main
immune cell in the brain, accounting for an estimated 10-20% of all non-neuronal
cells in the central nervous system (CNS) (Lawson et al., 1990). Microglia are
known to have multiple phenotypes that are seen depending on their
environment (Gehrmann et al., 1995). In normal brain, resting microglia have
small cell bodies and numerous long processes that constantly elongate and
shorten giving the impression that they have a surveillance role (Kreutzberg,
1996; Nimmerjahn et al., 2005). Several factors are known to lead to microglial
activation, including pro-inflammatory cytokines and cell necrosis factors. Such
conditions can be found in the brain under neurodegenerative or injury states,
which leads to the transformation of microglia to an activated state (Ransohoff
and Perry, 2009). The activation of microglia can be very rapid; several studies
have shown that activation can be detected within hours or minutes of an insult
(Kelley et al., 2007; Liu et al., 2009; Raghavendra Rao et al., 2000; Suma et al.,
2008). The transformation of quiescent microglia to a fully activated phagocytic
cell is a graded response.

Non-phagocytic activated microglia exhibit fewer,

thicker, retracted processes and larger cell bodies. Activated microglia begin to
proliferate and secrete cytotoxic factors and pro-inflammatory cytokines. When
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fully activated they are phagocytic, taking on a completely amoeboid appearance
(Gehrmann et al., 1995). These phagocytic microglia migrate to the site of injury
and engulf foreign material and cellular debris, while also secreting proinflammatory cytokines to amplify the immune response. Therefore, modulation
of microglial cell activation may be one possible way to decrease brain
inflammation and secondary neuropathology following TBI.
1.1.6 Current treatment strategies for TBI patients
In individuals that suffer a TBI the primary focus is on stabilizing the
patient to improve their chances of a favorable clinical outcome. This can be
achieved by first immobilizing the patient to lessen the risk of further CNS injury.
To reduce the risk of cerebral ischemia healthcare workers must ensure the
patient has adequate airway patency, breathing and oxygenation.

Close

attention is paid to insure a proper oxygen supply to the brain by maintaining
blood flow and blood pressure. In the hospital careful monitoring of intracranial
pressure (ICP), and mean arterial blood pressure provides an estimate of the
cerebral perfusion pressure (CPP). The CPP is maintained at a satisfactory level
to prevent additional brain damage (Rosner, 1995; van Santbrink et al., 2002).
ICP can be continuously monitored by surgically implanting a catheter into one of
the lateral ventricles. Maintenance of ICP can be achieved by administering
sedatives, paralytics, and if necessary by draining cerebrospinal fluid (CSF) from
a lateral ventricle.

More drastic measures may be taken in severe cases,

including a decompressive craniectomy to allow the brain to swell until ICP is
resolved (Schirmer et al., 2008).
When ready, moderately and severely injured patients discharged from
the acute care setting will receive physical/occupational, speech/language
therapy, or be referred to a psychiatrist, or social worker as required.
Rehabilitation and therapy for survivors of TBI focuses on helping the patient to
function independently at home and at work. However, the services received
often fail to address the emotional, cognitive, and behavioral needs of the patient
(Martin et al., 2001). Even victims of mild injuries can experience long-lasting
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cognitive deficits that include memory loss, problems with concentration and
attention, and deficits in executive functions such as judgment, planning,
problem-solving and reasoning.
1.2

Modeling TBI in the laboratory

1.2.1 Overview of in vivo TBI paradigms
In the clinic a wide range of types and severity of head injury are seen that
often result in vastly different outcomes. Due to this heterogeneity in TBI there is
no one model that can mimic the full range of injury severities and clinical
sequelae seen in human TBI (Park et al., 2007; Saatman et al., 2008). For this
reason several models are widely used in pre-clinical TBI research to model the
full range of injury severities and pathological characteristics seen in TBI
patients.

Although in vitro models of TBI facilitate the evaluation of

pharmacological treatments in a rapid and cost-efficient manner, they lack face
validity. In vivo models, summarized below, allow for assessment of the whole
animal response to injury, including measurement of cognitive and behavioral
deficits after experimental brain injury. This makes for a more relevant model at
the expense of increased cost, variability, and difficulty in sampling.
One of the first standardized in vivo models of TBI was the weight-drop
model in which a free-falling weight impacts the exposed skull of an anesthetized
rat to produce what is usually referred to as a ‘focal’ injury (Shapira et al., 1988).
The model has since been adapted for use on mice (Chen et al., 1996; Flierl et
al., 2009).

A key feature of this model is its simplicity; minimal surgical

preparation required and the severity of injury can be easily altered by adjusting
the mass and height of the impacting weight.

Weight drop injury leads to

immediate and brief unconsciousness, cortical contusion, selective neuronal
death in the cortex, hippocampus and thalamus, and behavioral deficits (Chen et
al., 1996).

The model does have disadvantages, including the likelihood of

rebound injury and a high variability, necessitating larger group sizes to see
effects of a comparable magnitude as those seen in similar models.
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Furthermore, this model has a relatively high mortality rate, again increasing the
number of animals that must be used.
A related model is the impact acceleration model (Foda and Marmarou,
1994; Marmarou et al., 1994), in which the injury is again produced by a free
falling weight. However, in this model a stainless steel plate is glued to the skull
to distribute the force of impact over a wide area, minimizing the probability of
skull fracture and producing a more diffuse injury. A second critical difference
between this model and the weight-drop model is that the animal is unrestrained,
and its head is placed on a piece of foam of known spring constant to allow
movement of the head after impact.

The physical properties of the foam,

combined with the mass and height from which the weight is dropped, determine
the severity of injury (Piper et al., 1996).

This model produces measurable

neurological and cognitive deficits in rats, and more severe injuries can be
obtained by increasing the height at which the weight is dropped from or by the
addition of a hypoxic insult (Beaumont et al., 1999). More recently the impactacceleration model has been modified to produce a diffuse axonal injury (DAI)
(Kallakuri et al., 2003), or to produce mild TBIs (Ucar et al., 2006) since the
model is predominantly used to produce severe injuries. Like the weight-drop
model, since this model also utilizes a free-falling weight to produce injury there
remains the possibility of a second rebound injury.
Fluid percussion injury (FPI) is one of the most commonly used and best
characterized in vivo models of TBI. Before performing the injury, the rat is
anaesthetized, its skull exposed, and a craniotomy performed. Like the previous
two models, the energy used to produce injury comes from a falling weight, here
in the form of a pendulum. Unlike the other models the pendulum strikes a
saline-filled syringe that forces a saline bolus through the sealed craniotomy to
impact the dural membrane causing a pressure wave that spreads throughout
the epidural space producing a diffuse injury (McIntosh et al., 1989). The injury
severity can be adjusted by changing the height of the pendulum, and therefore
the force of the pressure pulse that is transmitted through the saline reservoir.
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The model produces damage with characteristics consistent with that of a diffuse
brain injury.

However, a significant drawback of the FPI model is the high

mortality rate associated with injury to the brainstem, especially at higher injury
severities (McIntosh et al., 1989; Thibault et al., 1992).
The controlled cortical injury (CCI) model of TBI was developed in 1988
for use by General Motors and was originally designed for ferrets (Lighthall,
1988). It was modified for use in rodents (Dixon et al., 1991; Hamm et al., 1992)
and is now commonly used in rats and mice to produce fairly consistent focal
injuries (relative to other TBI models). The model utilizes a pneumatically driven
impactor to administer a single mechanical deformation of the exposed brain
without rebound injury. Due to the precision machinery used the injury severity
and type can be adjusted by using different shape and size impactor tips,
adjusting the impactor velocity, or altering the depth of cortical deformation. In
our laboratory the surgery is performed on anesthetized rats that have been
immobilized in a Kopf stereotaxic frame (David Kopf Instruments, CA).

This

allows for the precise positioning of a craniotomy midway between bregma and
lambda (bregma -4.5 mm), and 5-7 mm laterally over the somatosensory cortex.
Injury in this location on the somatosensory cortex leads to cortical tissue loss
and damage to the hippocampus either through direct energy transfer or via the
perforant pathway following damage to the entorhinal cortex.

Work in our

laboratory and others have shown that this placement produces measurable
cognitive deficits (Dixon et al., 1995b; Guseva et al., 2008; Verbois et al., 2003a).
In addition, this model benefits from a lower rate of mortality when compared to
other models of brain injury (Kochanek et al., 1995).
1.2.2 Measuring CNS damage following experimental TBI
Well

established

neuropathological

methods

effects

of

pharmacotherapies are needed.

to
the

assess

the

short

and

long-term

experimental

TBI

and

potential

Post-mortem assessments of gross tissue

loss/disruption, individual neuronal or glial cell loss, and expression of cell or cell
cycle specific enzymes and genes help provide a more detailed characterization
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of the injury. Post-injury assessments can measure markers such as cell death
via apoptosis or necrosis, or could utilize markers of reactive gliosis. Reactive
gliosis refers to the accumulation of activated glial cells including microglia,
macrophages and astrocytes immediately after CNS injury.

The term

‘neuroinflammation’ is now more commonly used to describe this process.
Astrocytes synthesize more glial fibrillary acidic protein (GFAP) and undergo
some morphological changes including the elongation of more pseudopodia that
form a dense mesh to fill space left by dead neurons.

Microglia, the CNS

equivalent of macrophages, rapidly become activated and secrete cytokines,
neurotropic factors, and other biologically active factors.

Macrophages are

difficult to delineate from microglia, being from the same lineage.

They are

known to cross the blood brain barrier after brain injury and are thought to play a
similar role to microglia.
For models that result in a visible loss of cortical tissue the simplest and
quickest assessment that can be made is that of cortical tissue sparing analysis
(Scheff and Sullivan, 1999). The analysis is carried out on nissl-stained (e.g.
Cresyl violet) coronal brain sections. This makes it easy to distinguish viable
tissue so that measurements can be made of the area of tissue remaining, i.e.
spared.

For unilateral injuries measurements of area can be taken for both

hemispheres, allowing for a calculation of the lesion’s area by subtracting the
ipsilateral area from the contralateral ‘control’ area in each section.

When

studying the neuroprotective effects of certain treatments it makes more sense to
express these numbers as ‘tissue spared’ as opposed to lesion size. This is
easily achieved by dividing the ipsilateral area by the contralateral area (and
multiplying by 100) to yield a percentage of tissue spared. While this method is a
good measure of the severity and extent of injury, it does not give any indication
of functional injury or cell loss that could be occurring in other areas of the brain,
or indeed in regions of the ipsilateral cortex distal to the site of impact. More
sensitive techniques are required to quickly assess and quantify these more
subtle, but potentially significant changes.
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To assess changes that occur on a cellular level after injury, radioligands
or antibodies can be employed to mark specific receptors or antigens expressed
by certain cell types.

For example, neuronal survival can be assessed with

antibodies against NeuN (neuronal nuclei), a DNA binding protein found in most
neuronal nuclei (Mullen et al., 1992). Degenerating neurons long been known to
be argyrophilic and silver staining methods have developed to visualize the cell
bodies and neuronal processes of these neurons (Tenkova and Goldberg, 2007).
A more straightforward and recent technique to label degenerating neurons is
fluoro-jade, an anionic fluorescein derivative. Fluoro-jade is thought to bind to
polyamines that are found in degenerating cells (Schmued and Hopkins, 2000a,
b). Additionally, apoptotic cells can be visualized by terminal deoxynucleotidyl
transferase mediated dUTP nick end labeling (TUNEL). To be useful in
identifying the cell types that are dying TUNEL is often carried out as a double or
triple

staining

with

antibodies

against

specific

cell

types

such

as

microglia/macrophages (e.g. anti-CD68, OX-42, F4/80, iba-1), astrocytes (e.g.
anti-GFAP), or neurons (e.g. NeuN). In addition, the identification of microglial
activation and macrophage infiltration by immunohistochemical techniques can
provide a good assessment of the degree of cellular damage resulting from a
particular injury or damaging agent (Nixon et al., 2008). A drawback of each of
these assessments is the difficulty of obtaining an accurate quantification.
Precise quantification of cell numbers can be very time-consuming and little
information on expression on individual cells can be acquired.

To this end,

another useful tool to assess damage and inflammation after TBI may be
autoradiography using the ligand [3H]-PK11195 (Banati et al., 1997; Sitte et al.,
2001; Vowinckel et al., 1997). Autoradiography allows for a rapid assessment of
ligand binding density in multiple discrete regions within the brain. Studies that
have utilized [3H]-PK11195 autoradiography have demonstrated its potential as a
sensitive marker of inflammation in models of neurodegenerative disease and
brain injury (Chen and Guilarte, 2006; Grossman et al., 2003; Pedersen et al.,
2006; Roberts et al., 2009). Although the precise antigen and cell types to which
PK11195 binds have not been fully elucidated, it appears to be associated with
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mitochondrial cholesterol transport in inflammatory cell types (Banati et al., 1997;
Giannaccini et al., 2000).

Further evaluation of the binding profile of [3H]-

PK11195 in a model of TBI could help to establish the technique as a valuable
tool in the assessment of post-traumatic inflammation.
1.2.3 Assessing functional deficits
To be clinically relevant, models of TBI should be able to produce
functional and cognitive deficits that are measureable by well defined tests in the
laboratory. To this end several methods have been developed to characterize
the deficits seen after injury in rodent models. The rotorod is one such test in
which a mouse or rat is placed on a rotating drum in a semi-enclosed chamber.
The drum slowly accelerates and the latency of the animal to fall is recorded,
giving an indication of motor coordination, balance and stamina. Another test is
the ledged tapered beam, in which animals must traverse a suspended ledged
beam which begins wide enough to walk comfortably, and tapers to a point. The
number of times each paw slips onto the ledge and at what point on the beam
can be recorded as an indication of balance and motor function.

Other

assessments include locomotor activity monitoring and open field testing. More
complete assessments of overall neurological functioning can be made using a
battery of simple tests. An example of such a scoring modality is the composite
“neuroscore”, which takes into account forelimb flexion when suspended by the
tail, resistance to pulsion, hindlimb splay, toe-spread and toe-extension, and
ability to stand on an inclined surface facing up, down, left or right (Gruner et al.,
1996; McIntosh et al., 1989). Another battery of tests is the neurological severity
score (NSS) which assesses hemiparesis, ability to traverse beams of various
widths, ability to balance on round or square sticks, failure to exit a circle, startle
reflex, and seeking behavior (Beni-Adani et al., 2001; Panikashvili et al., 2005).
While useful in assessing acute motor deficits it should be remembered that a
large number of people suffer mild injuries in which cognitive and other
neuropsychiatric changes cause the most damage to the routines of daily living.
Fortunately, there are some well established tests of cognitive performance in the
rodent, including the T-maze and the commonly used Morris water-maze (MWM).
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The MWM was developed in 1984 by Richard Morris to test spatial
memory in rats (Morris, 1984). The testing apparatus consists of a circular pool
1.5-2 m in diameter and about 60 cm deep, filled with water to a depth of about
30 cm. The water is made opaque by the addition of a pigment to obscure the
location of a 15 cm diameter escape platform hidden approximately 1 cm below
the water level, and to provide contrast against the color of the animal being
tested. Visual cues are placed around the outside of the pool in plain sight of the
test subject. The rat or mouse is carefully placed in the pool rear end first facing
the edge of the pool to reduce stress and bias respectively. The animal then
searches the pool for an exit, and its escape from the pool and rescue by the
experimenter reinforces its desire to find the escape platform swiftly in
subsequent trials.

Improvement in performance in the MWM comes about

because the rat/mouse has learned the position of the escape platform in the
pool relative to the visual cues around the test room. The entire experiment is
recorded using a video camera mounted above the pool so that a more thorough
evaluation of each rats’ search pattern can be made.
Various training paradigms exist that include acquisition training and
memory retention testing (Brandeis et al., 1989; Wenk, 1998).

Acquisition

training usually consists of a block of 4 swim trials in which the animal starts at
each of 4 randomly chosen positions around the pool. If the animal successfully
finds the platform it must remain there for a short amount of time (e.g. 15 s)
before being rescued. If a pre-determined amount of time passes without the
animal finding the platform (e.g. 60 s) it is manually guided or placed on the
platform. The data from each of the 4 trials in the block can then be averaged.
Further blocks of training trials can be performed on consecutive days or even on
the same day (Kraemer et al., 1996). Following the acquisition testing, a memory
retention test is usually performed in which the escape platform is removed from
the pool. Each animal is allowed to swim in the pool for a set amount of time
(e.g. 30 s, 60 s, 120 s). During this memory retention test the animals’ spatial
ability can be assessed by measuring the amount of time it spends searching in
the vicinity of the escape platform, the number of times it crosses into the
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platform area, or the number of times it crosses into the target quadrant. The
ability of researchers to make accurate assessments of these parameters has
been greatly improved by the availability of electronic tracking systems such as
Videomex (Columbus Instruments, Columbus, OH).
Since the first description of the water maze by Morris in 1984, which
utilized hooded rats, there have been thousands of studies utilizing the technique
with a variety of both rat and mouse strains. It is therefore important to consider
whether these or indeed other factors could influence MWM performance when
comparing studies. For example, differences in spatial performance between
men and women have been well documented (Astur et al., 1998; Duff and
Hampson, 2001; Newhouse et al., 2007; Rizk-Jackson et al., 2006), and similar
sex-differences have been reported in rodents (Frye, 1995; Galea et al., 1996).
These differences could obviously be due to sex hormones as suggested in
several studies (Daniel et al., 1999; Roof, 1993; Warren and Juraska, 1997). In
addition to sex differences significant differences have been found in the
performance of different rodent species, specifically mice in the MWM (Lipp and
Wolfer, 1998). Mice have a tendency to float or swim along the edge of the pool
(thigmotaxis) more than rats, and often perform quite poorly in comparison. A
comparison study has found similar performance for mice and rats in ‘dry’ spatial
learning tasks but not for the water maze task, indicating that a difference in
spatial ability is not the factor at play (Whishaw and Tomie, 1996). Another major
factor to consider is the age of animals within a study, as it is well established
that MWM performance declines with age (Brandeis et al., 1989; Gower and
Lamberty, 1993). Furthermore, it has been recognized that the MWM causes a
stress response in rodents that could potentially confound results (Engelmann et
al., 2006).
The MWM is known as a hippocampal dependant task because the
hippocampal formation is clearly essential for spatial learning, as demonstrated
by impaired performance in animals with hippocampal lesions (Morris, 1984;
Morris et al., 1982; Moser et al., 1993; Pearce et al., 1998).
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However, the

involvement of other brain regions cannot be ruled-out.

In addition to the

involvement of the hippocampal formation in spatial learning other brain regions
including the caudate putamen (a.k.a. stiatum) (Whishaw et al., 1987), basal
forebrain (Mandel et al., 1989), cortical regions (Liu and Bilkey, 1998; Mogensen
et al., 1995; Roof et al., 1993), and cerebellum (Lalonde, 1994) have been
implicated.

This demonstrates that spatial learning requires the coordinated

action of multiple brain regions and is a complex process. Despite the apparent
complexity the process, long-term potentiation (LTP), is considered to be one of
the major cellular/synaptic mechanisms involved in learning (Lynch, 2004). LTP
is process by which the efficacy of signaling between two neurons is increased
following repeated stimulation. This effect is long-term and mediated by changes
in gene expression and protein synthesis. In the hippocampus spatial learning is
thought to involve place cells, which exhibit a high rate of firing when an animal is
in a specific position within and environment corresponding to the cell’s ‘place
field’ (Buzsaki, 2005; O'Keefe and Dostrovsky, 1971; Poucet et al., 2000). In the
rat hippocampus there are hundreds of thousands of pyramidal cells in close
proximity with a high degree of connectivity (Li et al., 1994). The fields of place
cells within this population are distributed evenly across the environment (Muller
et al., 1987), so any pair of fields in the environment could be represented by
hundreds of connected cells. Therefore, because the firing frequency of each
place cell varies as a function of the distance between them, place cells with
overlapping place fields could undergo LTP and thus encode spatial distance
(Isaac et al., 2009; Muller et al., 1996). The importance of LTP in spatial learning
is highlighted by studies in which NMDA antagonists are administered. Morris et
al.

originally

demonstrated

impaired

water

maze

performance

of

rats

administered the NMDA antagonist (2R)-amino-5-phosphonovaleric acid (AP5)
via intraventricular infusion (Morris et al., 1986), and subsequent studies have
highlighted the role of NMDA receptors in spatial learning (McNamara and
Skelton, 1993). As well as NMDA involvement it has long been known that the
cholinergic system plays a significant role in spatial localization (Sutherland et al.,
1982).
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The neuropharmacology of spatial learning continues to be studied, but
the involvement of cholinergic and glutamatergic neurotransmitter systems are
well established (Hagan and Morris, 1987; McNamara and Skelton, 1993).
Several studies have shown that NMDA receptor blockade impairs MWM
performance (Davis et al., 1992; Hauben et al., 1999; McLamb et al., 1990;
Morris et al., 1986; Upchurch and Wehner, 1990). It has also been shown that
acute treatment with an NMDA agonist (D-cycloserine) can improve spatial
memory following lesioning of the hippocampus in rats (Schuster and Schmidt,
1992). The water maze has been used extensively in the study of neurotrauma
because of the need for a treatment for the cognitive impairments reported after
TBI in humans. The MWM has been shown to be capable of testing for cognitive
deficits in rodents following experimental trauma (Kraemer et al., 1996; Scheff et
al., 1997; Smith et al., 1995; Yamaki et al., 1998). The precise mechanisms
leading to these deficits are unclear, but glutamatergic and cholinergic disruption
has been demonstrated (Dixon et al., 1999).
1.2.4 Acetylcholine receptors
Acetylcholine is a major neurotransmitter in the mammalian nervous
system where it acts on a diverse family of receptors.

Sir Henry Dale first

discovered that there are 2 distinct subclasses of cholinergic receptors in 1914
when he observed that crude extracts of Amanita muscarina (muscarine) or
Nicotinana tabacum (nicotine) mimicked the effects of ‘esters of choline’ (now
known as acetylcholine) in different tissues (Dale, 1914). It is now known that
the mAChRs are G-protein coupled receptors that function via activation of
secondary messenger molecules, and nAChRs are ligand-gated ion channels
permeable to sodium and calcium ions (Millar and Gotti, 2009).
The mAChRs can be excitatory or inhibitory depending on the secondary
messenger system that they are coupled with. The M1, M3, and M5 subtypes
activate phospholipase C via the Gαq protein (Guo and Schofield, 2003), which
produces phosphatidylinositol trisphosphate (IP3) that leads to release of calcium
from intracellular stores. In contrast, the M2 and M4 subtypes inhibit adenylyl
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cyclase via Gαi/o thereby giving ACh an inhibitory action (Caulfield and Birdsall,
1998; Ishii and Kurachi, 2006). Although mAChRs are more abundant in the
brain and have been implicated in several neurological conditions, compared to
nAChRs they are not as diverse in their subtypes and pharmacological
properties.
Relative to mAChRs, nAChRs elicit a fast response by directly facilitating
the flow of cations across the plasma membrane, thereby leading to a rapid
depolarization. The first nAChR to be characterized was from the electric organ
of the marine ray Torpedo. The natural abundance of receptors in this species
made it well suited to studies of nAChR structure and dynamics (Kosower, 1987;
Mishina et al., 1984).

Since these early studies nAChRs have been found

throughout the CNS as well as the PNS (Sargent, 1993). Electron microscopic
techniques have made it clear that nAChR subunits form pentamers around a
central ion channel (Miyazawa et al., 1999).

However, the lack of

crystallographic data has precluded the acquisition of more detailed atomic
structures. In the well studied NMJ the nicotinic receptor is composed of two α
subunits (termed “α1”), a β subunit (termed “β1”), a δ subunit, and a γ or ε
subunit (Green and Millar, 1995).

In contrast, the stoichiometry of neuronal

nAChRs is still being elucidated. Two subtypes of nAChR subunits have been
identified in the CNS: alpha (α) subunits of which 9 are known (α2-α10), and beta
(β) subunits of which 3 are known (β2-β4). Although the number of subunit types
presents the possibility of a huge array of nAChR compositions it appears that
the assembly of nAChRs is tightly regulated and results in a limited number of
channel types. In general, nAChR subunits form heteromeric receptors made up
of three alpha and two beta subunits (α(3) β(2)) (Anand et al., 1991; Boorman et
al., 2000; Cooper et al., 1991), and are selectively permeable to sodium.
Exceptions to the rule are the α7, α8, and α9 subunits, which are able to form
functional homomeric receptors in vivo (Elgoyhen et al., 1994; Gerzanich et al.,
1994; Gotti et al., 1994).

The predominant nAChR compositions in the

mammalian brain are thought to be α4β2 (Lindstrom et al., 1995; Papke et al.,
1989; Picciotto et al., 1998; Zoli et al., 1998), and the homomeric α7 receptor
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(Chen and Patrick, 1997; Couturier et al., 1990; Orr-Urtreger et al., 1997). Unlike
other nAChRs, the α7 nAChR has been found to be much more permeable to
calcium than sodium (Delbono et al., 1997; Sands et al., 1993).

This high

permeability to calcium is intriguing because calcium is an important secondary
messenger in the CNS, and plays a major role in excitotoxicity as discussed
earlier.
1.2.5 Evidence for cholinergic disruption following TBI
It is now well established that the cholinergic system is significantly
impaired following brain injury. Impaired choline transport (Dixon et al., 1994a)
and decreases in the activity of the ACh synthesizing enzyme choline
acetyltransferase (ChAT) (Leonard et al., 1994), contribute to a widespread
disruption of the cholinergic system. Earlier receptor binding studies focused on
the expression of mAChRs, and found variable effects of injury, including
increased, decreased and unchanged expression in animal models of
neurotrauma (DeAngelis et al., 1994; Jiang et al., 1994; Lyeth et al., 1994; Sihver
et al., 2001).

A reduction in nAChR expression following brain injury could

contribute to impaired cognitive ability in these animals (Verbois et al., 2002;
Verbois et al., 2000). Indeed, improvements in cognitive functioning have been
correlated with increased levels of nAChRs (Kadir et al., 2006). Further support
for the role of nAChRs in cognition and cholinergic disruption in TBI comes from
studies in our laboratory that have demonstrated a modest recovery of MWM
performance in animals given chronic intermittent nicotine injections (Verbois et
al., 2003a). Interestingly, this nicotine treatment regimen did not attenuate the
reduction in α7 nAChRs suggesting that the stimulation of the remaining
receptors may be sufficient for cognitive enhancement.
Further information on cholinergic disruption after injury comes from some
interesting parallels between the pathophysiology of TBI patients and sufferers of
chronic neurodegenerative diseases. For instance, TBI has some parallels with
schizophrenia, in that deficits in auditory and sensory gating are found in both
schizophrenics (Adler et al., 1982; Braff and Geyer, 1990) and TBI patients
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(Arciniegas et al., 1999; Arciniegas et al., 2000). Furthermore, TBI patients with
sensory gating deficits have shown improvement when administered an
acetylcholinesterase (AChE) inhibitor (Arciniegas et al., 2000; Arciniegas et al.,
2002), implicating the involvement of AChRs.

The α7 nAChR is of special

interest since decreased levels of the receptor in post-mortem brains may explain
the lack of pre-pulse inhibition of sensory stimuli in schizophrenics compared to
controls (Freedman et al., 1995). This hypothesis is bolstered by studies that
determined that the deficit in sensory gating in schizophrenics can be linked to a
genetic mutation of the α7 nAChR gene (Freedman et al., 1997; Raux et al.,
2002). Several studies have demonstrated a normalization of auditory gating in
schizophrenics after nicotine administration (Adler et al., 1993; Adler et al.,
1992), as well as more general improvements (Myers et al., 2004; Smith et al.,
2002). Furthermore, the rate of smoking is much higher amongst schizophrenics
(around 80%) than in the general population (de Leon et al., 1995), raising the
possibility that schizophrenics are self-medicating with nicotine to treat their
symptoms. It should also be noted that one of the treatments for schizophrenia
is clozapine.

Clozapine is pharmacologically non-selective drug that acts on

serotinergic, dopaminergic, and cholinergic receptors. It is clozapines’ agonist
activity on α7 nAChRs which is thought to normalize sensory gating in
schizophrenics (Martin et al., 2004a).
Another neurodegenerative condition with some similarities to TBI is AD,
where those inflicted have a significantly impaired cholinergic system (Terry and
Buccafusco, 2003). Furthermore, TBI has been identified as a positive risk-factor
for developing AD (Jellinger et al., 2001). The decline of cholinergic activity is
hypothesized to contribute significantly to the devastating cognitive deficits seen
in AD patients. A loss of α4β2 nAChRs has been well documented in AD (Perry
et al., 2000; Schmaljohann et al., 2004; Wevers et al., 1999). The role of the α7
nAChR in AD is less clear, some studies have reported a modest increase (Chu
et al., 2005; Counts et al., 2007; Dineley et al., 2001), and some a decrease
(Wevers et al., 1999). Studies in our laboratory have consistently found similar
reductions in α7 nAChR binding following brain injury (Guseva et al., 2008; Kelso
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et al., 2006; Verbois et al., 2002; Verbois et al., 2000), but only modest
reductions in α4 nAChR binding (Verbois et al., 2002). In addition, people with
AD have a significant reduction in high affinity choline uptake sites (RodriguezPuertas et al., 1994) and a reduction in ChAT activity (Waller et al., 1986).
Current therapies seek to maintain cholinergic signaling by inhibiting AChE, and
evidence gathered from rodent studies suggests that nAChR agonists may
enhance cognition (Arendash et al., 1995a; Boess et al., 2007; Kem, 2000).
Taken together these findings demonstrate a deficit in nAChR expression in both
AD and TBI that could be liked to cognitive deficits.
1.2.6 Agonists, antagonists and partial agonists of nAChRs
The study of nAChRs has been significantly aided by the discovery and
molecular characterization of selective pharmacological antagonists and
agonists. Since nicotinic cholinergic transmission regulates the NMJ and somatic
nervous system a large number of predatory animals have evolved potent
venoms that target the α1 nAChR. One of the first of such toxins discovered was
α-bungarotoxin (α-BTX) from the banded krait (Bungarus multicinctus) which is
an irreversible antagonist at the NMJ nAChR (Changeux et al., 1970). Shortly
after, α-BTX was found to bind in brain fractions (Salvaterra and Moore, 1973),
and autoradiographic characterization of its binding in the brain was carried out
(Polz-Tejera et al., 1975). Later the α7 nAChR was shown to be the site to which
α-BTX binds in the CNS (Couturier et al., 1990). In addition to snake venom,
venoms from the many species of predatory cone snails are now of great interest
and since they have been shown to contain an abundance of selective nAChR
ligands (Cartier et al., 1996; Luo et al., 1998; Luo et al., 1999; McIntosh et al.,
1999; McIntosh et al., 1994; Terlau and Olivera, 2004).

While only a small

proportion of these toxins have been purified and characterized their value and
utility in studying the structure and function of specific nAChR subtypes is clear
(Nicke et al., 2004). It is not only animal venom derived toxins that are of interest
with relation to nAChRs. Aside from nicotine there is a range of plant alkaloids
that act upon various nAChR subtypes, including curare, and methyllycaconitine
(MLA, see appendix Figure 7.1).

MLA is an alkaloid isolated from the tall
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larkspur (Delphinium brownii) and is responsible for numerous cattle poisonings
in the American Midwest. It causes paralysis in cattle by antagonizing the NMJ
nAChRs (Pfister et al., 1999).

In addition to its NMJ effects MLA has been

shown to be a potent and competitive antagonist at CNS α7 nAChRs (Macallan
et al., 1988). This property makes MLA a valuable tool for use in studying the
function and localization of α7 nAChR subunits in the brain (Ward et al., 1990).
Furthermore, unlike the large polypeptide chains of α-bungarotoxins and αconotoxins, MLA has some ability to cross the blood-brain barrier (BBB) in
rodents (Navarro et al., 2002; Stegelmeier et al., 2003; Turek et al., 1995).
Combined, these properties make MLA a potential therapeutic agent with which
to inhibit the calcium-mediated effects of ACh in the CNS.
In addition to full agonists and antagonists a range of nicotinic receptor
partial agonists are available. Similar to a full agonist, a partial agonist binds to
and activates the target receptor. However, unlike a full agonist the partial
agonist has limited efficacy, meaning that a smaller proportion of the target
receptors are in an activated state when saturated with ligand. For example,
varenicline is a partial agonist of α4β2 nAChRs, and is now marketed as a tool
for smoking cessation. As a partial agonist it can alleviate the symptoms of
nicotine cravings and withdrawal, while also inhibiting the effects of nicotine
exposure.

α7-nAChR partial agonists

such as 3-2,4 dimethoxybenzylidene

anabaseine (DMXB-A, code-name GTS-21), tropisetron and ondansetron (for
molecular structures see appendix, Figure 7.1) have been tested, and continue to
be tested for therapeutic value in conditions such as AD and schizophrenia
(Freedman et al., 2008; Kem, 2000; Koike et al., 2005; Oliveira et al., 2008). The
utility of these α7 nAChR partial agonists in TBI remains to be determined.
However, the potential for partial agonists to treat TBI has been demonstrated in
a rat model, in which an NMDA partial agonist (D-cycloserine) or mAChR partial
agonist (Lu 25-109-T) improved cognitive performance following injury (Pike and
Hamm, 1997b; Temple and Hamm, 1996).
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1.3

Specific aims and hypotheses
Evidence to-date suggests that following TBI acute increases in ACh could

contribute to excitotoxicity, and more long-term deficits in ACh may contribute to
cognitive deficits and other neuropsychiatric aspects of recovery. The α7 nAChR
is of particular interest because it is widely expressed in the brain, is highly
permeable to calcium (Fucile et al., 2003; Sands et al., 1993; Seguela et al.,
1993), and its expression is significantly affected by brain injury (Verbois et al.,
2002; Verbois et al., 2000). Previous studies in our laboratory have shown that
post-traumatic nicotine can attenuate cognitive deficits in rats (Verbois et al.,
2003a).

In a separate study chronic nicotine treatment reversed α7 nAChR

binding deficits (Verbois et al., 2003b). Furthermore, we have demonstrated that
dietary supplementation with the selective agonist choline results in a modest
degree of improvement in the MWM, spares cortical tissue, and reduces
neuroinflammation in a rat model of TBI (Guseva et al., 2008).
Since nicotine has numerous central and peripheral effects a more
selective drug is needed to target the post-injury excitotoxic cascade and to treat
long-term cognitive deficits. Therefore, we hypothesize that administration of a
selective antagonist immediately after injury will attenuate excitotoxicity and
consequently lead to measurable improvements in cognition. While attenuating
the excitotoxic effects of ACh may be neuroprotective, it does not directly treat
the long-term cognitive deficits frequently reported by TBI patients.

Another

strategy might be to administer a partial agonist, thereby forgoing the efficacy of
a full agonist or antagonist but eliminating some concerns over the timing of
administration. Administration of a competitive partial agonist immediately after
injury may attenuate α7 nAChR activation, potentially reducing the excitotoxic
effects of elevated acetylcholine levels. Furthermore, administration of partial
agonists beyond the initial period of increased cholinergic activity may still be
therapeutic by improving cholinergic tone and thereby potentially improving
cognitive outcomes.
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In order to easily quantify the level of brain injury and make assessments
of neuroprotective effects of experimental treatments it is important to have new,
innovative tools. Although tissue sparing is frequently used it is only relevant if
the injury is severe enough to produce tissue loss, and animals must be
euthanatized at a time point long enough to allow tissue encavitation. To this
end we propose the use of labeled PK11195 as a sensitive tool for assessment
of brain damage.

Previous studies in both rodents and humans have

demonstrated the ability of PK11195 to reveal subtle brain damage likely
attributable to a microglial response (Banati et al., 1997; Chen and Guilarte,
2006; Grossman et al., 2003; Pedersen et al., 2006; Roberts et al., 2009; Sitte et
al., 2001; Vowinckel et al., 1997). Therefore, we aim to develop this tool for easy
assessment of brain inflammation that can be used to evaluate the
pharmacological studies.
With these aims in mind we hypothesize that the characterization of a
post-CCI time-course of neuroinflammation will aid in the assessment of the
efficacy of α7 nAChR antagonist and α7 nAChR partial agonist treatments
following experimental rat brain injury. Additionally, post-CCI treatment with a α7
nAChR antagonist or α7 nAChR partial agonists will lead to a significant
improvement in cellular and functional outcomes.
This hypothesis will be tested by performing a series of experiments that
will (1) characterize the time course of post-traumatic neuroinflammation; (2)
assess the ability of an α7 nAChR antagonist to produce a neuroprotective effect
and improve functional recovery; and (3) determine the therapeutic potential of
α7 nAChR partial agonists in alleviating CCI-induced cognitive deficits and
improving cellular outcomes.

•

Hypothesis #1 – PK11195 binding to TSPO can be used to detect
differences in the timing and magnitude of microglial activation and
macrophage infiltration following brain injury
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•

Specific Aim 1: Conduct

a

detailed

time-course

of

[3H]-PK11195

autoradiography in a CCI model of TBI and make assessments of the
changes in binding that occur in multiple brain regions
•

Specific Aim 2: Compare the timing and magnitude of changes in [3H]PK11195 binding to a marker of activated microglia/macrophages and to a
marker of neuronal death

•

Hypothesis #2 – Administration of the α7 nAChR antagonist MLA after
experimental brain injury will spare cortical tissue, reduce neuroinflammation,
and improve cognitive outcomes
•

Specific Aim 1: Evaluate cognitive performance in rats administered
either MLA or saline following CCI

•

Specific Aim 2: Assess the neuroprotective effects of MLA by conducting
a cortical tissue sparing analysis

•

Specific Aim 3: Determine the effect of MLA on post-CCI α7 nAChR
binding and measure the magnitude of post-CCI neuroinflammation using
[3H]-PK11195 autoradiography

•

Hypothesis #3: - Administration of a α7 nAChR partial agonist following
brain injury will improve spatial learning in the MWM, spare cortical tissue
and attenuate neuroinflammation
•

Specific Aim 1: Compare the post-CCI cognitive performance of rats
treated with either tropisetron or saline

•

Specific Aim 2: Determine

whether

post-CCI

tropisetron

is

neuroprotective, and resolve regional differences in neuroinflammation
•

Specific Aim 3: Assess the effect of tropisetron on CCI-induced α7
nAChR binding deficits

•

Specific Aim 4: Evaluate two other α7 nAChR partial agonists as
potential treatments for post-CCI cognitive impairments
Copyright  Thomas M Woodcock 2009

27

2. CHAPTER 2
[3H]-PK11195 Autoradiography as a Tool to Assess TBI-Induced Brain
Inflammation
2.1

Introduction
Over one and a half million people sustain a TBI every year in the United

States alone, and the majority of these people will be left with motor and/or
neuropsychiatric impairments that significantly affect sufferers’ quality of live.
The majority of TBI cases are the result of motor vehicle accidents, yet while
great advances have been made in automobile safety and accident prevention
there has been no significant improvement in the pharmacological interventions
available clinically for those that suffer a TBI. The lack of drugs specifically
tailored to TBI reflects the complexity and heterogeneity of the condition, and
comes despite intensive research in the area.

Several promising candidate

pharmacological strategies and lead compounds have all failed in human clinical
trials for neuroprotection and functional recovery following TBI (Bolland et al.,
1998; Harders et al., 1996; Marmarou et al., 1999; Marshall et al., 1998; Morris et
al., 1999; Muizelaar, 1994; Muizelaar et al., 1993; Stewart et al., 1999; Ward,
1950).
A large proportion of the research conducted in TBI to date has focused
on the idea of excitotoxicity. The primary insult causes shearing and tearing of
axons and cell bodies that releases non-physiological amounts of the excitatory
neurotransmitter glutamate. Glutamate binds to and activates NMDA receptors,
which are highly permeable to calcium; therefore, over-stimulation of these
receptors will lead to calcium overload, mitochondrial dysfunction, free radical
formation, endonuclease, protease, and phospholipase activation, culminating in
neuronal cell death via apoptotic or necrotic mechanisms. Thus blockade or
inhibition of NMDA receptors could protect cells that survive the primary insult
from an excitotoxic fate. Unfortunately NMDA antagonists have lacked efficacy
in human trials despite promising results in animal studies. The failure of these
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trials has prompted much discussion and speculation as to the possible reason
for discrepancy between animal and human data (Albensi et al., 2004; Muir,
2006).

One issue is the lack of a well defined time-course of cellular and

molecular events that occur after TBI in animals and humans. New markers of
tissue damage could provide a better understanding of the pathogenesis of TBI,
and help to define windows for possible therapeutic intervention.
In recent years the role played by reactive gliosis has garnered increasing
attention as inflammation is now though to play a significant role in many
neurodegenerative conditions.

For example, the activation of brain-resident

microglia has been implicated in the pathogenesis of AD (Eikelenboom et al.,
1994; Moore and O'Banion, 2002; Rogers, 1995), Parkinson’s disease (Gao et
al., 2002; McGeer and McGeer, 2004), stroke (Denes et al., 2007; Wiart et al.,
2007), amyotrophic lateral sclerosis (ALS) (Almer et al., 2001; Weydt et al., 2002)
and TBI (Adelson et al., 1998; Morganti-Kossman et al., 1997). Activation of glial
cells occurs as a graded response to insult, and is typically related to the degree
of injury (Raivich et al., 1999). Therefore, a selective and sensitive marker to
facilitate

the

characterization

of

neuroinflammation

in

models

of

neurodegeneration and brain injury may be very useful.
One promising candidate for such a marker is the peripheral
benzodiazepine receptor (PBR). As its name suggests, the PBR was initially
found to be expressed in the peripheral tissues of the heart, liver, adrenal gland,
testis, lymphatic cells, and hemopoietic cells (reviewed in Woods and Williams,
1996).

Subsequent studies however, demonstrated that the brain (primarily

olfactory bulb) also expresses PBRs (Benavides et al., 1984; Marangos et al.,
1982; Schoemaker et al., 1983), eventually leading to a change of nomenclature
to the translocator protein 18kDa (TSPO) (Papadopoulos et al., 2006a). The
potential for the TSPO as a marker of inflammation is demonstrated by marked
increases in expression following CNS damage. Increased TSPO expression
has been reported following chemical-induced injury, such as trimethyltin
(Guilarte et al., 1995; Kuhlmann and Guilarte, 2000), domoic acid (Kuhlmann and
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Guilarte, 1997), and MPTP (Kuhlmann and Guilarte, 1999). Increases are also
seen in ischemic stroke models (Stephenson et al., 1995) and patients (Gerhard
et al., 2000; Gerhard et al., 2005; Pappata et al., 2000). Other studies have
demonstrated increases in TSPO expression in neurodegenerative disease
(Cagnin et al., 2001; Gerhard et al., 2003; Versijpt et al., 2003), and brain trauma
(Miyazawa et al., 1995; Raghavendra Rao et al., 2000). Changes in the levels of
TSPO expression are therefore thought to reflect the progression of
neuroinflammation.
A growing body of evidence suggests that the TSPO is localized primarily
on the outer mitochondrial membrane (Anholt et al., 1986; Antkiewicz-Michaluk et
al., 1988; Bribes et al., 2004; Garnier et al., 1994). However, early evidence of
TSPO expression on erythrocytes (Olson et al., 1988), which lack mitochondria,
and studies in other tissues (O'Beirne et al., 1990; Woods and Williams, 1996)
suggest a possible plasma-membrane population of TSPO. In addition, some
evidence exists for nuclear localization of TSPOs in glial cells (Kuhlmann and
Guilarte, 2000). Several different functions have been attributed to the TSPO
such as porphyrin transport (O'Hara et al., 2002; Taketani et al., 1994),
explaining the mitochondrial localization (porphyrin is needed for hemoglobin
synthesis in mitochondria).

Other functions suggested include cholesterol

transport and regulation of steroid synthesis (Costa et al., 1994; Jamin et al.,
2005; Lacapere and Papadopoulos, 2003; Li et al., 2001; Papadopoulos et al.,
2006b), regulation of apoptosis (Maaser et al., 2001) or proliferation (Galiegue et
al., 2004), and others (Faure et al., 2003; Gavish et al., 1999; Lacapere and
Papadopoulos, 2003; Larcher et al., 1989; Ostuni et al., 2004; Torres et al., 2000;
Veenman and Gavish, 2006).
The most widely used radioligand for tissue localization of the TSPO is
the isoquinoline carboxamide PK11195, possibly because of its high affinity for
the TSPO (Le Fur et al., 1983) in animals and humans (Casellas et al., 2002).
PK11195 has already been used to image inflammation in a number of brain
inflammatory disorders including ischemia (Dubois et al., 1988), encephalitis

30

(Vowinckel et al., 1997), thiamin deficiency (Leong et al., 1994), and closed head
injury (Raghavendra Rao et al., 2000). Using [3H]-PK11195 autoradiography it is
possible to track the evolution of brain damage over time in multiple brain
regions. In injured animals significant increases in [3H]-PK11195 binding have
been observed in the ipsilateral cortex, hippocampus and thalamus (Grossman et
al., 2003; Raghavendra Rao et al., 2000). These increases are thought to reflect
the activation of brain-resident microglia or the presence of infiltrating peripheral
macrophages.

Comparisons of PK11195 with markers of microglia and

macrophages support this idea, but until now the time-course of changes in [3H]PK11195 binding have not been carefully evaluated in a well-controlled animal
model of TBI. Therefore, the purpose of the present study is to establish the time
course of microglial infiltration into rat brain regions following a cortical contusion
injury.
2.2

Materials and methods

2.2.1 Animals and surgery
All experiments were conducted in accordance with the guidelines of the
University of Kentucky Institutional Animal Care and Use Committee (IACUC)
that follows the guidelines set forth by the National Institutes of Health guide for
the care and use of laboratory animals. Experiments were designed to minimize
animal suffering and the number of animals required for the study.

For all

experiments, male Sprague-Dawley rats weighing 275-300 g housed 3 per cage
were obtained from Harlan Breeding Laboratories (Indianapolis, IN) and
randomly assigned into treatment groups. Surgical manipulations were carried
out as previously described (Verbois et al., 2003a; Verbois et al., 2002, 2003b;
Verbois et al., 2000). Briefly, animals were anaesthetized with 3% isoflorane and
immobilized in a stereotaxic frame. A 6 mm craniotomy was performed using a
Michele trephine just above the somatosensory cortex (Bregma –2.8, 2.5 mm
lateral) and an electronically controlled piston (5 mm diameter) was used to
administer a 1.5 mm cortical deformation at a velocity of 3.5 m/s. Following the
injury the skull disc was replaced and sealed with dental acrylic.
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2.2.2 [3H]-PK11195 autoradiography
Animals were euthanatized 30 minutes, 12 hours, 2, 4 or 6 days following
trauma and the brains immediately removed and frozen in isopentane. Brain
sections (16 µm) were prepared using a Lecia CM1850 cryostat and were
mounted onto Super-Frost Plus™ slides (Fisher Scientific, Pittsburgh, PA). The
slides were stored at -80°C until radioligand binding studies could be carried out.
Neuroinflammation was assessed by [3H]-PK11195 autoradiography on a set of
slides from each animal.

For [3H]-PK11195 autoradiography, slides were

warmed to room temperature and pre-incubated in buffer for 15 minutes, then
transferred to fresh buffer containing 1 nM [3H]-PK11195 for 2 hours, then
washed in buffer, and dried overnight. The slides were exposed to RayMax Beta
High Performance Autoradiography Film (ICN Biomedicals Inc., Aurora, OH) to
visualize the areas of ligand binding. Radioactive rat brain tissue standards were
included with each film X-ray cassette in order to determine the response of the
film to different amounts of radioactivity. A Northern Lights illuminator with a
digital camera (a CFW-1310M, Scion Corp) was used to capture images that
were analyzed with ImageJ (v1.39) on an iMac. Molar quantities of bound ligand
were determined by constructing a standard curve from radioactivity tissue
standards fitted to an exponential curve. To test the specificity of [3H]-PK11195
binding a parallel binding assay was carried out in the presence of a saturating
amount of unlabelled Ro5-4864, which also has high affinity for binding to the
TSPO.

Inclusion of an excess amount of Ro5-4864 reduced [3H]-PK11195

binding to control levels, indicating that these ligands are competing for the same
binding sites (data not shown). Changes in [3H]-PK11195 binding following CCI
were quantified in several regions of the cortex, hippocampus and thalamus.
Binding density was measured in both the ipsilateral and contralateral cortex to
give an indication of the inflammatory response in tissue directly affected by the
impact. This was achieved by outlining the cortex from its dorsal side, ventral to
the entorhinal rhinal fissure. In the hippocampus [3H]-PK11195 was measured in
the CA1 and CA2/3 fields, the hilus, the lateral blade of the dentate gyrus, and
the ventral blade of the dentate gyrus.
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In addition to the cortex and

hippocampus, thalamic nuclei have numerous projections into the cerebral cortex
(Castro-Alamancos and Connors, 1997), which could be affected by CCI.
Therefore, binding was assessed in the lateral dorsal (LD) thalamus, and the
ventral posterolateral (VPL) thalamic areas.
2.2.3 Cortical tissue sparing analysis
Tissue sparing analysis was carried out in each of the animals to follow
the progression of tissue encavitation at each time point and to facilitate
comparisons with binding data. Analysis of the amount of tissue lost following
injury was carried out as previously described (Scheff and Sullivan, 1999). To
summarize, 8 Cresyl violet stained sections from each animal were included in
the analysis, each evenly spaced throughout the lesion site. For each section
the area of the ipsilateral cortex and contralateral cortex was measured
separately. The average area of each side of the cortex was calculated and by
dividing the ipsilateral area by the contralateral area, then multiplying by 100, a
percentage of cortical tissue remaining is produced.
2.2.4 Fluoro-Jade B staining
Fluoro-Jade B (FJ-B) staining was used to assess neuronal degeneration
following CCI.

Fluoro-Jade (A) is an anionic fluorochrome that was first

described in 1997 as sensitive marker for neuronal degeneration (Schmued et
al., 1997).

In this study we utilized FJ-B; a related compound with higher

specificity (Schmued and Hopkins, 2000a). Dying and dysfunctional cells were
visualized by FJ-B staining as described previously (Anderson et al., 2005).
Briefly, fresh-frozen sections mounted on Super-Frost Plus™ slides (Fisher
Scientific, Pittsburgh, PA) were post-fixed in 4% paraformaldehyde for 10
minutes and washed in water prior to immersing in a solution of 1% sodium
hydroxide in 80% ethanol for 5 minutes. Slides were then hydrated in a series of
ethanol washes and placed in a solution of 0.06% potassium permanganate for
10 minutes.

Next, slides were rinsed in distilled water for 2 minutes and

incubated in a 0.0004% solution of FJ-B (Histo-Chem Inc., Jefferson, AR) for 20
minutes. Lastly, the sections were then rinsed in distilled water, air-dried and
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cover slipped. FJ-B-positive neurons were visualized using an Olympus BX-51
microscope with a fluorescein isothiocyanate (FITC) filter cube.

Individual

stained cells were manually counted throughout specific regions of interest in 6
equally spaced sections. Regions of interest were the cerebral cortex (Bregma 2.5 mm to Bregma -4.5 mm), the dentate gyrus (dorsal and ventral blades
individually), the CA1 and CA2/3 fields of the hippocampus, the hilus, and the LD
thalamus (Bregma -3.0 mm to Bregma -3.8 mm).
2.2.5 Immunohistochemistry
Immunohistochemistry for activated microglia and macrophages was
carried out with a monoclonal mouse anti-rat CD68 [ED-1] antibody (Abcam,
Cambridge, MA). CD68 is a transmembrane protein expressed on macrophages
and activated microglia, which is thought to be involved in cellular phagocytosis
(Holness and Simmons, 1993). Fresh-frozen tissue sections mounted on slides
were post-fixed by immersion in 4% paraformaldehyde for 10 minutes. Sections
were washed in phosphate-buffered saline (PBS) containing 0.1% Triton-X and
blocked in the same solution containing 3% normal horse serum for 1 hour.
Endogenous peroxidases were quenched by incubating sections is PBS
containing 0.3% hydrogen peroxide. Next, the ED-1 antibody was diluted 1:100
in blocking solution, applied to sections in a humidified chamber and incubated
overnight at 4˚C.

Sections were then washed in PBS and incubated with

biotinylated horse anti-mouse IgG (Vector Labs, Burlingame, CA) for 60 minutes.
Following further washing, the secondary antibodies were detected using a
Vector Avidin: Biotinylated enzyme Complex (ABC) Elite kit (Vector Labs, CA),
and

visualized

by

the

3,3'-Diaminobenzidine (DAB).

addition

of

Nickel

and

Cobalt

enhanced

Finally, the sections were dehydrated and

coverslipped prior to analysis. ED-1 stained cells were counted in the same
regions as FJ-B positive cells so that direct comparisons could be made.
2.2.6 Statistics
[3H]-PK11195 binding was measured in 6 equally-spaced sections for
each region of interest and an average value was calculated. Data from each
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animal was analyzed by a 2-way analysis of variance (ANOVA) in which timepoint and hemisphere were independent variables, and the [3H]-PK11195 binding
density was the dependant variable.

Individual group comparisons were

assessed by carrying out a Tukey’s honestly significant difference (HSD) posthoc test.
Tissue sparing analysis was analyzed with a one-way ANOVA, with timepoint as the independent variable and tissue sparing as the dependant variable.
Group comparisons were analyzed using the Tukey’s HSD post-hoc test.
For FJ-B staining and CD68 immunohistochemistry cells were counted
within a defined region of interest in 6 equally spaced sections. The cell count
was averaged for each animal and data were analyzed using a Kruskal-Wallis
test with time-point as the independent variable and number of cell profiles as the
dependent variable. Dunn’s multiple comparisons were used as the post-hoc
test to address individual group differences. All statistical analyses were carried
out using GraphPad Prism (GraphPad Software Inc, La Jolla, CA).
2.3

Results

2.3.1 [3H]-PK11195 binding is a sensitive marker of tissue damage
In the cortex increases in [3H]-PK11195 binding were visible after 2 days
but only became significant 4 days after injury (Figure 2-1). Data were analyzed
by 2-way ANOVA, which indicated a significant effect of day (F(5,32) = 4.83, p <
0.005) and hemisphere (F(1,32) = 14.1, p < 0.001), with a significant interaction
(F(5,32) = 3.83, p < 0.01).

Interestingly [3H]-PK11195 binding appears to be

elevated throughout the entire dorsal-ventral span of the cerebral cortex (Figure
2-3).
In the hippocampus increased [3H]-PK11195 binding is initially limited to
the ipsilateral dentate gyrus 12 hours after injury, and by 24 hours is increased in
other regions of the hippocampus (Figure 2-2).

In the dentate gyrus, CA1,

CA2/3, and hilus a 2-way ANOVA revealed a significant effect of time-point
(F(5,32) = 33.3, p < 0.001; F(5,32) = 23.9, p < 0.001; F(5,32) = 36.5, p < 0.001; F(5, 32) =
35

Figure 2-1 - The time-course of [3H]-PK11195 binding in the rat cerebral
cortex following a 1.5 mm CCI
In the ipsilateral cerebral cortex, increases in TSPO expression following injury
began 2 days after injury and reached significance by the fourth day. Mean
binding densities +/- standard deviation are plotted for ipsilateral and
contralateral regions of the cortex (n = 4). Asterisks denote significant
differences from binding in the contralateral hemisphere as found by Tukey’s
HSD (*p < 0.05, **p < 0.01).
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Figure 2-2 - [3H]-PK11195 binding in regions of the rat hippocampus
following a 1.5 mm CCI
Changes in [3H]-PK11195 binding were seen starting at 12 hours in some
hippocampal regions, but significant increases were not found until 2 days after
injury in this study. Binding densities were measured in each of the dentate
gyrus, CA1 field, CA2/3 field, and in the hilus at selected time-points following
CCI (n = 4). Data presented are for ipsilateral and contralateral areas and are
mean binding densities +/- standard deviation. Asterisks denote significant
differences from binding in the contralateral hemisphere (**p < 0.01).
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26.5, p < 0.001 respectively), hemisphere (F(1,32) = 82.2, p < 0.001; F(1,32) = 47.4,
p < 0.001; F(1,32) = 128, p < 0.001; F(1, 32) = 96.3, p < 0.001 respectively), and a
significant interaction term (F(5,32) = 12.7, p < 0.001; F(5,32) = 13.3, p < 0.001; F(5,32)
= 29.7, p < 0.001; F(5, 32) = 15.2, p < 0.001 respectively). Tukey’s HSD test was
used for individual group comparisons. In the dentate gyrus, CA2/3 field and
hilus binding was significantly elevated in the ipsilateral hemisphere on day 2, 4,
and 6 (p < 0.01), and in the CA1 field significantly increased binding was
revealed on days 4 and 6 (p < 0.01).
Interestingly, data for the contralateral dentate gyrus seemed to show an
increase in binding at later time points. When the contralateral dentate gyrus
data was analyzed by one-way ANOVA a significant effect of time post-CCI was
found (F(5,16) = 3.91, p < 0.05). A small increase can be seen after 4 days (Figure
2-3), and Tukey’s HSD post-hoc revealed a significant elevation 6 days after
injury when compared to levels measured immediately after injury (p < 0.05).
In addition to the cortex and hippocampus, localized increases in binding
density were observed in the thalamus (Figure 2-4). The thalamus is 3.5 mm
distal from the surface of the impacted cortex (Paxinos and Watson, 1998).
Despite this, significant increases in binding were seen in the ipsilateral side
versus contralateral following a 1.5 mm CCI in the LD thalamus (F(5,32) = 38.4, p <
0.001), and in the VPL thalamus (F(5,32) = 43.5, p < 0.001).
Tukey’s HSD multiple comparisons were performed to reveal significant
increases in binding to ipsilateral regions of the thalamus versus contralateral
beginning 2 days after injury. At 4 and 6 day time-points [3H]-PK11195 binding
continued to increase in both thalamic regions (Figure 2-4, 2-5).
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Figure 2-3 - [3H]-PK11195 binding in the contralateral dentate gyrus
In the contralateral dentate gyrus, increases in [3H]-PK11195 binding were
found versus ipsilateral measurements that became significant 6 days after
CCI (*p < 0.05). This could represent a delayed damage to this region,
possibly mediated by disruption of commissural fibers connecting the two
hemispheres. Data plotted are means +/- standard deviations (n = 4).
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Figure 2-4 - [3H]-PK11195 binding in the lateral-dorsal and ventralposterolateral thalamus at selected time-points after CCI
Increases in [3H]-PK11195 binding in the thalamus began at 2 days after injury
and steadily increased at 4 and 6 days (n = 4). These data for the LD and VPL
thalamus were analyzed by two-way ANOVA, and individual comparisons were
made using Tukey’s HSD. Significant increases in binding were found between
hemispheres in both regions at 2, 4, and 6 day time-points (**p < 0.01).
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Figure 2-5 - Images of coronal brain sections representative of [3H]-PK11195 binding at each time-point post-CCI

This figure shows the time-course of increases in binding following a 1.5 mm CCI. Note the early increases in the dentate
gyrus at 12 hours, and the increases in the thalamic regions at 4 and 6 days post-injury.
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2.3.2 Cortical tissue loss following CCI
There was no apparent tissue loss on days 1 to 4 post-CCI, and an 83%
tissue sparing observed 6 days after injury (Figure 2-6). The data were analyzed
by one-way ANOVA, which demonstrated an overall effect of time post-CCI on
cortical tissue loss (F(17,5) = 7.15, p < 0.001). Subsequent Tukey’s HSD post-hoc
tests revealed a significant loss of tissue at day 6 post-CCI compared to other
time-points (p < 0.05).
2.3.3 Increases in FJ-B positive cells occur early after CCI
Numerous FJ-B positive cells were observed throughout the ipsilateral
cortex at 12 hours and 24 hours after injury. The majority of these cells are
clustered around the impact site (Figure 2-13). By 2 days there were fewer dying
cells, and FJ-B positive cells continued to decrease in number through day 6
(Figure 2-7). This is in direct contrast to [3H]-PK11195 binding density, which
only begins to increase at 2 days and is significantly elevated versus control at 4
and 6 days post-CCI.
Cell count data were analyzed using a Kruskal-Wallis test, which reported
a significant effect of time-point on the number of FJ-B-positive cells (H = 17.64,
df = 5, p = 0.0034, N = 30). Comparisons of each group to the 30 minute control
group were made with a Dunn’s multiple comparisons test. Significant increases
in FJ-B positive cells were found in the 12 hour and 1 day time-point groups (p <
0.01, p < 0.05 respectively).
In the hippocampus FJ-B positive neurons were first observed at the 12
hour time-point, and were also most numerous at this time-point (Figure 2-8). In
the dentate gyrus a Kruskal-Wallis test determined that the group means did not
significantly differ.

However, a Dunn’s multiple comparison found significant

increases in FJ-B-positive cells at 12 hours, 1 day and 2 days. In the CA1,
CA2/3 and hilus there was a significant effect of time-point on the number of FJ-B
positive cells ([H = 11.77, df = 5, p = 0.0381, N = 30], [H = 14.75, df = 5, p =
0.0115, N = 30], [H = 13.22, df = 5, p = 0.0214, N = 30] respectively). For each
region Dunn’s multiple comparisons were made between the 30 minute time42

Figure 2-6 - Tissue sparing analysis performed at various time-points after
a 1.5 mm CCI in the rat
There was no apparent tissue loss at time-points up to 4 days post-CCI, but an
83% tissue sparing was found on day 6 post-CCI. Data were analyzed by oneway ANOVA with Tukey’s HSD post-hoc (*p < 0.05). Data plotted are means
plus or minus standard deviation (n = 4).
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Figure 2-7 - The time-course of FJ-B positive cells in the cerebral cortex
following CCI in the rat
FJ-B cells were abundant in the cortex at 12 hours post-CCI, with fewer
positively stained cells counted in the region at subsequent time points. Data
for the ipsilateral cortex were analyzed by Kruskal-Wallis test, and Dunn’s
multiple comparison was used to determine significant differences from the 30
minute post-CCI group (asterisks denote a significant difference versus 30
minute time-point [*p < 0.05, **p < 0.01]). Data are plotted as means plus or
minus standard deviation (n = 4).
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Figure 2-8 - Time-course of FJ-B staining in the hippocampus following
CCI
FJ-B positive cells were counted in the dentate gyrus, CA1 field, CA2/3 fields
and the hilus following CCI. Data are plotted as means plus or minus standard
deviation (n = 4). Asterisks denote a significant difference from the 30 minute
group as determined with a Dunn’s multiple comparisons test (p < 0.05).
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point and each of the other groups. In the CA2/3 fields and in the hilus significant
numbers of FJ-B positive cells were found up to 24 hours after injury (p < 0.05).
Interestingly, in the medial portion of the CA1 field of the hippocampus at the 12
hour time point a small but significant (p < 0.05) number of FJ-B cells were seen.
In the LD thalamus a Kruskal-Wallis test found a significant effect of time
on the numbers of FJ-B positive cell profiles (H = 18.81, df = 5, p = 0.0021, N =
30). Significant numbers of FJ-B positive cell profiles were not quantified until 4
days after injury, and significant numbers remained at the 6 day time-point
(Figure 2-9, and Figure 2-14).
2.3.4 The time-course of changes in CD68 positive cells following trauma
The spatial and temporal pattern of CD68 positive microglia and
macrophages was used to make comparisons to [3H]-PK11195 autoradiographs
from adjacent brain sections. CD68 positive cells were found in all regions where
[3H]-PK11195 binding was elevated. In the ipsilateral cortex CD68 positive cell
profiles were observed in small numbers in the areas surrounding the contusion
starting at 12 hours, and were present in large numbers by 4 days post-injury
(Figure 2-10, and Figure 2-13). A Kruskal-Wallis test revealed significant group
differences (H = 17.61, df = 5, p = 0.0035, N = 30), and a Dunn’s post-hoc test
showed that the numbers of CD68 positive cell profiles per section were
significantly more in the 4 and 6 day post-CCI groups versus the 30 minute postCCI group (p < 0.005, and p < 0.05 respectively).
In the dentate gyrus, hilus, and CA2/3 fields of the hippocampus CD68
stained cell profiles were seen beginning at 12 hours post-CCI and were
widespread and numerous by 1 day after injury (Figure 2-11). Large amounts of
staining persisted in these areas at all subsequent time points. A Kruskal-Wallis
test carried out on these data did not find any significant differences ([H = 7.531,
df = 5, p = 0.1840, N = 30], [H = 9.079, df = 5, p = 0.1060, N = 30], and H =
8.754, df = 5, p = 0.1193, N = 30, respectively. The CA1 was unique in that only
a few CD68 positive cell profiles were found in the region beginning at 1, 2 and 4
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Figure 2-9 – FJ-B positive cell profiles in the lateral dorsal thalamus
following CCI
Very few FJ-B positive cells were seen in the thalamus up to 2 days after injury,
but statistically significant numbers were observed in the region at 4 and 6 day
time-points (Dunn’s multiple comparisons, *p < 0.05, **p < 0.01). Data are
plotted as means plus or minus standard deviation (n = 4).
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Figure 2-10 - CD68 immunohistochemistry for activated macrophages in
the cortex following CCI
Activated macrophages and microglia were stained using ED-1 antibodies
against the marker CD68. Positively stained cell profiles were counted in the
ipsilateral cortex and data are presented as means for each time-point plus or
minus standard deviation (n = 4). A significant increase versus data from the
30 minute post-CCI group is denoted by an asterisk (p < 0.01).
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Figure 2-11 - The time-course of CD68 positive cells in hippocampal
regions following CCI
CD68 positive cells were not seen in any hippocampal region 30 minutes after
injury. In the CA1 field a small number of cells were found at 1, 2 and 4 days
post injury, but there was no significant effect. In other regions CD68 positive
cells were present from 12 hours and up to the 6 day time-point. Data are
plotted as means plus or minus standard deviation (n = 4).
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days post-injury, and at no point was there a significant effect of time-point (H =
7.760, df = 5, p = 0.1700, N = 30).
The LD thalamus contrasts the cortex and hippocampus in that changes in
the numbers of CD68+ cell profiles do not seem to mirror changes in [3H]PK11195 binding density. Analysis of [3H]-PK11195 autoradiographs showed
significant increases in binding density beginning at 2 days (Figure 2-4).

In

+

comparison, very few CD68 cells were observed in the LD thalamus at any time
point (Figures 2-12), and although there appears to be a trend to increased
numbers between 2 and 6 days post-injury, these changes were small and not
significant (H = 5.731, df = 5, p = 0.3332, N = 30).
2.3.5 Numbers of CD68+ cell profiles correlate with [3H]-PK11195 binding
The amount of [3H]-PK11195 binding, CD68 staining, and FJ-B staining
vary widely with time in the cortex. As the largest area, and as the area most
affected by the contusion, data for this region were the most robust and therefore
used for correlation analysis (Figures 2-1, 2-7, 2-10). Therefore, all three of
these assessments were carried out in the same area of the cortex in each
animal and correlations of CD68 and FJ-B were made to [3H]-PK11195 binding
density (Figure 2-15). Analysis of the data using a Spearman’s test revealed a
moderate positive correlation between [3H]-PK11195 binding density and CD68
staining, (r = 0.687 (19), p(two-tailed) = 0.0012). In contrast there was a negative
correlation between [3H]-PK11195 binding and FJ-B staining, (r = -0.4357 (21),
p(two-tailed) = 0.0483).
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Figure 2-12 - CD68 positive cells in the thalamus at selected time-points
after CCI
Very few cells stained positive for CD68 in the thalamus at any time-point
following CCI. A Kruskal-Wallis test did not report a significant effect of time on
CD68 cell count, and no significant differences were found between any timepoint. Data are plotted as means plus or minus standard deviation (n = 4).
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Figure 2-13 - Representative images of FJ-B and CD68 staining in cortex following CCI

No FJ-B or CD68+ cell profiles were seen in any animals at the 30 minute time-point. By 12 hours FJ-B staining was
widespread in the cortex, while relatively few CD68 cell profiles were counted. Four days after the injury the number of
FJ-B cell profiles had reduced significantly from their peak at 12 hours, while the number of CD68 positive cell profiles
had increased significantly.
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Figure 2-14 – FJ-B and CD68 staining in the hippocampus and thalamus following CCI

In the hippocampus at 4 days FJ-B staining was primarily seen in the dentate gyrus and hilus, which corresponded with
increased numbers of CD68 positive cells found In that region at the same time-point. In the thalamus at 6 days, very
significant numbers of FJ-B positive cells were found, but interestingly very few CD68 positive cells were present
demonstrating difference in the pattern of TSPO expression and CD68 expression in this brain region.
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Figure 2-15 - Correlation of FJ-B and CD68 positive cell counts to [3H]PK11195 binding data
There is a moderate positive correlation of CD68 cell counts with PK11195
binding data. Data for FJ-B and CD68 staining were plotted against PK11195
binding data and a Spearman’s correlation coefficient was calculated (r = 0.687).
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2.4

Discussion
A thorough evaluation of the time-course of molecular and cellular events

following TBI is essential to support the ongoing efforts to develop efficacious
treatments for this condition. The vast differences between laboratory animal
and human brains in terms of size, organization, and complexity require that
detailed assessments be made in both animal and human brain injury. PK11195
is a molecule of particular interest for this task because it has been utilized
successfully to make assessments of inflammation in human patients as well as
in post-mortem studies in laboratory animals (Chen and Guilarte, 2008).
PK11195 can be used as a sensitive marker to assess and track inflammation in
neurodegenerative conditions including TBI. Correlations to cell specific markers
(Raghavendra Rao et al., 2000; Venneti et al., 2008a; Vowinckel et al., 1997),
and co-localization studies (Myers et al., 1991a; Venneti et al., 2007a), support a
binding site in activated microglia and/or macrophages.

Furthermore,

radiolabelled PK11195 has been successfully used to visualize inflammation in
positron emission tomography (PET) studies (Bartels and Leenders, 2007;
Gerhard et al., 2006; Venneti et al., 2008a; Vowinckel et al., 1997). In rodent
brain injury models, sham-operated animals show the expected pattern of [3H]PK11195 binding, i.e. binding is largely restricted to the choroid plexus,
ependymal cells lining the ventricles, and olfactory bulb (Raghavendra Rao et al.,
2000).

Previous studies that used PK11195 to visualize neuroinflammation

following TBI found significant increases in PK11195 binding sites in the
hippocampus and thalamus at 3 and 14 days post-injury (Raghavendra Rao et
al., 2000), and a co-localization of PK11195 binding sites with CD68-positive
cells (Venneti et al., 2007a). Furthermore, previously published data from other
groups have demonstrated that increases in [3H]-PK11195 binding following
brain injury are not due to a change in receptor affinity (Pedersen et al., 2006;
Raghavendra Rao et al., 2000). At all time points assessed, TBI had no effect on
Kd values in either the ipsilateral or contralateral brain regions. This study builds
on previous research from other laboratories by providing a detailed assessment
of [3H]-PK11195 binding in multiple brain regions following CCI.
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There is a clear difference between individual brain regions with respect to
the time-course of [3H]-PK11195 binding following injury. As expected, in shamoperated animals [3H]-PK11195 binding was very low with the expression only
detected in the choroid plexus lining the ventricles.

In the cortex relatively

modest increases were found at 4 and 6 days post-injury. While it was not
possible to quantify binding in discrete regions of the cortex due to the nature of
the injury, visual assessment of the autoradiographs (Figure 2-5) reveals that the
highest densities are found surrounding the lesion. An additional observation
was that at 2, 4, and 6 days post-injury [3H]-PK11195 binding was elevated
throughout the ipsilateral cortex. This could represent the disruption of neuronal
networks associated with the lesioned portion of the cortex.
The most obvious increase in [3H]-PK11195 binding density began in the
dentate gyrus at just 12 hours after injury, and reached significance at 2 days.
Binding increases in this region occurred before any significant increases were
measured in other brain regions, including the contused cortex. In a previous
study in our laboratory we were able to detect a significant increase in [3H]PK11195 binding in the dentate gyrus just 6 hours after injury (Figure 2-16). The
sensitivity of the dentate gyrus to CCI is further highlighted by the detection of
significant increases in [3H]-PK11195 binding in the contralateral dentate gyrus 6
days after injury (Figure 2-3). The sensitivity of cells in the region to injury has
been reported previously (Baudry and Altar, 1991).

In that study, chemical

lesioning of the entorhinal cortex resulted in a significant increase in [3H]-Ro54864 (a TSPO ligand) binding to ipsilateral dentate gyrus homogenates (Deller et
al., 1996). One other interesting observation was a small but significant increase
in binding to contralateral dentate gyrus homogenates 4 days after the lesion was
induced. The vulnerability of dentate gyrus cells could be due to excitotoxicity
brought about by the release of glutamate as a result of injury to neurons in the
entorhinal cortex that project into the hippocampus.
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Figure 2-16 - [3H]-PK11195 binding following a 2 mm CCI

In the dentate gyrus of the hippocampus significant increases in [3H]-PK11195 binding were found just 6 hours after a 2.0
mm CCI. Maximal [3H]-PK11195 binding in all hippocampal regions occurred on day 7, and by day 21 was returning to
sham levels. Significant differences from contralateral regions were found by Tukey’s HSD (*p < 0.05, **p < 0.01, ***p <
0.005). Data plotted are means +/- standard deviations (n = 8).
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In the thalamus we found that binding of [3H]-PK11195 does not robustly
increase until approximately 3 days after CCI, and increases through all
subsequent time points examined. Delayed microglial activation in the thalamus
may represent retrograde cell death of thalamocortical neurons as a result of
deafferentation in the projection region of the somatosensory cortex. This finding
fits well with previous studies from our laboratory that have shown a delayed loss
of nicotinic receptor binding in the thalamus, starting at 21 days post injury
(Verbois et al., 2002).

Further support for this mechanism as the basis of

delayed microglial activation in the thalamus comes from studies in which lesions
of the thalamus lead to a delayed loss of nicotinic binding in the cortex (Gioanni
et al., 1999; Lavine et al., 1997).

In addition, we have collected data in a

previous study which shows that 3 weeks after injury [3H]-PK11195 binding is
returning to sham levels in all regions except for the thalamus (Figure 2-16, and
2-17).
The anionic fluorescein derivative FJ-B was utilized in brain sections
adjacent to sections used for [3H]-PK11195 autoradiography to assess the
numbers of degenerating neurons.

It has been shown that FJ-B staining

correlates to a high degree with silver stains; a traditional marker of neuronal
degeneration (Schmued and Hopkins, 2000a). In this study the time-course of
FJ-B staining in the post-CCI rat brain was found to be different to the timecourse of [3H]-PK11195 binding.

In the cortex a significant amount of FJ-B

staining was seen at 12 hours after injury, but less at 24 hours and 2 days, and
very little staining thereafter. In contrast, [3H]-PK11195 binding begins increasing
in the cortex at 2 days and peaks at 6 days.

58

Figure 2-17 - [3H]-PK11195 binding in the thalamus following a 2 mm CCI

In the thalamic regions, CCI results in significant increases in [3H]-PK11195 binding that persist for at least 21 days.
Unlike other regions measured, there was an increase in [3H]-PK11195 binding between 7 and 21 days post injury. All
data are displayed as means +/- standard deviation, with significant differences from contralateral measurements as
found by Tukey.s HSD shown by asterisks (*p < 0.05, **p < 0.01, ***p < 0.005).
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In the hippocampus numerous FJ-B stained neurons were visible in the
dentate gyrus, CA4 (hilus), and in the CA2/3 field at 12 hours after injury.
Significant numbers of degenerating neurons persisted in the CA2/3 and CA4
regions at the 1 day time-point and at later time points fewer were seen. In
comparison, a large number of FJ-B stained neurons remained visible in the
dentate gyrus at 2, 4 and to a lesser extent 6 days after CCI.

A previous

assessment of FJ-B staining in the hippocampus after CCI using stereological
techniques made similar findings (Anderson et al., 2005). In the dentate gyrus
FJ-B staining was confined to the granule cell layer at all time-points.

The

significant amount of neurons degenerating in this region for a prolonged length
of time could significantly affect cognitive performance of these head injured
animals. In addition to the dentate gyrus, the CA1, CA2/3, and CA4 (hilus) fields
of the hippocampus also contain areas of neuronal degeneration. In the CA1 a
small population of neurons in the medial portion of the field was stained at 12
hours and to a lesser extent at later time points. Then in the CA2/3 field of the
hippocampus a large number of cells are stained starting just 12 hours with the
highest numbers counted 24 hours after CCI.

It has been suggested that

proportionately, the amount of dying neurons in this region of the hippocampus is
greater than any other (Anderson et al., 2005).
Finally, in the thalamus no significant numbers of FJ-B stained cells were
seen until 4 and 6 days after CCI. The presence of degenerating neurons in this
region at these time points lends credence to the hypothesis that the increased
[3H]-PK11195 binding is due to retrograde degeneration of thalamocortical
projections. More FJ-B cells were counted in the thalamus at 4 days than at 6
days, although the difference was not significant. In comparison, [3H]-PK11195
binding increases begin on day 2 and increase at each subsequent time-point.
There was a significant increase in [3H]-PK11195 binding between day 4 and 6
when assessed by Tukey’s HSD (p < 0.01).
In an effort to correlate CD68 staining with [3H]-PK11195 binding we
quantified the numbers of CD68 positive cell profiles in different brain regions. In
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the cortex, as with [3H]-PK11195 binding data, significant increases in the
numbers of CD68 positive cells were found at 4 and 6 days post injury.
Interestingly, a larger number of CD68 positive cells were found on day 4 versus
day 6 after CCI, this may represent a difference in the expression of each of
these markers. In the hippocampus the time points with the most CD68 staining
appeared to be 1 and 2 days post injury. However, staining persisted in all
regions at 4 and 6 days, and overall there were no significant differences
between time-points.

Interestingly the pattern of CD68 staining in the

hippocampus seems to follow the pattern of FJ-B staining, in that an increase in
FJ-B staining at one time-point is followed by an increase in CD68 staining at the
subsequent time-point. This observation was also made in the cortex, where
large numbers of FJ-B staining at 12, 24 and 48 hours is followed by increased
CD68 staining at 24 and 48 hours, and increasing till 4 days post-CCI. Since the
post-CCI cortex contained large numbers of CD68 positive cells and FJ-B
positive neurons, [3H]-PK11195 binding was assessed in this area and correlated
with these markers. While there was no positive correlation of [3H]-PK11195
binding with FJ-B staining, there was a moderate positive correlation with CD68
staining (r = 0.69). By squaring the r-value one can make a crude assessment of
the amount of variation in [3H]-PK11195 binding that CD68 positive cells are
responsible for, in this case ~48%. It is likely that other changes in [3H]-PK11195
binding can be explained by sub-phagocytic activation of microglia, as has
already been suggested (Banati et al., 1997). This fits with our assessment of
CD68 staining in the thalamus, where very few CD68 positive cell profiles were
counted despite the increases in [3H]-PK11195 binding in this region.
Indeed, this previous assessment of [3H]-PK11195 determined that [3H]PK11195 binding was associated with an ‘activated’ microglial phonotype in
addition to the ‘phagocytic’ phenotype without any difference in the binding
density of [3H]-PK11195 (Banati et al., 1997). One might hypothesize that the
neurons in the thalamus are distressed/dysfunctional but not dying at the same
rate as neurons in the cortex or hippocampus.

Therefore, microglia in the

thalamus are becoming activated to provide support to these neurons thereby
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expressing [3H]-PK11195 binding sites. Since the CD68 antigen is a marker of
phagocytic cells it may suggest that [3H]-PK11195 is binding to microglial cells
that are activated, but have not made the transition to a phagocytic phenotype.
A final consideration in these studies pertains to the possibility of
increases in [3H]-PK11195 binding being related to the process of astrocytosis.
Astrocytosis is defined as an activation and accumulation of astrocytes as a
response to injury.

It is a key element of neuroinflammation and as such

increased astrocyte activation and accumulation would be expected to occur at
the same times as increases in microglial activation. Indeed, one previous study
has found a moderate positive correlation of [3H]-PK11195 binding with GFAP
immunoreactivity following CNS injury (Raghavendra Rao et al., 2000). It may
therefore, have been beneficial to perform some co-labelling experiment to
determine the contribution of astrocyte activation to increases in [3H]-PK11195
binding in the CCI model.
In conclusion, this study provides a detailed assessment of [3H]-PK11195
binding following a mild/moderate CCI in rat brain.

The correlation of

[3H]-PK11195 binding with ED-1 immunohistochemistry adds to a growing body
of evidence that this ligand binds to activated microglia and macrophages (Banati
et al., 1997; Myers et al., 1991b; Raghavendra Rao et al., 2000; Venneti et al.,
2007a; Venneti et al., 2008b; Vowinckel et al., 1997). Microglia are the brains’
injury surveillance cells and are very sensitive to tissue damage. When resting
they are observed as having many long thin processes to ‘listen’ for signs of
neuronal distress or death. Upon activation the processes become thicker and
often polarized towards the site of injury. At this point they are believed to begin
expressing the TSPO, most likely on the mitochondrial membrane. Then, if they
receive the appropriate signals they can take on a phagocytic role to clear
cellular debris. It is at this point that they start expressing the CD68 antigen, but
no changes in the level of TSPO expression has been associated with this shift in
phenotype.

Therefore, although PK11195 cannot discriminate between the

62

various activation stages of microglia, it can detect changes in microglial cells
that conventional analysis by CD68 immunohistochemistry cannot.
In addition, our study has highlighted the differences in the timing and
magnitude of the microglial response, and indeed the pattern of neuronal
degeneration following TBI.

This should be an important consideration for

targeting of pharmacological therapies. Moreover, PK11195 represents a useful
marker for the assessment inflammation in animal models and human patients,
and has significant potential for the evaluation of neuroprotective effects of
pharmacological interventions.
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3. CHAPTER 3
Neuroprotective Actions of the Nicotinic Receptor Antagonist
Methyllycaconitine Following Experimental Brain Injury
3.1

Introduction
It is estimated that over 1.4 million Americans experience a TBI every year

(Sosin et al., 1996), however only a small fraction of these individuals sustain a
injury that results in death or significant long term morbidity (Thurman et al.,
1999).

The remaining milder TBI patients also suffer from a wide variety of

neuropsychological, behavioral and cognitive problems.

These deficits are

frequently left untreated, can persist for years following TBI and significantly
detract from the quality of daily life for those affected (Oddy et al., 1985; Rao and
Lyketsos, 2002).
It is well accepted that excessive synaptic levels of the excitatory amino
acid glutamate can lead to a significant increase in neuronal dysfunction and cell
death.

The neurotoxic properties of glutamate are thought to be mediated

primarily through calcium permeable ionotrophic NMDA receptors that are widely
expressed throughout the nervous system (Olney, 1969). After traumatic injury
sustained activation of NMDA receptors increases intra-neuronal calcium,
leading directly or indirectly to mitochondrial impairment, an increase in ROS
production, protein degradation, DNA damage, lipid peroxidation and ultimately
neuronal death by necrosis and/or apoptosis. Thus it is not surprising that NMDA
receptor

antagonists

have

drawn

substantial

attention

as

potential

neuroprotective drugs that could be useful for the CNS disorders involving
excitotoxicity including TBI, spinal cord injury and stroke.

However, human

clinical trials of NMDA receptor antagonists for the acute and/or chronic
treatment of these disorders have consistently ended in failure (Albers et al.,
1999; Bullock et al., 1999; Haley et al., 2005; Ikonomidou and Turski, 2002).
One significant problem with the use of NMDA receptor antagonists for the
treatment of neurotrauma may be an inadequate understanding of the
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therapeutic window of opportunity for successful treatment.

While the acute

actions of NMDA receptor antagonists might block some trauma-induced
excitotoxicity, extended treatment might inhibit other critical functions of
endogenous glutamate, including promotion of synaptic activity, neuronal survival
and cognitive processing (Biegon et al., 2004).

One study found that

administering NMDA itself to mice 24 or 48 hours after head injury improved
cellular and functional outcomes (Biegon et al., 2004), challenging the dogma
regarding NMDA blockers and neuroprotection. Considering the short window of
opportunity of NMDA receptor antagonist treatment and the importance of NMDA
receptor stimulation in synaptic plasticity, an alternative approach to the acute
treatment of TBI might be useful.
Targeting the brain cholinergic system could be one such approach;
persistent deficits in neuropsychological and cognitive function are common
following mild or moderate head injury, and research has supported involvement
of the brain cholinergic system (Dixon et al., 1994b; Dixon et al., 1999; Griffin et
al., 2003; Pike and Hamm, 1997a, b; Pike et al., 1997). Indeed, TBI has been
shown to cause long-term changes in cholinergic function in the brains of both
animals and humans (Dewar and Graham, 1996; Dixon et al., 1995b; Murdoch et
al., 1998).

Previous studies from our laboratory have demonstrated a time-

dependant and consistent loss of α7 nAChR expression in rat cortical and
hippocampal regions following experimental TBI (Verbois et al., 2003a; Verbois
et al., 2002, 2003b; Verbois et al., 2000). The mechanism underlying selective
loss of α7 nAChR expression following CCI remains unknown, but we
hypothesize an elevated level of cholinergic activity immediately following CCI
may play a crucial role. Similar to NMDA receptors, the α7 nAChR has high
permeability to calcium ions (Zhao et al., 2003) and plays a role in hippocampal
dependant cognitive processing. Furthermore, studies support a predominant
presynaptic localization of α7 nAChRs, where they regulate the release of other
neurotransmitters including ACh and glutamate (Albuquerque et al., 1997;
Lagostena et al., 2008; McGehee et al., 1995).
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In the current study we evaluated the neuroprotective properties of the α7
nAChR antagonist MLA.

MLA was originally isolated from the seeds of

Delphinium brownii, and has been found to be a potent inhibitor of α-BTX binding
to nAChRs (Macallan et al., 1988). MLA is one of the most potent diterpenoid
alkaloids found in Delphinium brownii, and is known to cause poisoning of
livestock in the American Midwest due to its’ actions on the neuromuscular
nAChR (Pfister et al., 1999). As a potent and competitive antagonist of the CNS
α7 nAChr, MLA has been found to be neuroprotective in models of β-amyloid and
methamphetamine-induced toxicity (Escubedo et al., 2005; Martin et al., 2004b).
The current study tested the hypothesis that antagonism of α7 nAChRs acutely
following TBI will be associated with improved anatomical, histological and
behavioral outcomes.
3.2

Materials and methods

3.2.1 Animals and surgery
All experiments were conducted in accordance with the guidelines of the
University of Kentucky Institutional Animal Care and Use Committee (IACUC)
that follows the guidelines set forth by the National Institutes of Health guide for
the care and use of laboratory animals. All efforts were made to minimize the
number of animals used in this study and to minimize animal suffering. Male
Sprague-Dawley rats weighing 275-300 g were obtained from Harlan Breeding
Laboratories (Indianapolis, IN) housed 3 per cage and randomly assigned into
five treatment groups (n = 8 per group). Animals were anaesthetized with 3%
isoflorane and immobilized in a stereotaxic frame.

A 6 mm craniotomy was

performed using a Michele trephine just above the somatosensory cortex
(Bregma –2.8, 2.5 mm lateral). The stereotaxic frame was then positioned under
a TBI 0310 impaction device (Precision Systems & Instrumentation, Fairfax
Station, VA) that was used to administer a 1.5 mm cortical deformation at a
velocity of 3.5 m/s (Baldwin et al., 1996; 5 mm impactor diameter). Following the
injury the skull disc was replaced and sealed with dental acrylic. Sham animals
underwent the same procedure with the exception of the administration of the
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cortical contusion injury CCI. Five minutes after surgery the animals were given
an intraperitoneal injection of MLA (1, 5, or 10 mg/kg) or saline; animals received
three additional injections of saline or MLA 8, 24 and 32 hours post-CCI.
3.2.2 Behavioral testing
Cognitive function was assessed on days 11-15 post-CCI, using a
standard MWM procedure (Morris, 1984). The behavioral testing room contained
a circular 150 cm diameter pool with a 13.5 cm diameter submerged escape
platform in the center of one quadrant. Visual cues distributed throughout the
room helped to aid spatial orientation. All cognitive evaluations were videotaped
and analyzed using Videomax software (Columbus Instruments, Columbus, OH).
Quadrant entry was randomized for different starting positions, and animals were
allowed to swim until they found the platform, up to a maximum of 60 seconds.
Rats that were unable to locate the platform in 60 seconds were guided to and
manually placed on the platform, and then allowed observe their position within
the pool 15 seconds. The acquisition phase of MWM testing consisted of four
trials conducted each day for five consecutive days, with a 5 minute inter-trial
interval. Four hours following the last acquisition trial, the platform was removed
and a 30 second memory retention trial was performed. Videomax software was
used to analyze several aspects of each animals search strategy on the retention
trial. MWM acquisition phase data were analyzed using the two-way repeated
measure ANOVA (treatment × day), where the day of training was used as a
repeated measure. A Tukey’s HSD test was used to assess differences between
the individual groups. MWM retention data were analyzed by one-way ANOVA,
and a Tukey’s HSD post-hoc test to determine individual group differences.
3.2.3 Cortical tissue sparing analysis
Following the completion of behavioral testing the animals were
euthanatized and their brains were immediately removed and frozen in
isopentane.

Brains sections (16 µm) were prepared using a Lecia CM1850

cryostat and were mounted onto slides coated with gelatin, chromium potassium
sulfate and poly-L-lysine to ensure tissue adhesion. A cortical tissue sparing
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analysis was performed to assess the potential neuroprotective actions of MLA
administration. Briefly, fourteen equally spaced cryostat sections through the
damaged area were obtained from each animal and stained with cresyl violet.
Images of each stained section were captured and digitized, then, using NIH
image calibrated to measure area, the ipsilateral and contralateral cortices were
outlined separately and measured. The percentage of cortical tissue spared was
calculated by dividing the mean cortical area for the ipsilateral cortex by the
mean cortical area for the contralateral cortex (×100) (Scheff and Sullivan, 1999).
3.2.4 Receptor autoradiography
α7 nAChR density was measured using [125I]-α-BTX autoradiography, as
previously described (Sparks and Pauly, 1999) using a ligand concentration of
2.5 nmol [125I]-Tyr54-α-BTX (PerkinElmer Life Sciences, Inc., Boston, MA; specific
activity = 102.9 Ci/mmol).

Sections adjacent to those used for [125I]-α-BTX

binding were labeled with [3H]-PK11195 to identify the TPSO, formerly known as
the PBR (Papadopoulos et al., 2006a). This protein is thought to be primarily
associated with mitochondrial cholesterol transport in activated microglia.
Previous studies have used autoradiographic localization of [3H]-PK11195
binding to detect the presence of activated microglia as a marker of
neuroinflammation. Briefly, slides were incubated in buffer containing 1 nM [3H]PK11195 for 2 hours, washed in buffer, and dried overnight. RayMax Beta High
Performance Autoradiography Film (ICN Biomedicals Inc., Aurora, Ohio) was
used to visualize the areas of ligand binding.

Radioactive rat brain tissue

standards were included with each film X-ray cassette in order to determine the
response of the film to the increasing amounts of radioactivity. Binding data were
analyzed using NIH image v1.59 on a Power Macintosh connected to a Sony
XC-77 CCD camera via a Scion LG-3 frame-grabber. Molar quantities of bound
ligand were determined by constructing a standard curve from radioactivity tissue
standards fitted to a third degree polynomial curve.

Changes in [125I]-α-BTX

binding following CCI and MLA treatment were quantified in several hippocampal
sub-regions.

[125I]-α-BTX binding data were normalized relative to levels

measured in sham animals since two separate binding experiments had to be
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performed on these sections.

Based on the results from Chapter 2, [3H]-

PK11195 binding was measured in the cortex, the dentate gyrus, the hilus, the
CA1 and CA2/3 fields, and in the lateral dorsal and ventral posterolateral
thalamus. Binding data were analyzed by a 2-way ANOVA where treatment and
hemisphere were the independent variables and binding density the dependant
variable.

Tukey’s HSD post-hoc tests were used when the ANOVA found a

significant overall effect.
3.3

Results

3.3.1 Post-CCI MLA administration produces modest improvement in MWM
performance
Figure 3-1 depicts the acquisition of spatial learning in groups of animals
tested in the MWM following CCI and MLA administration.

ANOVA results

indicated a significant main effects of training day (F(4,112) = 19.65, p < 0.001) and
treatment (F(4,112) = 20.99, p < 0.001), as well as a significant treatment X day
interaction (F(16,112) = 1.76, p < 0.05). Each dose of MLA administered resulted in
a slight decrease in escape latency on each test day of acquisition testing.
However, Tukey’s HSD post-hoc analysis revealed significant group differences
on day 4 of testing only. Compared to CCI animals treated with saline, treatment
with 1 or 5 mg/kg MLA significantly decreased distance traveled to platform on
day 4 of acquisition testing (p < 0.05). However on day 5 of acquisition testing
MLA-treated animals performed much more poorly than would be expected by
the trajectory of learning observed on days 1 to 4. This was unexpected, and the
reasons for this apparent relapse of behavior on day 5 of testing are unclear.
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Figure 3-1 - The effect of MLA treatment on MWM acquisition phase performance

MLA treatment partially attenuates cognitive deficits following CCI in the acquisition phase of Morris water maze
testing. Day 1 represents the day of the first trial and also the 11th day after injury. The mean distance traveled by
animals in each group was calculated and plotted against day of trial (mean ± SD). Animals treated with 1 mg/kg or
5 mg/kg MLA performed better than saline treated animals on day 4 of testing (*p<0.01).
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Four hours following the completion of the acquisition phase of the MWM
test, the platform was removed from the pool and animals swim strategy was
assessed for 30 seconds (Figure 3-2).

One-way ANOVA found a significant

effect of treatment on entries made into target quadrant (F(4,36) = 3.05, p < 0.05),
time spent in the target quadrant (F(4,36) = 3.35, p < 0.05), and distance traveled
in target quadrant (F(4,35) = 4.26, p < 0.01). However post-hoc analysis showed
that sham operated rats performed better than injured animals in each measure,
and there were no improvements associated with MLA treatment. The lack of
clear cognitive enhancement in the retention phase of MWM testing was not
surprising since the performance of these groups in acquisition trials on day 5
was also unexpectedly poor.
3.3.2 Post-CCI MLA administration results in dose-dependent cortical tissue
sparing
One-way ANOVA analysis of cortical tissue sparing data revealed a
significant effect of treatment, F(4,32) = 5.44, p < 0.005; Figures 3-3, 3-4). Fifteen
days following CCI, saline treated animals had 76% of their cortical tissue spared
ipsilateral to the site of impact. In contrast, animals treated 4 times over 2 days
with 1 mg/kg (85%) or 5 mg/kg (87%) MLA has significantly greater tissue
sparing as compared to saline treated animals (p < 0.05). In rats that treated
with the highest dose of MLA, 93% of cortical tissue was spared, which was not
significantly different from estimated cortical volume in sham-operated animals.
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Figure 3-2 - The effect of MLA treatment on memory retention in the MWM
High dose MLA generally impairs memory performance in a 30 second
retention test, conducted one day following the completion of MWM acquisition
training. CCI animals treated with saline surprisingly had only deficits in
distance traversed in the target quadrant (TQ) compared to sham operated
controls (mean ± SD). In contrast animals treated with 5 mg/kg and 10 mg/kg
MLA were significantly impaired compared to sham operated animals in terms
of entries into, time spent in, and distanced traveled in the target quadrant (*p
< 0.05, **p < 0.01). Animals treated with the lowest MLA dose (1 mg/kg)
performed at the same level as sham-operated controls on each measure of
memory retention, and there were no group differences in swim speed.
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Figure 3-3 - Cortical tissue sparing in rats treated with MLA following CCI
There is a dose-related cortical tissue sparing following post-CCI MLA
administration. Saline treated animals had 76% (mean ± SD) cortical tissue
spared (**p < 0.005 versus sham operated animals) compared to 83% sparing
in animals that received 1 mg/kg MLA (*p < 0.05 versus sham operated
animals), 88% sparing after 5 mg/kg MLA (*p<0.05 versus sham operated
animals) and 93% spared following 10 mg/kg (not significantly different from
sham operated controls). Furthermore, the animals treated with 10 mg/kg MLA
had a significantly higher tissue sparing than saline treated animals following
CCI (#p < 0.01).
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Figure 3-4 - Representative images of cresyl violet-stained rat brain sections

Representative nissl-stained tissue sections illustrating dose-related cortical tissue sparing following post-CCI saline or
MLA administration. All images were obtained from the epicenter of the cortical tissue loss in each group
(approximately Bregma -2.8 mm).
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3.3.3 MLA administration exacerbates CCI-induced loss of hippocampal α7
nAChR expression
In saline injected animals, CCI was associated with a significant loss of α7
nAChR expression in the ipsilateral stratum oriens and CA2/3 regions of the
hippocampus (Table 3-1), consistent with previous studies from our lab.
Surprisingly, all animals treated sub-acutely with MLA had significant reductions
in hippocampal α7 nAChR binding. In MLA treated rats, bilateral reductions in
[125I]-α-BTX binding were seen throughout the hippocampus.
3.3.4 Post-CCI administration of MLA reduces regional brain inflammation
Previous studies have shown that CCI produces a widespread and
significant increase in [3H]-PK11195 binding beginning within hours in areas
proximal to the injury, and persisting for days to weeks in brain regions more
distal to the site of injury (Banati et al., 1997; Miyazawa et al., 1995;
Raghavendra Rao et al., 2000). Our analyses focused on hippocampal, cortical
and thalamic neuroinflammation. The cortex adjacent to the impaction site and
the hippocampus have early expression of inflammatory markers following TBI,
and thalamic inflammation is more delayed and may occur only secondary to
cortical tissue encavitation (Chapter 2). Table 3-2 shows the effects of TBI and
MLA administration on changes in the density of [3H]-PK11195 binding
(Representative tissue sections are depicted in Figure 3-5). In saline treated
animals subjected to a 1.5 mm TBI, significant increases in [3H]-PK11195 were
observed on the ipsilateral side of the brain, in each area evaluated (p < 0.001)
consistent with previous studies. Animals treated with the lowest dose of MLA
had no significant changes in regional brain inflammation compared to saline
treated TBI animals, except that a significant increase in [3H]-PK11195 binding
was observed in the laterodorsal nucleus of the thalamus. In comparison, 5
mg/kg and 10 mg/kg MLA both caused a significant attenuation of
neuroinflammation in the somatosensory cortex adjacent to the injury, and the
CA1 and CA2/3 sub-regions of the hippocampus. Post TBI administration of
MLA did not affect [3H]-PK11195 binding in the dentate gyrus of the
hippocampus or thalamus.
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Stratum oriens
Hippocampal CA1
field
Hippocampal
CA2/3 field
Hippocampal CA4
field (Hilus)
Dentate gyrus
(dorsal blade)

1.02±0.09
0.98±0.06

0.84±0.08**,†

0.77±0.28**

0.76±0.28**

0.84±0.28**

0.98±0.22

0.79±0.22**

0.75±0.28**

0.82±0.20**

0.79±0.20**

0.79±0.25**

0.84±0.17**

0.83±0.23**

0.78±0.20**

0.79±0.20**

0.80±0.20**

0.82±0.17**

0.86±0.17**

0.71±0.14**

0.85±0.23**

0.95±0.23

0.86±0.23**

0.85±0.31**

0.86±0.25**

0.86±0.11**

0.98±0.20

0.88±0.17**

0.85±0.25**

0.87±0.23**

10 mg/kg MLA
Contra
Ipsi

1.00±0.21
0.97±0.08
0.88±0.08**,†
0.90±0.22*

0.73±0.22**

5 mg/kg MLA
Contra
Ipsi

0.99±0.15
0.97±0.11
0.94±0.11

0.73±0.25**

1 mg/kg MLA
Contra
Ipsi

0.99±0.12
0.94±0.14
0.90±0.06*

0 mg/kg MLA
Contra
Ipsi

0.99±0.15
0.88±0.11

Sham
Ipsi

0.95±0.15

Table 3-1 - The effect of post-CCI MLA administration on binding density of [125I]-α-BTX in selected brain regions

[125I]-α-BTX binding to α7 nAChRs following CCI and MLA administration. In sham-operated animals there were no
hemispheric differences in the density of [125I]-α-BTX binding, so regional data were averaged (mean ± SD), and the
remainder of the data were expressed as a percent of sham-operated control values. CCI followed by saline
administration resulted in a unilateral deficit in [125I]-α-BTX binding in the stratum oriens, CA2/3 and dorsal blade of the
dentate gyrus. Surprisingly acute post-CCI administration of MLA caused significant bilateral reductions in α7 nAChR
expression in all areas measured, persisting for up to 15 days post-injury.
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Cortex
Hippocampal CA1
field
Hippocampal
CA2/3 field
Hippocampal CA4
field (Hilus)
Dentate gyrus
(dorsal blade)
Dentate gyrus
(ventral blade)
Lateral dorsal
thalamus
Ventroposterolater
al thalamus

Contra
1.02±0.16

Ipsi

0.94±0.16

0.78±0.12

4.85±1.52*

4.19±1.14*

3.44±0.65*

1.05±0.26

0.86±0.17

0.90±0.16

0.99±0.31

4.06±0.86*

5.09±0.97*

4.55±1.18*

3.38±1.37*

3.37±0.69*

1.17±0.15

0.88±0.12

0.80±0.15

0.84±0.12

1.00±0.23

3.34±0.99*

4.64±0.69*

3.27±0.61*†

2.72±1.12*†

2.12±0.83*†

1.38±0.30

1.03±0.26

0.86±0.14

0.90±0.12

0.91±0.16

3.39±1.17*

5.23±1.45*

3.69±1.03*†

3.10±1.28*†

2.29±1.25*†

10 mg/kg MLA
Contra
Ipsi

0.78±0.10
0.82±0.08
0.85±0.15
5.21±1.55*

1.45±0.35

5 mg/kg MLA
Contra
Ipsi

0.79±0.07
0.84±0.08
1.01±0.30
4.02±0.99*

1 mg/kg MLA
Contra
Ipsi

0.81±0.09
0.85±0.08
1.28±0.36

0 mg/kg MLA
Contra
Ipsi

0.83±0.08
1.11±0.11

Sham

1.09±0.11

3.14±0.42*

4.31±1.00*

0.81±0.19

2.48±0.61*

1.63±0.40
2.80±0.57*

0.79±0.15

3.56±0.79*
0.73±0.15

2.42±0.51*

1.30±0.17
3.49±0.79*†

0.66±0.13

3.72±1.21*
0.78±0.14

2.65±0.71*

1.64±0.38

2.75±0.63*

0.67±0.12

4.11±0.73*

0.67±0.12

2.60±0.52*

1.46±0.36

0.73±0.06
0.64±0.06

1.12±0.13

0.72±0.06
0.74±0.07

1.11±0.10

0.73±0.07

Table 3-2 - The effect of post-CCI MLA administration on binding density of [3H]-PK11195 in selected brain
regions

Neuroinflammation following CCI and MLA administration as assessed by [3H]-PK11195 autoradiography. All CCI
animals had significant increases in [3H]-PK11195 binding compared to sham-operated controls (*p < 0.01). However,
animals treated with 5 or 10 mg/kg MLA had significantly less neuroinflammation in several regions evaluated (†p < 0.01
compared to the ipsilateral side in saline-treated controls)
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Figure 3-5 - Autoradiographs of rat brain sections bound with [3H]-PK11195

Representative sections demonstrating [3H]-PK11195 binding in animals treated with saline or MLA following CCI. The
sensitivity of [3H]-PK11195 binding as a marker of neuroinflammation following brain injury is illustrated by the increased
binding seen ventral to the craniotomy site in sham-operated animals (arrow). In CCI-saline animals a highly significant
increase in binding was pervasive in the cerebral cortex, hippocampus, and thalamus. The 5 mg/kg and 10 mg/kg doses
of MLA significantly attenuated TBI-induced increases in neuroinflammation in the cerebral cortex, and the CA fields of
the hippocampus.
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3.4

Discussion
Previous studies from our lab have postulated that α7 nAChR activation

may contribute to calcium-mediated neurotoxicity following TBI.

The high

calcium permeability of α7 nAChR (Gilbert et al., 2009) and their prominent
location in brain regions affected indirectly and directly by TBI make these
receptors plausible targets for neuroprotection. Pharmacological antagonism of
these receptors during the first 32 hours following injury produced some
beneficial results, but other outcome measures were unaffected or exacerbated.
The most consistent outcome measure in this study was cortical tissue sparing,
where post-injury MLA administration was associated with dose dependant
preservation of tissue. In saline treated animals, a 1.5 mm CCI was associated
with loss of 26% of ipsilateral cortical volume, 15 days following the initial
surgery.

Loss of cortical mass was attenuated by post-surgery MLA

administration, with the highest dose (10 mg/kg) producing a level of tissue
sparing that was not significantly different from sham-operated animals.
However neuroprotection evidenced by preservation of cortical mass was
generally not correlated with improved outcomes in the hippocampal-dependant
MWM spatial memory task. In fact animals treated with 10 mg/kg MLA, had the
greatest cortical tissue sparing, but no cognitive improvement compared to CCI
animals treated with saline in the acquisition phase of testing.

Furthermore

animals treated with the higher doses of MLA performed worse than saline
treated CCI rats in the memory retention phase of cognitive testing. The dose
inversion of the MWM results suggests that higher doses of MLA may produce
pharmacological actions that are inconsistent with improved functional outcomes,
in spite of significant cortical tissue preservation.
Studies from the Levin laboratory have conclusively shown that acute,
intracerebral injection of nicotinic receptor antagonists impairs performance in
cognitive tests including the radial arm maze. When the α4β2 nAChR antagonist
dihydro-β-erythroidine (DHβE) or MLA were injected into the basolateral
amygdala or ventral hippocampus, cognitive deficits were observed (Addy et al.,
2003; Nott and Levin, 2006). There were no additive effects of DHβE and MLA
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when administered simultaneously, however DHβE co-administration prevented
the amnestic actions of MLA delivered into the ventral hippocampus, suggesting
a more complicated interaction between nicotinic receptor subtypes and
regulation of cognitive function.

Also in the Levin studies, behavioral

performance was assessed 10 minutes following injection of nAChR antagonists.
In our experiment, rats received 4 injections of MLA in the first 32 hours following
experimental injury, and no further drug treatments. Behavioral testing ensued 9
days later, and continued across days 11 to 15 post-injury. Since the half-life of
MLA is only approximately 20 minutes in rodents (Stegelmeier et al., 2003; Turek
et al., 1995) it seems highly unlikely that residual MLA caused cognitive
impairment by direct blockade of α7 nAChRs.

However long-term functional

changes in nicotinic receptor sensitivity following acute administration of nAChR
antagonists are not without precedence. Several studies have previously shown
that a single injection of the nicotinic receptor antagonist chlorisondamine blocks
the actions of a nicotine challenge dose for up to 5 weeks, or more (Clarke, 1984;
el-Bizri and Clarke, 1994). Thus it is possible that the nAChR blocking actions of
MLA greatly outlast receptor occupancy, and confounded the MWM results in our
study, particularly at the higher doses that were employed. Another surprising
action of MLA that was observed in these studies was a persistent down
regulation of hippocampal α7 nAChR expression. In saline treated animals, 1.5
mm CCI caused ipsilateral down-regulation of α7 nAChR expression in the
stratum oriens, CA2/3 and the dentate gyrus, consistent with previous findings
from our lab (Verbois et al., 2003a; Verbois et al., 2002, 2003b; Verbois et al.,
2000).

Each dose of MLA administered caused a bilateral decrease in

hippocampal α7 nAChR expression that persisted for up to 13 days following the
last MLA injection. However [125I]-α-BTX deficits caused by MLA administration
were generally not dose-dependent.
Interestingly in spite of MLA-associated deficits in α7 nAChR expression,
each dose of MLA administered to rats after trauma was associated with some
degree of improvement in the acquisition phase of MWM testing. This effect was
most pronounced in rats given 1 mg/kg MLA on the fourth day of testing. On the
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same day rats administered 5 mg/kg MLA showed some improvement over
saline animals, and the 10 mg/kg MLA group did not perform significantly better
than saline-injected animals. This inverse-dose response suggests that while 1
mg/kg MLA is therapeutic, higher doses of MLA are detrimental to the function of
neurons involved in acquisition of the MWM task. It is possible that the higher
doses of MLA impeded the recovery of neurons by inhibiting basal levels of
signaling required for survival or for the induction of LTP. On the fifth day of
testing there were no significant differences in performance of MLA-treated
animals versus saline-treated animals. MLA treated animals took longer to find
the platform [data not shown], and traveled further around the pool before finding
the escape platform. There is no obvious explanation for this sudden relapse in
performance. Coincidentally, the animals also performed poorly on the memoryretention phase of the MWM that was carried out later on the same day. In this
phase of the MWM the search strategy of each animal was assessed without the
submerged platform for 30 seconds. The distance traveled in, entries into, and
time spent in the quadrant of the pool that had contained the platform were
measured. Sham animals performed well by all measures, and saline treated
CCI animals performed poorly as expected. Unexpectedly, animals which had
received MLA injections did not perform any better than saline-treated controls.
The apparent lack of effect of MLA in this memory retention task could be linked
to the poor performance of these animals on the fifth acquisition trial carried out
on the same day.
In contrast to the inverse-dose response found in the MWM, cortical tissue
sparing analysis revealed a direct relationship between dose and tissue sparing.
Indeed, the 10 mg/kg dose of MLA spared 93% of cortical tissue; a figure that
was not significantly different from sham-operated animals. A dose of 5 mg/kg
spared 88% of cortical tissue, 1 mg/kg spared 84%, and saline spared 76%.
Clearly MLA is sparing cortical neurons in a dose dependant manner.

We

believe this effect is due to the inhibition of the α7 nAChRs by MLA, since the
reduced calcium flow into cells expressing these receptors will attenuate the
calcium load and protect them from cellular death.
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The lack of concordance between the dose response curves for tissue
sparing and cognitive recovery in the MWM was intriguing. Animals given 1 or 5
mg/kg of MLA performed better than animals that received a dose of 10 mg/kg,
while the highest level of tissue sparing was achieved in animals that received
the highest dose of MLA. While the highest dose may protect neurons from
excitotoxicity, it may also cause long-term changes in neuronal function that
affect the learning and memory process. Importantly, it should be noted that the
MWM is a hippocampal dependant task (Liang et al., 1994) and that we only
measured tissue loss in the cerebral cortex. The use of a cortical-dependant test
such as pre-pulse inhibition could have yielded a positive correlation between
functional and tissue sparing results.
Autoradiographic study of TSPO expression (a marker of inflammation
and cellular damage) revealed a marked increase in [3H]-PK11195 binding in the
ipsilateral cortex, hippocampus and thalamus of all injured animals. However,
treatment with 5 and 10 mg/kg MLA significantly reduced binding in the CA1,
CA2/3 and cortex. This reduction corresponds well with results from the tissue
sparing analysis, supporting the notion that inhibition of the α7 nAChR by MLA is
protecting cells from apoptosis and necrosis. In contrast to the attenuation of
[3H]-PK11195 binding in the cortex and hippocampus, no measurable effect of
MLA was found in the thalamus. This could merely be a timing issue, since
increases in thalamic [3H]-PK11195 binding are delayed compared to those in
the cortex and hippocampus (Chapter 2). Elevated [3H]-PK11195 binding first
appears in the thalamus about 3 days after injury and may still be increasing 2
weeks after injury.

It is possible that any changes in thalamic binding of

[3H]-PK11195 would not be seen until later time points.
Our results show that MLA attenuates cognitive deficits following CCI,
spares tissue, and reduces tissue damage as assessed by [3H]-PK11195
binding. While these actions are most likely to be mediated via the α7 nAChR, it
should be noted that MLA has affinity for other nicotinic subunits including α3 and
α6 (Anderson et al., 2008; Mogg et al., 2002). Furthermore, MLA has a relatively
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large molecule with an atomic mass of 683, so there are some questions about
its ability to cross the BBB.

To date there has only been one detailed

pharmacokinetic analysis of plasma and brain levels of MLA following
intravenous or intraperitoneal administration (Turek et al., 1995). In this study
peak plasma levels of MLA were attained approximately 15 minutes following IP
MLA administration, and brain levels peaked about 15 minutes later. Brain levels
of MLA were approximately 95% lower than that observed in plasma, indicating
minimal BBB penetration. However, we were undeterred by these results since
CCI is known to cause transient and delayed opening of the BBB (Baldwin et al.,
1996). The primary insult leads to a compromise of the BBB from the time of
impact until about 3 hours post-injury. The BBB then opens again between 12
and 48 hours after injury, possibly caused by a secondary wave of brain damage
(Baldwin et al., 1996).
Another consideration in this study is the possibility of MLA acting
indirectly via the cerebrovascular response to generate positive functional
outcomes. For example, stimulation of basal forebrain cholinbergic receptors
can increase cerebral cortical blood flow (Linville et al., 1993). In addition, there
is some evidence to suggest that acetylcholine receptors located on the vessel
walls could modulate vascular tone, though current data support a role for
muscarinic receptors only (Elhusseiny and Hamel, 2000).

However, the

expression of α7 nAChR on cortical vessel walls has been demonstrated (Clifford
et al., 2008), so a role in regulation of cerebral blood flow cannot be ruled out.
Control of cerebral blood flow via these mechanisms by a nicotinic antagonist
and resultant changes in the supply of oxygenated blood could potentially effect
outcome from CCI.
An additional concern in the use of MLA is inhibition of a cholinergic antiinflammatory pathway (Wang et al., 2003). Electrical stimulation of the vagus
nerve has been shown to cause a significant decrease in tumor necrosis factor
(TNF) release from macrophages, which express α7 nAChRs; the effects of
vagal activation were blocked by administration of MLA and absent in α7 nAChR

83

knockout mice.

More recently it has been found that in the CNS microglia

express α7 nAChRs and that exposure to ACh or nicotine reduces inflammatory
markers following the administration of lipopolysaccharide (Shytle et al., 2004).
α7 nAChR antagonists attenuated the effects of nicotine and ACh, directly
implicating the α7 nAChR as a mediator of these responses. Thus α7 nAChRs
are key players in the cholinergically mediated anti-inflammatory pathway in the
periphery and CNS, and MLA inhibition of this system might limit the usefulness
of this compound, especially in long-term studies.
Taken together, these results show that blockade of α7 nAChR stimulation
immediately following CCI can be neuroprotective. This is the first study aiming
to assess the effects of MLA in an in vivo animal model of TBI; some important
issues have been raised. The validation of our hypothesis relies on MLA being
administered early in the acute phase of injury in which cholinergic activity is
elevated. In rat brain the acute period of cholinergic excitotoxicity appears to be
followed by a more chronic period of cholinergic hypofunction (DeAngelis et al.,
1994; Dixon et al., 1994a; Dixon et al., 1995a; Dixon et al., 1996; Dixon et al.,
1997; Saija et al., 1988).

The precise timing of the post CCI-changes in

cholinergic activity have yet to be fully elucidated. The first MLA injection was
administered immediately following surgery, and then subsequent injections were
administered at 8, 24 and 32 hours thereafter. It is possible that the window of
opportunity for efficacious MLA treatment is relatively short and that
administering drug at later time-points is detrimental to neuronal survival. An
improved understanding of the time frame of cholinergic hyperactivity is required
to guide future cholinergic treatment regimens.
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4. CHAPTER 4
Alpha-7 Nicotinic Acetylcholine Receptor Partial Agonists Improve
Functional Outcome Following Controlled Cortical Impact in the Rat
4.1

Introduction
Increased public awareness of TBI has been brought about in recent

years by the wars in Afghanistan and Iraq (Galarneau et al., 2008). While reports
are widespread on the effects of TBI on the many soldiers and civilians who are
victims of improvied explosive devices (IEDs), many more people fall victim to
TBIs each year in the USA as a result of motor vehicle accidents or falls
(Langlois et al., 2006).

The vast majority of TBI sufferers recover from the

physical effects of their injuries, but many are left with significant behavioral,
emotional, and cognitive deficits that remain untreated (Corrigan et al., 2004;
Resch et al., 2009). These deficits often result in significant reductions in quality
of life measures for patients, place a great burden on families and care-givers,
and make the transition back into the workforce very difficult (Oddy et al., 1985;
Rao and Lyketsos, 2002). Despite an estimated 1.5 million people suffering a
TBI in the USA alone each year (Sosin et al., 1996; Thurman et al., 1999), and
the huge financial burden imposed by this condition, there is no pharmacological
treatment for TBI. There is a great need for new and novel approaches aimed at
reducing secondary damage and improving functional and cognitive outcomes.
While there has been widespread interest in researching the role of
excitatory amino acids (EAAs) in brain injury, the roles played by nAChRs have
been largely ignored until recently. These receptors are known to be widely
distributed and highly expressed in the brain (Sargent, 1993), and are intimately
involved in cognition and other neurobiological processes (Kadir et al., 2006).
Among nAChRs, the α7 nAChR is of particular interest due to its high levels of
expression in the hippocampus; a region known to be vitally important for
learning and memory, and also very sensitive to brain injury related pathology
(Verbois et al., 2000). Furthermore, the α7 nAChR possesses a uniquely high
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permeability to calcium ions (Delbono et al., 1997), which play a significant role in
the well characterized secondary injury cascades. Studies into the expression of
the α7 nAChR in AD and Parkinson’s disease have demonstrated a decreased
α7 nAChR expression with increased severity of disease (Perry et al., 2000;
Schmaljohann et al., 2004; Wevers et al., 1999).
Our laboratory has been investigating the potential role played by the α7
nAChR in brain injury induced post-traumatic cognitive impairment. Initial studies
found that the α7 nAChR is particularly sensitive to experimental brain injury and
exhibits significant reductions in expression in several brain regions that can
persist for weeks after injury (Verbois et al., 2002; Verbois et al., 2000). These
significant reductions in α7 nAChR expression were of particular interest because
the α7 nAChR deficit was of greater magnitude than the NMDA receptor deficit
after injury (Verbois et al., 2000). Twice-daily nicotine administration following
experimental brain injury attenuated some cognitive deficits in animals subjected
to brain injury, but did not normalize deficits in α7 nAChR expression (Verbois et
al., 2003a). In a separate experiment chronic nicotine infusions were associated
with an increase in post-surgical convulsions, and failed to spare cortical tissue
(Verbois et al., 2003b).
It is thought that immediately after a brain injury there is a period of
increased extracellular ACh and excessive cholinergic receptor stimulation (Saija
et al., 1988).

The excessive entry of cations into neurons overloads natural

buffering systems and leads directly or indirectly to necrotic or apoptotic cell
death. We have shown that targeting the initial period of elevated cholinergic
activity with an α7 nAChR antagonist results in significant tissue-sparing and a
modest improvement in cognitive performance (Chapter 3). At some-point after
injury there is a transition to a more chronic hypocholinergic state (Arciniegas,
2003).

Studies in our lab have shown that animals maintained on a diet

containing choline, a selective α7 nAChR agonist, showed modest improvements
in MWM performance, increased tissue-sparing, and reduced brain inflammation
compared to rats on normal chow (Guseva et al., 2008).
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The studies in Chapter 3 of this dissertation showed some beneficial
effects of short-term treatment with nicotinic antagonists following CCI. Other
studies from our laboratory have shown that long-term dietary supplementation
with the low affinity, but selective α7 nAChR full agonist choline, results in
neuroprotection (Guseva et al., 2008). However, the most efficacious time-points
for administration of these compounds remains to be elucidated, and beyond the
technical expertise of our research group. While a detailed analysis of post-CCI
cholinergic activity in rats could be useful for these rodent studies the timecourse may not accurately reflect the time-course in human head injury. Indeed,
the failures of several NMDA antagonists in clinical trials for TBI have been
blamed in part on poorly predicted therapeutic windows in human versus rodent
TBI (Albensi et al., 2004; Muir, 2006). A potential solution to the animal versus
human therapeutic “window of cholinergic hyper/hypofunction” conundrum may
be to administer a partial agonist. A partial agonist is simply an agonist that
binds to a receptor but only has partial efficacy (compared to the full agonist of
that receptor).

Theoretically, in the presence high concentrations of the

endogenous full agonist ACh, a partial agonist would serve as a “functional”
antagonist of α7 nAChR, possibly contributing to an attenuation of calcium
mediated excitotoxicity. Conversely, when endogenous levels of ACh are low, a
partial agonist would provide some level of receptor agonism.
The administration of a partial nAChR agonist during the initial period of
hypercholinergic activity could be neuroprotective. A high affinity partial agonist
would compete with ACh for binding sites, but because it lacks full efficacy would
lead to a relative reduction in the activation of receptors. At later time-points
when there is a deficit in cholinergic signaling, a partial agonist may help to
maintain α7 nAChR cholinergic signaling. Although a partial agonist may not be
as effective as targeting a full antagonist to the period of hypercholinergic activity,
and treating the deficit with a full agonist, it negates the need for these
treatments to be carefully timed to avoid exacerbating the condition.
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In this study we assessed the neuroprotective and cognitive-enhancing
potential of

three α7 nAChR partial agonists tropisetron (Navoban®),

ondansetron (Zofran®), and DMXB-A (also known as GTS-21) in TBI.
Tropisetron is best known for its use as an anti-emetic following chemotherapy,
and acts by antagonizing 5-HT3 receptors in the chemoreceptor trigger zone
(CTZ). In addition to its action on 5-HT3 receptors, tropisetron has been found to
have a high affinity for α7 nAChRs at which it acts as a partial agonist (Macor et
al., 2001).

Ondansetron is another 5-HT3 antagonist which acts as a partial

agonist at α7 nAChRs, but with much lower affinity (Macor et al., 2001).
Ondansetron is also used to reduce nausea and vomiting in chemotherapy
patients (Framarino dei Malatesta et al., 1995).

A lot of interest currently

surrounds the potential of DMXB-A to treat the symptoms of schizophrenia via its
actions on the α7 nAChR (Freedman et al., 2008; Martin et al., 2004a; Olincy and
Stevens, 2007). It is also being investigated for treatment of AD (Kem, 2000;
Wei et al., 2005).
Given the beneficial effects of α7 nAChR agonists and antagonists in TBI
we hypothesize that a partial agonist of the α7 nAChR will be neuroprotective
and improve functional outcomes following brain injury.

The need for a well

defined therapeutic window is negated by the partial agonist’s ability to reduce α7
nAChR activation immediately after injury, while maintaining some cholinergic
activity at later time points. To test this hypothesis we began by assessing the
effect of post-CCI tropisetron treatment on MWM performance, tissue sparing,
and neuroinflammation. We then tested two other α7 nAChR partial agonists in
the same paradigm in order to demonstrate the therapeutic potential of α7
nAChR partial agonists following brain injury.
4.2

Materials and methods

4.2.1 Animals and surgery
All experiments were conducted in accordance with the guidelines of the
University of Kentucky Institutional Animal Care and Use Committee (IACUC),
which follow the guidelines set forth by the National Institutes of Health guide for
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the care and use of laboratory animals. All efforts were made to minimize the
number of animals used in this study and to minimize animal suffering.
4.2.1.1 Experiment 1 – Post-CCI tropisetron administration
A total of 35 male rats were obtained from Harlan Breeding Laboratories
(Indianapolis IN) for the experiments. Sprague-Dawley rats weighing 275-300 g
were divided into 4 groups (8-10 animals per group). All animals underwent
surgery to administer a CCI of moderate severity as described previously
(Verbois et al., 2000). Briefly, animals were anesthetized in 5% isofluorane and
placed in a Kropf stereotaxic frame (David Kopf Instruments, CA), then
maintained at 2.5% isofluorane for the rest of the surgical procedures.

A

longitudinal incision was made to expose the skull, and a 6 mm diameter
craniotomy was made using a Michelle trephine laterally, midway between
bregma and lambda. The animal was then placed beneath the CCI device and
oriented so that the impactor tip was aligned with the craniotomy. A calibration
was the performed to accurately set the position of the dural membrane and the
device was programmed to perform a 1.5 mm deformation of the cortex at 3.5
m/s with a dwell time of 400 ms. Following impact, the animal was removed from
the device and a piece of Surgiseal was placed on the wound. The skull disk
was then replaced and sealed with dental acrylic before stapling the wound
closed.

Immediately after surgery the animals received 1, 2, or 5 mg/kg

tropisetron (Sigma-Aldrich, MO), or saline via i.p. injections. Animals received
additional injections of tropisetron or saline 3, 24, 27, 48, 51, 72, and 75 hours
later. This dosing regimen was selected to target the initial period of cholinergic
hyperactivity, and to coincide with the increases in microglial activation in all
brain regions assessed in Chapter 2. Behavioral testing began one day after the
last injection had been administered. The doses of tropisetron administered in
this experiment were selected based on previously published data in rodents
(Candelario-Jalil et al., 2008). In this study sham-operated animals were not
included in the interest of reducing animal usage and because our aim was to
demonstrate an enhanced cellular and functional recovery versus saline-treated
animals.
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4.2.1.2 Experiment 2 – Post-CCI Ondansetron and DMXB-A treatment
In addition to the groups described above, a further 14 male rats were
obtained from Harlan Breeding Laboratories (Indianapolis IN) for this experiment.
Rats weighing 275-300 g were divided into 2 groups (7 animals per group) and
underwent surgery to administer a CCI of moderate severity as described above.
Ondansetron (2 mg/kg) (Sigma-Aldrich, MO) or DMXB-A (10 mg/kg) (kindly
provided by Dr. William Kem, University of Florida) was administered at 0, 3, 24,
27, 48, 51, 72, and 75 hours after CCI. Doses of these drugs were selected
based on previous studies demonstrating beneficial effects in rodents (Fontana
et al., 1995; Kem, 2000).
4.2.2 Behavioral testing
The MWM was used to assess cognitive performance in all animals
following CCI (Brandeis et al., 1989; Vorhees and Williams, 2006). Acquisition
testing began in the MWM 4 days after surgeries and continued for a total of 4
days, with a ‘retention’ test carried out on the fifth day. The test room contained
a 1.5 m diameter black plastic pool approximately 60 cm deep, filled with water to
a depth of 30 cm. The pool was arbitrarily divided into 4 quadrants by assigning
the points N, E, S, and W at equidistant points around the circumference of the
pool.

In the NE quadrant a 13.5 cm diameter platform was hidden by

submerging it approximately 1 cm below the water’s surface. The addition of
black water-based powder paint to the water helped to conceal the platform from
view and improved the contrast of the animal in the pool. Visual cues were
placed around the pool to enable the rats to orient themselves within the pool
and facilitate spatial learning. All tests were recorded on a digital camera placed
above the pool and analyzed with Videomex software (Columbus Instruments,
Columbus, OH).
Each trial consisted of placing the animals one at a time in the pool at a
randomly assigned point of the circumference (N, E, S, or W). The animal was
allowed to swim until it found and climbed onto the hidden platform, or until 60
seconds had passed. At this point any animal that had not found the platform
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was placed onto the hidden platform and was allowed to remain on the platform
for 15 seconds to gain awareness of the platform’s location. The rat was then
returned to its home cage for 5 minutes and then tested again. A total of 4 such
trials were carried out each day for 4 days to assess learning and memory.
Although there was no significant difference in the swim speed of animals in each
group the distance each animal traveled to the platform from the edge of the pool
was used as a measure of performance to nullify possible intra-animal
differences.
On day 5 of cognitive testing the platform was removed from the pool and
each animal was placed at the SW edge of the pool and allowed to swim for 60
seconds. This test is used to assess the animal’s search strategy and therefore
memory retention. Measures of performance in the retention test were ‘distance
traveled in target quadrant’, ‘time spent in target quadrant’, and ‘entries made
into target quadrant’.
4.2.3 Cortical tissue sparing analysis
Following completion of the MWM testing animals were euthanatized by
rapid decapitation. The brains were quickly removed, frozen in isopentane, and
stored at -80˚C until further processing could be performed. The brains were
sliced on a Leica 1850 cryostat (Nussloch, Germany) at 16 μm thick and
mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA). Eight serial
sets of sections were cut for each brain to enable comparisons to be made
between subsequent autoradiographical and staining procedures.

For tissue

sparing analysis a set of slides were stained with Cresyl Violet to visualize cell
bodies and enable assessment of spared tissue (Scheff and Sullivan, 1999).
Analysis was performed with ImageJ v1.34 (National Institutes of Health, MA)
calibrated to measure area.

Twelve equally spaced sections throughout the

lesion were chosen for analysis. In each section the area of the ipsilateral and
the contralateral cortex were measured separately and averaged over the 12
sections. To calculate tissue sparing, the area of the ipsilateral cortex remaining
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was divided by the area of the contralateral cortex and multiplied by one
hundred.
4.2.4 Receptor autoradiography
Autoradiography was used to assess nicotinic receptor expression and
neuroinflammation/microglial activation following experimental brain injury and
drug treatment. Slides were removed from the freezer and thawed overnight in a
desiccator at 4˚C. For assessment of α7 nAChR expression [125I]-α-BTX binding
was carried out as previously described (Sparks and Pauly, 1999) using 2.5 nM
of [125I]-Tyr54-α-BTX (PerkinElmer Life Sciences Inc., Boston, MA). A ligand of
the TSPO, [3H]-PK11195 was used to assess neuroinflammation following injury.
PK11195 binding has been shown to correlate well with the activation of
microglia and macrophages (Stephenson et al., 1995; Vowinckel et al., 1997),
which in turn are useful indicators of tissue damage and repair. Briefly, slides
were pre-incubated in 50 mM Tris-HCl buffer for 15 minutes at 4˚C, and then
transferred to fresh buffer containing 2 nM [3H]-PK11195 (PerkinElmer Life
Sciences Inc., Boston, MA) for 2 hours at 4˚C. Slides were then washed, and
dried overnight before being exposed to RayMax Beta High Performance
Autoradiography Film (ICN Biomedicals Inc., Aurora, Ohio) for 8 weeks.
4.2.5 Analysis of autoradiographs
Films were imaged using a Northern Lights trans-illuminator with a
monochrome digital camera (a CFW-1310M, Scion Corp) mounted directly
above. Settings on the lightbox and camera were adjusted to produce a high
resolution image with the best possible contrast and then left unchanged during
subsequent image captures.

Images were captured on an iMac G5 using

Visi-capture software (Scion Corp.) and saved as lossless TIFF files. Images
from the same animal were combined into image ‘stacks’ without modification of
individual images using ImageJ for ease of storage and analysis. Image stacks
were analyzed with ImageJ v1.34 with the ‘Measure Stack’ plug-in (OptiNav Inc.,
Bellevue, WA). Briefly, the area of interest was outlined on each slice in the
stack and then the mean pixel value was measured for each slice. An average
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pixel value for each region was then calculated for every animal in the study.
Binding in each ipsilateral region was expressed as a percentage of the same
region in the contralateral hemisphere. Based on the results from Chapter 2,
[3H]-PK11195 binding was measured in the cortex, the dentate gyrus, the hilus,
the CA1 and CA2/3 fields, and in the lateral dorsal and ventral posterolateral
thalamus.
4.3

Results

4.3.1 Tropisetron improves MWM performance
Four days following CCI the rats began testing in the MWM to assess their
spatial memory performance (Figure 4-1). Two-way ANOVA analysis of the data
revealed a significant effect of treatment (F[3,119] = 8.34, p < 0.001) and day (F[3,
119]

= 18.75, p < 0.001), but no significant interaction (F[9,119] = 1.00, p = 0.45).

On average, saline-treated animals performed worse on all days, traveling further
in the pool before reaching the platform than any other group. All treated animals
had shorter path-length traces for every day of the test, but only animals
administered 2 mg/kg tropisetron performed significantly better than salinetreated controls.

Post-hoc analysis using Tukey’s HSD test showed that on

days 3 and 4 of testing, animals treated with 2 mg/kg tropisetron performed
significantly better than saline controls (p < 0.01).
Analysis of memory retention-test data did not reveal conclusive evidence
of improved memory retention in any group (Figure 4-2).

Overall, one-way

ANOVA found a significant difference between groups in terms of distance
traveled in target quadrant (F[3,32] = 4.03, p = 0.016), entries made into the target
quadrant (F[3,32] = 4.71, p = 0.008), and time spent in target quadrant (F[3,32] =
1.62, p = 0.203). Despite their performance in the acquisition phase of the test,
animals treated with 2 mg/kg of tropisetron only performed marginally better than
saline-treated animals in terms of distance traveled in the target quad, and the
difference was non-significant.
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Figure 4-1 - The effect of α7 nAChR partial agonist treatment on MWM
acquisition performance
Cognitive performance of each animal was assessed in the MWM beginning 4
days after injury. Partial agonist treatment reduced distance traveled to
platform versus saline treatment on all days. A significant effect of 2 mg/kg
tropisetron treatment was observed on days 3 and 4. Data have been plotted
as means plus or minus standard deviations (n = 8). Data-points have been
slightly displaced for clarity and do not represent different testing times. An
asterisk represents a significant difference from saline-treated controls as
determined by Tukey’s HSD (*p < 0.01).
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Figure 4-2 - MWM retention task in brain injured animals treated with
Tropisetron
Spatial memory retention was assessed in injured animals by analyzing various
parameters of their search strategy after the escape platform had been
removed. Mean values are plotted for each group with bars representing the
standard deviation of the sample (n = 8). Despite an overall effect of treatment
found by one-way ANOVA, Tukey’s HSD tests did not reveal any differences
between saline treated animals and tropisetron treated animals. There was no
significant difference in the swim speeds of animals between treatment groups.
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4.3.2 There is no clear effect of tropisetron treatment on tissue sparing
Following completion of behavioral testing the rats were euthanatized and
their brains removed and processed for histological analysis (Figure 4-3). Cresyl
violet stained sections were used for assessment of cortical tissue sparing.
There was a slight trend for animals treated with 2 mg/kg tropisetron to exhibit
higher tissue sparing than saline-treated controls. However, one-way ANOVA
reported no significant difference between groups (F[3,36] = 2.32, p = 0.094).
4.3.3

Post-CCI tropisetron does not have an effect on α7 nAChR expression
For analysis of [125I]-α-BTX autoradiographs the binding density in the

contralateral hemisphere was used as a baseline to which the effect of injury in
the ipsilateral (injured) hemisphere was compared. Binding in each brain region
was therefore expressed as a proportion of the binding density in the
contralateral hemisphere so that each brain acted as its own control (Table 4-1).
One-way ANOVA did not report a significant effect of post-CCI tropisetron
treatment on α7 nAChR expression in any of the regions analyzed.

Further

analysis of the data using one-sample t-tests to determine differences between
ipsilateral means and the theoretical contralateral mean binding density (100%)
revealed significant reductions in the hilus and superior colliculus (p < 0.05) of
saline treated animals.
4.3.4 No effect of α7-nAChR partial agonist tropisetron on [3H]-PK11195 binding
As with the [125I]-α-BTX binding data, [3H]-PK11195 binding was
expressed as a proportion relative to the contralateral side of each brain (Table
4-2). Analysis of these data by one-way ANOVA failed to find a significant effect
of tropisetron treatment on [3H]-PK11195 binding in any brain region. However,
as expected there were very significant increases in [3H]-PK11195 binding in all
ipsilateral regions compared to contralateral (control) regions (assessed by t-test,
p < 0.01 in every region).

96

Figure 4-3 - Cortical tissue sparing following CCI and tropisetron
treatment
There was no significant effect of treatment on cortical tissue sparing measured
9 days after CCI. Saline-treated controls had a 79% tissue sparing, and
although 2 mg/kg tropisetron resulted in 88% tissue sparing, analysis of the data
by one-way ANOVA reported no effect of treatment. Data are plotted as mean ±
standard deviation (n = 8).

97

Superior colliculus

Dentate gyrus (lateral blade)

Hippocampal field CA4 (Hilus)

Hippocampal field CA2/3

Hippocampal field CA1

Stratum oriens

Cortex layers 1-4

0.97±0.02*

0.95±0.05

0.94±0.03*

0.97±0.05

0.97±0.07

0.98±0.07

0.97±0.08

Saline

0.96±0.04

0.99±0.04

0.95±0.08

0.95±0.07

0.99±0.04

0.92±0.08*

1.05±0.10

1 mg/kg
Tropisetron

0.98±0.03*

0.92±0.05*

0.95±0.07*

0.96±0.05*

0.98±0.07

0.97±0.07

0.97±0.07

2 mg/kg
Tropisetron

0.95±0.05

0.95±0.05*

0.91±0.05*

0.94±0.10

0.93±0.12

0.97±0.09

0.96±0.03*

5 mg/kg
Tropisetron

Table 4-1 - The effect of CCI and tropisetron treatment on α7 nAChR expression in the cortex and hippocampus

[125I]-α-BTX binding density was measured in both ipsilateral and contralateral regions of the cortex and hippocampus in
order to assess post injury α7 nAChR expression and any possible effects of tropisetron treatment. Since more than one
binding was performed data for the ipsilateral (hit) side were expressed as a proportion of the contralateral binding
density. In this way each brain served as its own control. One-way ANOVA did not find any effect of treatment on α7
nAChR expression. Significant reductions in α7 nAChR expression in the ipsilateral hemisphere versus a theoretical
mean of 1 are signified with an asterisk (*p < 0.05).
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Thalamus (Ventral posterolateral)

Thalamus (Lateral dorsal)

Dentate gyrus (lateral blade)

Hippocampal field CA4 (Hilus)

Hippocampal field CA2/3

Hippocampal field CA1

Cortex

2.38±0.74

2.40±0.81

2.16±0.48

3.42±0.80

3.10±1.51

2.34±0.82

1.93±0.65

Saline

2.37±0.46

2.84±0.44

2.72±0.34

4.29±0.81

3.99±0.93

2.95±0.76

2.21±0.31

1 mg/kg
Tropisetron

1.89±0.38

2.07±0.48

2.14±0.57

3.40±1.29

2.58±1.29

2.18±0.95

1.75±0.52

2 mg/kg
Tropisetron

2.71±0.31

2.76±0.62

2.58±0.43

4.06±0.82

3.80±0.68

3.17±0.71

2.03±0.58

5 mg/kg
Tropisetron

Table 4-2 - Effect of injury and post-CCI tropisetron treatment on [3H]-PK11195 binding in the cortex,
hippocampus and thalamus

Data are presented are binding in ipsilateral regions expressed as a proportion of the binding density in the corresponding
contralateral region. Binding density in the ipsilateral hemisphere was increased in all regions analyzed, however,
tropisetron treatment did not have any significant effect on [3H]-PK11195 binding when compared to saline.
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4.3.5 Animals treated with other α7 nAChR partial agonists after CCI show
modest improvement in the MWM
Two other α7 nAChR partial agonists; DMXB-A and ondansetron were
tested for efficacy in this model. In the MWM acquisition phase animals treated
with either partial agonist traveled a shorter distance to the platform on every day
of the test (Figure 4-4).

Two-way ANOVA revealed a significant effect of

treatment (F[2,78] = 6.28, p < 0.005) and test-day (F[3,78] = 13.45, p < 0.001) on the
distance travelled, but no significant interaction term (F[6,78] = 0.47, p = 0.83).
Post-hoc analysis by Tukey’s HSD revealed that on the fourth day of testing
animals treated post-CCI with DMXB-A traveled a significantly shorter distance tp
the platform than saline-treated animals (p < 0.05).
In the memory retention test (Figure 4-5) one-way ANOVA returned a
significant effect of treatment with regard to both distance traveled in the target
quadrant (F[2,19] = 4.57, p < 0.05) and entries made into the target quadrant (F[2,19]
= 9.19, p < 0.005). Animals treated with DMXB-A traveled significantly further in
the target quadrant than saline-treated animals (Tukey’s HSD, p < 0.05).
However, when entries into the target quadrant and time spent in the target
quadrant were analyzed DMXB-A treated animals did not perform significantly
better than saline-treated controls. Also of note is the fact that ondansetrontreated animals performed significantly better than saline-treated animals with
regard to the number of entries they made into the target quadrant during the
memory retention trial (Tukey’s HSD, p < 0.05).

There were no significant

differences in the mean swim speeds of animals in each treatment group (F[2,19] =
1.23, p = 0.31).
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Figure 4-4 - The effect of α7 nAChR partial agonist treatment on CCIinduced cognitive deficits measured in the MWM acuisition phase
Partial agonist treated animals exhibited shorter path lengths to the platform
versus saline treated animals on all days of testing. However, a significantly
reduced distance traveled to platform was only found in DMXB-A treated
animals on the fourth day of acquisition testing. Data plotted are means plus or
minus standard deviation (n = 8). An asterisk denotes a significant difference
from saline-treated animals (p < 0.05).
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Figure 4-5 - Post-CCI differences in memory retention in animals treated
with α7 nAChR partial agonists
Post-CCI DMXB-A and ondansetron treatment resulted in a modest
improvements in memory recall in some measures. For example, animals
treated with DMXB-A travelled significantly further than saline-treated animals
in the target quadrant (which had contained the escape platform in preceding
acquisition trials.
In addition, animals treated with ondansetron made
significantly more entries into the target quadrant compared to saline-treated
animals. A significant difference from saline-treated controls is denoted with an
asterisk (p < 0.05).
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4.3.6 Neither DMXB-A nor ondansetron have any effect on cortical tissue
sparing following CCI
Cortical tissue sparing analysis did not reveal any significant effect of
partial agonist treatment (Figure 4-6). Saline animals has an 83% tissue sparing,
and although DMXB-A treatment resulted in an 88% tissue sparing it was not
statistically significant (p = 0.06). Data were analysed by one-way ANOVA which
reported no significant differences (F[2,19] = 1.85, p = 0.19).
4.3.7 Ondansetron exacerbates post-CCI α7 nAChR deficits
In saline treated animals there were significant reductions in α7 nAChR
expression in the hilus and superior colliculus following injury (t-test versus
theoretical mean of 1; p < 0.05).

Similar deficits were observed in animals

treated with DMXB-A and ondansetron. One-way ANOVA reported a significant
effect of treatment in the CA2/3 field of the hippocampus (F[2,16] = 4.60, p < 0.05),
and in the superior colliculus (F[2,16] = 6.90, p < 0.05). Post-hoc analysis revealed
significant differences between ondansetron and saline treated animals in the
superior colliculus (p < 0.05), and between DMXB-A and ondansetron treated
animals in the CA2/3 and superior colliculus (p < 0.05).
4.3.8 Ondansetron

treatment

exacerbates

neuroinflammation

in

the

hippocampus following CCI
As expected, [3H]-PK11195 binding was significantly increased following
injury in all regions analyzed (Table 4-4).

Analysis of the data by one-way

ANOVA revealed a significant effect of treatment in the hilus only (F[2,20] = 4.52, p
< 0.05). Further post-hoc analysis revealed a significantly higher binding density
in ondansetron-treated animals versus saline treated animals (p < 0.05).
Interestingly, [3H]-PK11195 binding was higher in ondansetron treated animals
than in saline or DMXB-A treated animals all regions of the hippocampus. An
additional observation was the trend towards a reduction in PK11195 binding in
DMXB-A treated animals versus saline treatment.
significant difference in any of the regions assessed.
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However, there was no

Figure 4-6 - Tissue sparing analysis in animals treated with DMXB-A or
ondansetron
Neither DMXB-A, nor ondansetron has any effect on cortical tissue sparing
following experimental brain injury. Saline treated animals had an 83% tissue
sparing, while DMXB-A and ondansetron resulted in 88% and 82% sparing,
respectively. Data are presented as means plus or minus standard deviation (n
= 6).
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Saline

10 mg/kg
DMXB-A

2 mg/kg
Ondansetron

Cortex layers 1-4

0.97±0.08

1.00±0.10

0.94±0.06

Stratum oriens

0.98±0.07

1.00±0.03

0.99±0.05

Hippocampal field CA1

0.97±0.07

0.97±0.05

0.92±0.09

Hippocampal field CA2/3

0.97±0.05

0.99±0.02

0.92±0.04*#

Hippocampal field CA4 (Hilus)

0.94±0.03*

0.93±0.04*

0.90±0.03*

Dentate gyrus (lateral blade)

0.95±0.05

0.97±0.05

0.91±0.08

Superior colliculus

0.97±0.02*

0.98±0.02*

0.93±0.03*#

Table 4-3 - The effect of DMXB-A or ondansetron on α7 nAChR expression
following CCI
α7 nAChR expression was assessed by [125I]-α-BTX binding density and results
are presented for the ipsilateral regions only expressed as a proportion of binding
in the contralateral regions. An asterisk indicates a significant difference from the
theoretical mean of 1 as assessed using a t-test (p < 0.05), and the pound sign
(#) denotes a significant difference from saline as found using Tukey’s HSD (*p <
0.05).
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Saline

10 mg/kg
DMXB-A

2 mg/kg
Ondansetron

Cortex

1.93±0.65**

1.83±0.56*

1.53±0.44*

Hippocampal field CA1

2.34±0.82***

1.84±0.35**

2.97±1.14**

Hippocampal field CA2/3

3.10±1.51***

2.40±0.66**

3.57±0.99***

Hippocampal field CA4 (Hilus)

3.42±0.80***

3.03±0.66**

4.49±1.09***#

Dentate gyrus (lateral blade)

2.16±0.48***

1.91±0.29***

2.55±0.60***

Thalamus (Lateral dorsal)

2.40±0.81***

2.05±0.44**

2.51±0.52***

Thalamus (Ventral posterolateral)

2.38±0.74***

1.75±0.35**

2.43±0.46***

Table 4-4 - Post-CCI [3H]-PK11195 binding density in animals treated with
DMXB-A or Ondansetron
[3H]-PK11195 binding density in the ipsilateral hemisphere expressed as a
proportion of the binding density in equivalent contralateral region. Significant
differences from the theoretical mean of 1 are shown with an asterisk (*p < 0.05,
**p < 0.01, and ***p < 0.005). A significant effect of treatment was found in the
hilus only, and Tukey’s HSD found a significant difference between the saline
and ondansetron groups (#p < 0.05).
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4.4

Discussion
In chapter 3 we demonstrated the therapeutic potential of the α7 nAChR

antagonist MLA following experimental brain injury. However, the highest dose
of MLA was not the most efficacious for reducing cognitive deficits in the MWM
despite sparing tissue and reducing neuroinflammation. Bilateral reductions in
α7 nAChR binding in all brain regions following MLA treatment could have
effected MWM performance. This result suggests the need for some α7 nAChR
stimulation, and therefore the possible utility of a α7 nAChR partial agonist. The
use of partial agonists as therapeutic agents is well established; buprenorphine,
for example, is a μ-opioid receptor partial agonist that has been used since the
1980s as an analgesic, and more recently was approved for the treatment of
opioid dependence (McClellan, 2002). Other approved partial agonists include
aripiprazole, a D2 partial agonist used to treat schizophrenia and bipolar disorder,
and buspirone, a 5-HT1A partial agonist approved as an anxiolytic and
antidepressant. More recently the α4β2 partial agonist varenicline (Chantix) has
been approved for smoking cessation treatment (Cahill et al., 2008; FDA, 2006).
This study has demonstrated that partial agonists of the α7 nAChR have
therapeutic potential in treating TBI. Rats that were treated with tropisetron or
DMXB-A performed significantly better in the MWM acquisition task than did
animals given saline-only injections. Attenuation in cognitive deficits resulting
from CCI was most pronounced in animals treated with 2 mg/kg of tropisetron,
while animals treated with DMXB-A preformed significantly better than salinetreated controls on day 4 only. It is however, interesting to note that the mean
distance traveled to the escape platform by all treatment groups was lower than
for saline-treated animals. Despite this result in the acquisition phase of the
MWM task there was no clear trend of improved performance in the retention test
for any treatment group. The finding that tropisetron attenuates cognitive deficits
in a model of TBI adds to other findings in which tropisetron has reduced
cognitive deficits in a mouse model of schizophrenia (Hashimoto et al., 2006;
Pitsikas and Borsini, 1997). In addition, the more modest effect of DMXB-A in
attenuating cognitive deficits is in agreement with other studies that have
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demonstrated DMXB-As cognitive enhancing effects (Arendash et al., 1995b;
Nanri et al., 1998a). The lack of any cognitive-enhancing effect for ondansetron
is surprising, since several previous studies in rodents (Boast et al., 1999; DiezAriza et al., 2003; Fontana et al., 1995; Harder and Kelly, 1997; Hodges et al.,
1996; Kumar and Kela, 2004; Reeta et al., 1999; Roychoudhury and Kulkarni,
1997), and primates (Barnes et al., 1989; Barnes et al., 1990) have reported
improvements in cognition. While cognitive enhancement after insult has been
reported for doses up to 10 mg/kg, one study assessing the effect of ondansetron
in ameliorating cognitive deficits after atropine injection found a loss of efficacy at
doses above 3 mg/kg (Fontana et al., 1995). It is possible that had a lower dose
of ondansetron been tested beneficial effects may have been found.
Interestingly, ondansetron treatment exacerbated post-CCI α7 nAChR binding
deficits, a finding which could help to explain the lack of a favorable functional
outcome. In chapter 3 of this dissertation a similar exacerbation of α7 nAChR
binding deficits was found following α7 nAChR antagonist treatment in the same
model. A more thorough investigation of ondansetron in TBI will be required to
assess its effects on α7 nAChR expression and cognition following injury.
In this study there was no significant effect of any treatment or dose on
tissue sparing. In contrast, a recent study from our laboratory with an α7 nAChR
full agonist (choline) produced a marked increase in tissue sparing following
injury (Guseva et al., 2008). Another study in which rats were treated with a full
α7 nAChR antagonist immediately after CCI also showed significant increases in
tissue sparing versus saline-treated animals (Woodcock et al., 2008).

The

absence of an effect here could be due to these molecules lacking full efficacy at
α7 nAChRs, or could be due to some other mechanism possibly involving their
antagonism of 5-HT3 receptors. It should also be noted here that a recent study
found that tropisetron administered to rats prior to permanent middle cerebral
artery occlusion (pMCAO) failed to reduce infarct size, and actually led to a
higher mortality rate and exacerbated neurological deficits (Candelario-Jalil et al.,
2008). However, this does not deter us from our results since the doses used in
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that study were relatively high (5-10 mg/kg), and the mechanism of injury in
pMCAO is very different to that in the CCI injury model we used.
In this study [3H]-PK11195 autoradiography was utilized as a more
sensitive marker of tissue damage.

PK11195 binds to the TSPO, which is

thought to located on the outer mitochondrial membrane within activated
microglia and macrophages.

We have previously shown that increases in

3

[ H]-PK11195 binding can be detected just 6 hours after CCI in the hippocampus,
while significant increases are not detected in the cortex until 12-24 hours after
injury (refer to chapter 2). Interestingly, there is a delayed increase in binding in
the thalamus, possibly due to retrograde degeneration of axonal projections to
the injured cortex. The pattern of [3H]-PK11195 binding was in agreement with
our previous studies using this tool.

In our past study we found that

[3H]-PK11195 binding peaks in the cortex and hippocampus at 3-7 days, so the 8
day time-point in this study comes just after the peak. In this study there was no
significant effect of treatment in the cortex, thalamus or any hippocampal region
measured.

Furthermore, cortical tissue sparing was used to assess

neuroprotective effects of α7 nAChR partial agonist treatment but failed to detect
any significant effect of treatment. There was a trend for animals treated with 2
mg/kg tropisetron to have a greater tissue sparing, but this did not reach
significance. The lack of a neuroprotective effect for any of the partial agonists
tested in this study was unexpected. MLA treatment following CCI resulted in a
significant neuroprotective effect and a modest improvement in functional
outcomes. It is possible that a full agonist is needed immediately following injury
in order to facilitate neuroprotection. The lack of efficacy of partial agonists in
this model may dictate the need for combination therapies with which to treat
TBI.
As mentioned earlier, tropisetron and ondansetron are both approved for
clinical use as antiemetics that function via their competitive antagonism of the
5-HT3 receptor, but it is recognized that they also act on α7 nAChRs. Both α7
nAChRs and 5-HT3 receptors are members of the cys-loop ligand-gated ion
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channel superfamily, which also includes other nAChRs, GABAA receptors and
glycine receptors (Sine and Engel, 2006). All receptors in the superfamily form
pentameric ion channels and each subunit has a characteristic loop formed by a
disulphide bond.

The receptors can be homomeric (made up of 5 identical

subunits) like the α7 nAChR and 5-HT3A, or heteromeric as can be the case for
some 5-HT3 receptors. For example, the 5-HT3 subunit subtypes 5-HT3B, 5-HT3C,
5-HT3D and 5-HT3E can form functional receptors in combination with the 5-HT3A
subtype (Barnes et al., 2009). While the 5-HT3 receptor does not bind ACh it
does share more structural homology with nAChRs than it does to other
serotonin receptors. It is this homology that makes it unsurprising that some
ligands with affinity for the 5-HT3 receptor also have affinity for the α7 nAChR
and vice-versa.

Tropisetron and ondansetron are both competitive partial

agonists of α7 nAChRs, although ondansetron seems to have a lower affinity for
these receptors (Macor et al., 2001). DMXB-A is slightly different, having been
developed as a partial agonist of α7 nAChRs (Briggs et al., 1995; de Fiebre et al.,
1995), it is also a weak competitive antagonist of α4β2 nAChRs. In vivo
experiments have since demonstrated that DMXB-A is also a weak antagonist of
5-HT3 receptors (Machu et al., 2001), though possibly through a non-competitive
mechanism (Gurley and Lanthorn, 1998; Kem, 2000). Given our results it is
possible that both antagonism of the 5-HT3 receptor and partial agonism of the
α7 nAChR are beneficial in TBI.
Interestingly, there is evidence that 5-HT3 antagonists might be able to
increase cholinergic tone via an indirect mechanism. It has been shown that
5-HT3 receptors in the entorhinal cortex are located on GABAergic neurons,
which inhibit cholinergic function (Barnes et al., 1989). Therefore, antagonism of
the 5-HT3 receptor could potentially improve cholinergic function independent of
the α7 nAChR.

Equally, 5-HT3 antagonism immediately after injury could

exacerbate excitotoxicity via this mechanism, and could explain the detrimental
effects of pretreatment with tropisetron in pMCAO (Candelario-Jalil et al., 2008).
This emerging evidence suggests that the 5-HT3 receptor itself could be a novel
target for neuroprotective strategies.

Also worthy of further study is the
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selectivity for each 5-HT3 antagonist for different isoforms of the receptor, and the
roles that these different 5-HT3 receptors might play in the CNS.

Different

affinities and efficacies of ondansetron and tropisetron for the various 5-HT3
receptors may help to explain the different effects we observed in this study.
An interesting aspect of this study was with regard to the results obtained
for DMXB-A treatment following CCI.

DMXB-A has been shown to be

neuroprotective in several studies and continues to be extensively evaluated,
especially with regard to its potential therapeutic effects in AD (Kem, 2000;
Meyer et al., 1998a; Nanri et al., 1998a; Nanri et al., 1998b; Ren et al., 2007). In
this study DMXB-A significantly improved MWM performance versus saline, and
although not statistically significant it also resulted in a greater degree of tissue
sparing and reduced [3H]-PK11195 binding in all regions assessed when
compared to saline treatment.

Further assessment of this molecule in

neurotrauma studies, including a refinement of the dosing and administration
regimen might uncover neuroprotective effects for this drug following brain injury.
In conclusion, our results have demonstrated that α7 nAChR partial
agonist treatment following CCI can produce modest improvements in functional
outcomes. This study adds to previously reported findings that tropisetron can
reverse cognitive deficits (Hashimoto et al., 2006; Koike et al., 2005; Pitsikas and
Borsini, 1997). The precise mechanism by which these drugs act to improve
cognition remains to be determined. The role of 5-HT3 receptors cannot be ruled
out, and their involvement in excitotoxicity and neuroprotection will require further
research.
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5. CHAPTER 5
Discussion and Conclusions
5.1

Review
The wars in Afghanistan and Iraq have brought traumatic brain injuries

into the limelight.

Blast injuries from IEDs are increasingly common among

combat soldiers (Galarneau et al., 2008), however, significant numbers of
Americans also suffer TBIs, primarily as a result of motor vehicle accidents
(Langlois et al., 2006). In addition to the physical effects of trauma many TBI
patients are left with behavioral and cognitive deficits that frequently go untreated
(Corrigan et al., 2004; Resch et al., 2009). As a result, many patients suffer
significant quality of life reductions and make the transition back into society and
the workforce difficult (Rao and Lyketsos, 2002). It is estimated that more than
1.5 million people sustain a TBI every year in the USA, which creates an
immense financial burden (Thurman et al., 1999).

Despite the scale of the

problem there are no successful pharmacological treatments for TBI, and
therefore there is a great need for new and novel treatment strategies aimed at
improving outcomes.
The present lack of efficacious treatments targeted at secondary injury
mechanisms in TBI means that injury prevention is of utmost importance. This
can be achieved by raising awareness of the condition and encouraging people
to take preventive or safety measures (such as wearing seatbelts and helmets).
Raised awareness, improvements in automobile safety, and advances in other
safety technologies must remain a focus if the impact of TBI on society and the
emotional wellbeing of individuals is to be reduced (Kraus and Peek, 1995). A
future pharmacological intervention could potentially improve the lives of
thousands of people by attenuating the behavioral and cognitive deficits brought
about by TBI.

The studies outlined in this dissertation add to the current

understanding of the time-course of secondary injury, and demonstrate the
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potential therapeutic effects of targeting α7 nAChRs of the cholinergic system
following a TBI.
The experiments detailed within this dissertation have demonstrated that
(1) [3H]-PK11195 is a sensitive and selective marker of microglial and
macrophage activation within the injured brain, which can be used to track
neuronal damage and potentially repair in many brain regions following injury
(Chapter 2); (2) Short-term administration of an α7 nAChR antagonist after CCI is
neuroprotective and leads to some improvement in cognitive performance
(Chapter 3); and (3), partial agonists of the α7 nAChR can attenuate cognitive
deficits associated with brain injury to a degree, but do not produce any
measurable neuroprotective effect (Chapter 4).
5.1.1 The time-course of damage and repair in TBI
It is difficult to generalize the time-course of tissue, cellular and molecular
changes that occur following a brain injury because of the heterogeneity of the
condition (Saatman et al., 2008). Affected brain regions can vary considerably
by injury method, severity and location. The injury paradigm we used in these
studies models a focal closed-head injury (immediately following injury the skull
cap is replaced and fixed in place with dental acrylic). We have found that a
small change in injury severity (1 mm cortical deformation versus 2 mm cortical
deformation) produces a markedly different pattern and intensity of [3H]-PK11195
binding throughout the brain (Figure 5-1).

However, in order to assess the

efficacy of any treatment in TBI and models of TBI there need to be clear
assessments made of the effect of injury on various measures of tissue and
cellular damage as well as the functional and cognitive consequences of the
injury.

These assessments need to be validated in human TBI so that

meaningful evaluations of TBI treatments can be made in our various models.
The easiest and most commonly employed methods for assessing injury
severity and neuroprotective effects are lesion volume analysis and tissue
sparing analysis, respectively. While it is excellent as an initial validation of injury
severity and uniformity and can be used to detect neuroprotective effects, its
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Figure 5-1 - Comparison of [3H]-PK11195 binding in rat brain following
different injury severities
[3H]-PK11195 binding to the TSPO 14 days after CCI surgery shows great
sensitivity to the degree of injury. Following a 2 mm CCI increased [3H]PK11195 binding is found throughout the injured cortex, in the hippocampus,
and in parts of the thalamus. In contrast, a 1 mm CCI only leads to modest
increases in binding to the ipsilateral cortex, small increases in the dentate
gyrus and hilus of the hippocampus, and no significant increases in binding in
the thalamus.
Furthermore, [3H]-PK11195 autoradiography can detect
microglial activation in the cortex directly beneath the site of craniotomy
following sham surgery (see arrowhead, ▼).
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utility in relating to clinical results is very limited.

Barring the fact that nissl

staining cannot be carried out on live patients, this is chiefly due to significant
differences in size, shape, and structure of the human cortex compared to rat
brain. Furthermore, an analysis of this type would be restricted to assessment of
injury in focal brain injured patients (possibly by computerized tomography [CT]),
who represent a relatively small proportion of the total brain injuries (Langlois et
al., 2006).

In addition, analysis of this type would not pick up smaller, but

potentially more significant disruption of other brain regions.
A

more

pertinent

analysis

of

post-injury

damage

and

possible

neuroprotective effects is to assess neuronal dysfunction and death (e.g. FJ-B
staining or de Olmos silver staining), or neuronal survival (e.g. NeuN
immunohistochemistry). Although more laborious than tissue sparing analysis, a
thorough appraisal of neuronal survival following injury and experimental
therapies can provide more detailed information on the brain areas affected and
the relative severity of injury that together could help to explain physical and
neurological alterations. Again though, there is no way of accurately measuring
neuronal death in live patients.
Glial cells, which account for more than half of the cells in the primate
brain (Azevedo et al., 2009) may be the key to relating injury in animals to human
patients. Microglia in particular have been attracting a lot of attention in recent
years as the critical role played by inflammation in many neurodegenerative
conditions becomes apparent. Microglia are the brain’s resident immune cells,
and play an important role in detecting damage to the brain parenchyma
(Carbonell et al., 2005). Following injury microglia quickly become activated,
taking on a different morphology and expressing a range of neurotrophic,
proinflammatory, and potentially neurotoxic factors (Ransohoff and Perry, 2009).
Whether these activated cells are detrimental to neuronal survival or promote
recovery from injury is still a topic of much contention, however, what is clear is
that their presence corresponds well to areas of neuronal dysfunction and death.
We therefore set about evaluating the potential of the microglial marker [3H]-
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PK11195 to image tissue damage and repair in a model of TBI (Chapter 2). Our
experiments have demonstrated the potential of [3H]-PK11195 as a marker of
microglial and macrophage activation, which in turn are markers of tissue
damage and neuronal dysfunction.
[3H]-PK11195 is believed to bind to the TSPO within activated microglia
and macrophages; a conclusion supported by the discovery of correlations
between [3H]-PK11195 binding density and immunohistochemical detection of
macrophages/microglia (Fujimura et al., 2008; Myers et al., 1991a; Venneti et al.,
2008a; Venneti et al., 2007a; Venneti et al., 2007b). In our study we were able to
confirm this correlation of [3H]-PK11195 binding to CD68, a marker of
phagocytosis. However, this correlation only held up in the injured cortex and not
in the thalamus where increases in [3H]-PK11195 binding were not accompanied
by any substantial increase in the numbers of CD68 positive cell profiles. This
finding could be due to the presence of activated, but not phagocytic, microglia.
As mentioned earlier, CD68 is a marker of phagocytic cells, yet microglia are
known to go through distinct ‘phases; of activation. Our study therefore, has
shown that the PK11195 binding site is expressed before significant numbers of
phagocytic microglia can be detected. Thus [3H]-PK11195 is a very sensitive
marker of tissue damage because it increases in injured regions before neuronal
death occurs.
The potential for use of the TSPO as a marker of neuroinflammation is
heightened by the development of PK11195 and other TSPO ligands for use in
PET.

PET is a 3D imaging technique that uses a positron-emitting

radionucleotide tracer introduced into the body of a patient or animal. PET is
often performed alongside a CT or MRI scan to give anatomical information in
addition to the biochemical information afforded by PET imaging. The use of
[11C]-(R)-PK11195 in PET has been demonstrated in AD (Edison et al., 2008),
Parkinson’s disease (Gerhard et al., 2006), Huntington’s disease (Pavese et al.,
2006; Tai et al., 2007a, b), schizophrenia (van Berckel et al., 2008), individuals
with human immunodeficiency virus (Hammoud et al., 2005), multiple sclerosis
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(Debruyne et al., 2003; Vas et al., 2008; Versijpt et al., 2005), ALS (Turner et al.,
2004a), stroke (Gerhard et al., 2000; Gerhard et al., 2005), and others (Banati et
al., 1999; Leong and Butterworth, 1996; Leong et al., 1994; Leong et al., 1996).
Most recently a study has found that PK11195 binding in AD brain correlates with
mini mental state exam (MMSE) scores (while amyloid load did not) (Edison et
al., 2008). Other interesting findings have been a correlation with HD severity
(Pavese et al., 2006), a correlation with brain atrophy in MS (Versijpt et al.,
2005), and a correlation with burden of upper motor neuron signs in ALS (Turner
et al., 2004a). Other studies have proposed that the utility of PK11195 in PET is
not limited to the nervous system, but may also be a valuable tool to detect
inflammation in atherosclerotic plaques (Fujimura et al., 2008), or in the lungs
(Hardwick et al., 2005). Despite the promising clinical results obtained using
PK11195 in PET studies, the molecule does have some disadvantages which
have prompted the development of new TSPO ligands. These disadvantages
include a relatively high level of non-specific binding in humans and primates
(Petit-Taboue et al., 1991; Shah et al., 1994), poor signal to noise ratio,
pharmacological effects independent of TSPO binding, and the necessity of
labeling PK11195 with carbon-11 which has a very short half-life (~20 min)
meaning that tracers must be synthesized very close to the point of use
(Chauveau et al., 2008).
PET is not limited to human patients. Recent advances in technology
have made PET with PK11195 possible in animal models, and a mini-PET device
is now available that can be attached to a rat’s head for ‘live’ measurements
(RatCAP, Brookhaven National Laboratory, NY). PK11195 binding, detected by
PET has been studied in rat transient focal ischemia (Rojas et al., 2007), a rat
model of ethanol injury (Toyama et al., 2008), a transgenic mouse model of AD
(Venneti et al., 2008a), and a macaque model of HIV encephalitis (Venneti et al.,
2007b).
While this technique promises great things for the future of animal studies,
technology is still expensive and out of reach for most labs. In the meantime
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[3H]-PK11195 autoradiography allows us to make detailed assessments of
microglial activation in post-mortem human and animal brain. Our studies have
revealed widespread increases in [3H]-PK11195 binding in the rat brain during
the days following CCI.

Furthermore, we reported that these increases vary

significantly in timing and magnitude between distinct brain regions. Increased
binding became apparent in the dentate gyrus of the hippocampus just 6 hours
after injury. This observation highlights two important aspects of this technique;
firstly, it demonstrates the sensitivity of [3H]-PK11195 autoradiography in
detecting cellular disruption at a time when no significant changes were found in
the impacted cortex. Secondly, it demonstrates how PK11195 binding can be
used to detect small and discrete areas of cellular damage and dysfunction distal
from the injury. The latter inference is further supported by our other finding that
[3H]-PK11195 binding sites are expressed in distinct thalamic nuclei after injury,
but increases are not observed until later time points and a peak is not reached
until after at least 6 days. We have hypothesized that this is due to lesioning of
the cortex as a result of the injury, and subsequent retrograde degeneration of
thalamocortical afferents culminating in neuronal death in the thalamus. Support
for this hypothesis comes from studies involving lesioning of the thalamus, in
which a delayed loss of nicotinic binding was observed in the cortex (Gioanni et
al., 1999; Lavine et al., 1997).

In addition, more recent studies have

demonstrated secondary thalamic damage following cortical injuries (Langen et
al., 2007), and delayed increases in thalamic PK11195 binding in stroke patients
in a PET study (Pappata et al., 2000). One similar study concluded that PET
with PK11195 would be a useful way in which to investigate remote changes in
neuroinflammation (i.e. via retrograde or anterograde degeneration) following
ischemic stroke (Gerhard et al., 2005). The most recent, and most compelling
evidence in support of this hypothesis found that the thalamic nuclei that
exhibited the greatest increases in inflammation varied depending on the area of
the cortex that was lesioned (Langen et al., 2007).
A further interesting observation in the thalamus from our study was the
presence of significant increases in PK11195 binding without any significant
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increase in CD68 staining in that region at the same time-point.

This was

surprising but not without possible explanations. First and foremost CD68 is an
antigen found on activated microglia and peripheral macrophages, while
PK11195 binds to a completely different site on these cells not necessarily
related to CD68.

Secondly, PK11195 binding is not limited to microglia and

macrophages. For example, in brain displaying a normal pathology PK11195
binding can still be observed in the choroid plexus and endothelium. It is also
expressed to some extent on erythrocytes. However, the most likely candidates
for TSPO expression in the brain besides microglia and macrophages are
astrocytes. It is now established that astrocytes express TSPO (Butterworth,
1990; Cosenza-Nashat et al., 2009; Panickar et al., 2007; Veiga et al., 2007;
Vlodavsky and Soustiel, 2007), and since they also lack CD68 this implicates
them in PK11195 binding increases seen in the thalamus. Evidence to support
this hypothesis comes from a recent study of a novel TSPO ligand (DPA-714) in
a rat model of focal cerebral ischemia (Martin et al., 2009).

In this study

immunohistochemistry was used to stain microglia (OX-42/CD11b), astrocytes
(GFAP), and the TSPO (NP155). Following the ischemic insult DPA-714 binding
increased, peaked at 11 days, and then decreased but not to control levels by 30
days.

This pattern matched well the temporal changes in TSPO-positive

microglia. Furthermore, numbers of TSPO-positive astrocytes increased at each
consecutive time-point to 30 days, but there was no resultant increase in DPA714 binding.

The lack of concordance between DPA-714 and TSPO/GFAP

staining in this study could be due to a lower level of TSPO expression by
astrocytes or possibly the presence of another subtype of TSPO with differing
affinity for the ligand. Regardless, astrocytic expression of TSPO following brain
injury, especially at later time-points may help to explain the increased PK11195
binding seen in the thalamus. In order to delineate the cellular expression profile
of TSPO in brain injury it might be interesting to double-stain brain sections with
GFAP and TSPO antibodies and look for double labeled cells within the
thalamus.
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Having assessed PK11195 binding in untreated rats after subjecting them
to a CCI we applied this technique to our pharmacological studies. In the first
study, 5 or 10 mg/kg MLA was found to significantly reduce [3H]-PK11195
binding versus saline-treated controls (Table 3-2). These differences were found
in the cortex and hippocampus, suggesting that either MLA is having a direct
effect on neuroinflammation, or that these changes in [3H]-PK11195 binding are
secondary to the neuroprotective effect of MLA that we observed.

The first

scenario seems unlikely, because current evidence suggests an inhibitory role for
nicotinic agonists on inflammation (Gallowitsch-Puerta and Tracey, 2005),

in

fact, the anti-inflammatory effects of nicotine in the brain are thought to be
mediated by the α7 nAChR receptor (Nizri et al., 2009; Shytle et al., 2004).
Therefore, we would certainly not expect an α7 nAChR antagonist to reduce
inflammation, but rather exacerbate microglial activation.

Further evidence

suggesting the reductions in [3H]-PK11195 binding we observed are not due to a
direct effect of MLA comes from a recent in vivo study in which rats were injected
Intracerebroventricularly with LPS to induce an inflammatory response and
cytokine expression was measured following drug treatment (Tyagi et al., 2009).
Nicotine treatment reduced cytokine expression, and pretreatment with MLA
antagonized nicotine’s effect, while DHβE (an α4β2 antagonist) had no effect.
In chapter 4 of this dissertation we tested partial agonists of the α7 nAChR
for neuroprotective effects and for their ability to improve functional outcomes.
We also measured neuroinflammation in these animals using [3H]-PK11195
autoradiography. In this study none of the partial agonists reduced [3H]-PK11195
binding, but ondansetron treatment did significantly increase [3H]-PK11195
binding in the hilus. This increase could be due to ondansetron’s agonistic effect,
since MLA reduced inflammation.

A second important observation from this

study was the lack of any tissue sparing with partial agonist treatment. This
could be the reason why there was no effect on neuroinflammation, suggesting
that the reduction in [3H]-PK11195 we observed in Chapter 3 with MLA treatment
was secondary to the tissue sparing effect.
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We conclude that [3H]-PK11195 autoradiography is an excellent tool with
which to assess the time-course of tissue disruption, which combines low cost
with sensitivity and resolution. It has already been utilized in an array of animals
models (Giannaccini et al., 2000; Katchanov et al., 2003; Mankowski et al., 2003;
Sitte et al., 2001), including brain injury (Grossman et al., 2003; Raghavendra
Rao et al., 2000), although our study was the first to fully characterize it in a CCI
model.

In addition, we have demonstrated in each of our studies that

autoradiography with this ligand is a very sensitive technique for detecting injury
and neuroprotective effects (Chapter 2, Chapter 3.3.4, and Chapter 4.3.4). We
demonstrated large and robust increases in [3H]-PK11195 binding in several
brain regions that were very consistent between animals (Chapter 2).
Furthermore, significant reductions in [3H]-PK11195 binding were detected in
some brain regions following CCI and MLA treatment (Chapter 3.3.4),
demonstrating its potential in detecting the effects of drug treatment.
Additionally, it has not escaped our attention that while PET studies with
PK11195 are becoming more common, an assessment of PK11195 binding sites
in human brain injury patients has yet to be conducted. Such a study would help
to completely validate the technique as a method to assess the effectiveness of
experimental therapies. Coupled with CT scanning, it could also be a valuable
method for the determination of injury type and severity in a clinical setting to
help direct treatments and therapies to individual TBI victims. Indeed, a recent
workshop was convened with the purpose of recommending ways in which to
develop a classification system for TBI that could be used to better target
therapies (Saatman et al., 2008).
In summary, imaging of the TSPO has great potential in providing a
detailed and quantitative assessment of neuroinflammation both in the laboratory
and in the clinic.

TSPO binding could be a valuable biomarker for use in

determination of inflammation in drug development and early clinical trials.

121

5.1.2 Excitotoxicity mediated by the α7 nAChR
Studies of excitotoxicity are generally focused on the NMDA receptor
because of its high degree of calcium permeability. However, despite promising
drug candidates all clinical trials to date have failed (Albers et al., 1999; Bullock
et al., 1999; Haley et al., 2005; Ikonomidou and Turski, 2002).

While the

difficulties in translating doses and therapeutic windows from well controlled
rodent models to the heterologous human condition could be partly to blame, it
would be worthwhile to investigate alternative strategies to the treatment of
excitotoxicity in TBI.
We chose to investigate the effects of α7 nAChR blockade on CCI induced
neuropathologies and functional recovery due to its interesting parallels with the
NMDA receptor. Firstly, the α7 nAChR is selectively and highly permeable to
calcium like the NMDA receptor. Studies in Xenopus oocytes have shown that
α7 subunits form functional homopentamers, and that stimulation of the receptors
causes a rapid influx of calcium (Hovda et al., 1995; Wolf et al., 2001; Young,
1992). Calcium flux through the α7 nAChR could lead directly to excitotoxicity
and may also lead to an increased probability of glutamate release from presynaptic terminals (Dickinson et al., 2008; Jiang and Role, 2008; Marchi et al.,
2002). Secondly, the α7 nAChR is widely expressed in the brain, and is thought
to be involved in cognitive processes. α7 knockout mice have been produced
(Orr-Urtreger et al., 1997), and although they do not display cognitive deficits,
antisense knockdown of the α7 gene in rats does result in loss of α7 nAChR
expression and cognitive deficits as measured in the MWM (Curzon et al., 2006).
In our laboratory we tested the hypothesis that these α7 nAChR knockout mice
would be less sensitive to post-CCI tissue loss and neuroinflammation (Kelso et
al., 2006).

However, there were no differences in tissue sparing or

neuroinflammation between wildtype, heterozygous, and knockout mice. This
result was surprising since we believe the α7 nAChR is involved in calciummediated excitotoxicity following brain injury. However, when interpreting results
from genetic knockout animals care must be taken since compensatory
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mechanisms may confound the results. All together, these results suggest that
α7 knockout mice may exhibit some compensatory developmental features.
Since we believe that the α7 nAChR is integral to induction of
excitotoxicity following a brain injury, modulation of this receptor might be
therapeutic. Fortunately, the well recognized therapeutic potential of nAChRs as
targets for treating neurodegenerative conditions has led to a number of
companies that are developing selective nicotinic agonists, antagonists and
PAMs (positive allosteric modulators, which increase receptor activity indirectly
via an allosteric site) for the α7 nAChR (Cincotta et al., 2008; Faghih et al.,
2007). Some recent compounds of interest are A-867744, an α7 nAChR PAM
which has been shown to potentiate ACh-evoked currents in recombinant α7
nAChR expressed in oocytes (Malysz et al., 2009), and SEN12333, another α7
nAChR PAM with demonstrated procognitive and neuroprotective properties
(Roncarati et al., 2009). Continued progress in the area promises to provide
researchers with a multitude of novel pharmacologically active compounds with
which to target nAChRs.
In chapters 3 and 4 of this dissertation we tested the neuroprotective
potential of an α7 nAChR antagonist and three different α7 nAChR partial
agonists for neuroprotective potential when administered after CCI.

We

hypothesized that the increased cholinergic activity in the brain after an injury
could be damaging by adding to calcium-mediated excitotoxicity via α7 nAChRs.
A full antagonist would be expected to block α7 nAChR activation, while a partial
agonist would behave as an antagonist in the presence of high levels of
endogenous agonist. We found that MLA treatment had a significant effect on
tissue sparing, an effect that was dose dependent and clearly demonstrated a
neuroprotective effect. In contrast, the α7 nAChR partial agonists tropisetron,
ondansetron and DMXB-A all failed to produce any tissue sparing effect. This
was unexpected, but it is possible that in order to produce neuroprotection a full
antagonist is required.
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We chose MLA as a full antagonist for investigation in these studies
because it is readily available and represents a potent and selective antagonist of
α7 nAChRs (Alkondon et al., 1992; Davies et al., 1999; Ward et al., 1990). MLA
is a plant alkaloid found in the larkspur, and its actions on the NMJ acetylcholine
receptor implicate it in animal poisonings (Pfister et al., 1999).

In these

experiments MLA was administered at 1, 5 or 10 mg/kg beginning immediately
after CCI surgery, again 8 hours later and then again at 24 and 32 hours
following CCI. The doses were selected based on previous studies in which MLA
was administered to rats in which no adverse effects were observed (Grottick
and Higgins, 2000). Since we were targeting excitotoxicity with this treatment we
began the regimen as soon as the rat’s wound had been stapled closed.
Because we were administering MLA via an intraperitoneal injection it is
important to know that it is able to penetrate the BBB. Based on previously
published pharmacokinetic studies in rodents, MLA exhibits relatively poor brain
penetration (approximately 5% of an IP dose) after peripheral injection (Turek et
al., 1995). However, since we are testing this molecule as a treatment for TBI its
access to the brain will be improved by a disruption of the BBB. Studies in the
CCI model of TBI have shown significant BBB disruption following injury (Baldwin
et al., 1996), which should allow or drug to reach its target receptors.

This

disruption appears to be biphasic, with maximal breach occurring in the minutes
immediately following injury.

The BBB appears to recover by 3 hours, but

increased disruption was observed between 1 and 2 days.

Based on these

findings only the injection of MLA administered 8 hours after injury would have
been impeded by the BBB. Even so, the amount of MLA that is able to cross the
BBB may still be therapeutic. Despite these considerations, the ability of MLA to
access the brain is supported by the detection of significant central effects in our
study. There was a clear and obvious dose-dependent effect of MLA treatment
on cortical tissue sparing, such that animals receiving the highest dose of MLA
(10 mg/kg) did not differ significantly from sham operated controls (Chapter
3.3.2). This neuroprotective effect is what would be expected of a treatment that
attenuates excitotoxicity after injury. In addition to this neuroprotection there was
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some attenuation of cognitive deficits as measured in the MWM swim test. The
results of this test were mixed; all animals treated with MLA performed
consistently better than untreated animals during the acquisition phase of the
test.

However, significant differences were only found on day 4 (of 5) and

occurred in animals treated with 5 or 1 mg/kg MLA (Chapter 3.3.1). This finding
was interesting in the regard that 10 mg/kg of MLA had yielded the greatest
tissue sparing, but had failed to produce a significant attenuation of cognitive
deficits. There are several possible explanations for this finding; firstly, the MWM
is a hippocampal dependant task, whereas our tissue sparing analysis
exclusively measures changes in cortical tissue volume.

Secondly, it is

conceivable that while α7 nAChR blockade is beneficial in the cortex it is
detrimental to neuronal survival at higher doses in the hippocampus. Indeed,
when we extended MLA treatment to 4 days there was no significant
improvement in MWM performance [unpublished data]. Thirdly, it is possible that
while MLA was able to save cells from an excitotoxic fate it was not able to
prevent the depression of cholinergic function that occurs in TBI. Indeed, our
assessment of α7 nAChR expression by [125I]-α-BTX binding actually revealed a
reduction in binding in MLA treated animals. This was unexpected, but could
help to explain the lack of well defined cognitive improvements in these animals.
Of course, there are other explanations for the apparent deficit in [125I]-α-BTX
binding in these animals, including a change in affinity of the α7 nAChRs for
[125I]-α-BTX. However, we consider this scenario unlikely for two reasons, (1) the
animals were euthanatized 15 days after injury, 13 days after the last MLA
injection had been administered. It is improbable that MLA-induced changes in
affinity of the α7 nAChR would persist this long after cessation of treatment. (2)
We have previously carried out a saturation analysis of [125I]-α-BTX binding to rat
brain tissue from animals euthanatized 2 days after CCI.

The analyses

confirmed that changes in binding were due to changes in the number of binding
sites (Bmax) rather than affinity (KD) of [125I]-α-BTX for the receptor (Verbois et al.,
2002). A separate scenario could be the accumulation of a pharmacologically
active MLA metabolite in the brain, which is unlikely but previously published
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work has demonstrated such a scenario with nicotine (Ghosheh et al., 2001). It
would have been useful to include a sham-operated group treated with MLA, but
this effect was not anticipated. An appropriate control group would have helped
us to explain the reduction in [125I]-α-BTX binding that we observed.

A final

consideration is with regard to the selectivity of MLA for the α7 nAChR, since
recent studies have determined that at certain concentrations it can interact with
α4β2 and α6β2 nAChRs (Mogg et al., 2002). With this in mind, the involvement
of other nAChRs in the effects we observed cannot be ruled out. Finally, the
peripheral effects of MLA on the NMJ would be a concern for its administration
clinically.

This work could be expanded upon by testing more selective α7

antagonists as they become available, preferably with more favorable
pharmacokinetic profiles.
From these experiments we surmise that the α7 nAChR plays a significant
role in post-traumatic cell death and possibly cognitive deficits. Antagonism of
the α7 nAChR at early time points after injury promotes cell survival in the cortex,
and leads to small improvements in the MWM versus saline treatment. We
believe this effect is mediated by the blockade of α7 nAChRs immediately
following injury when high levels of ACh are present. This α7 nAChR blockade
will directly reduce calcium-mediated excitotoxicity, and may also indirectly
attenuate excitotoxicity by reducing α7 nAChR-mediated glutamate release
(Jiang and Role, 2008; Konradsson-Geuken et al., 2009). In any case, treatment
strategies utilizing α7 nAChR antagonists would be better directed by a well
defined time-course of cholinergic function after injury. Furthermore, antagonists
with better BBB permeability, pharmacokinetic profile, and selectivity for the α7
nAChR would greatly benefit these studies.
5.1.3 Cholinergic deficits following TBI
Studies in our laboratory have consistently reported a reduced expression
of α7 nAChRs following experimental brain injury in rodents (Guseva et al., 2008;
Kelso et al., 2006; Verbois et al., 2003a; Verbois et al., 2002, 2003b; Verbois et
al., 2000, Chapter 3.3.3, Chapter 4.3.3). This deficit is most prominent 24 hours
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after injury, and persists in many brain regions until at least 3 weeks after injury.
Because there is a certain level of recovery from this deficit at later time points it
is unlikely that the deficit is a result of cell death in those regions. Furthermore,
these deficits can be reversed by administration of nicotine via osmotic minipumps (Verbois et al., 2003b), making cell loss an unlikely cause of reduced α7
nAChR binding.

In addition, the involvement of the cholinergic system in

cognition implicates the reduced expression of these receptors in the cognitive
deficits observed after TBI. As mentioned above, antisense knockdown of the α7
nAChR in rat produces impairments in MWM acquisition and retention tests
(Curzon et al., 2006). Examination of cholinergic tone following brain injury has
determined that there is an initial period of hyperactivity following brain injury
(Saija et al., 1988), similar to the hyperactivity observed in the glutaminergic
system that is responsible for excitotoxic injury. We therefore hypothesized that
an overactivation of the calcium-permeable α7 nAChR could lead to excitotoxicity
and neuronal dysfunction.

Our hypothesis is supported by the finding that

blockade of the α7 nAChR following CCI increases tissue sparing and reduces
[3H]-PK11195 binding in some brain regions (Chapter 3). Then, at some time
point the excess cholinergic activity becomes a deficit that could affect cognitive
function (Arciniegas, 2003; Murdoch et al., 1998). This finding is validated by
animal models in which significant reductions in ChAT (Leonard et al., 1994),
reduced basal and evoked ACh release (Dixon et al., 1996), and reduced choline
uptake (Dixon et al., 1994a) have been reported. Past studies in our laboratory
have shown that treatment with a non-specific nAChR agonist, nicotine, can
restore α7 nAChR binding following injury (Verbois et al., 2003b) and when
administered as a series of chronic intermittent injection can attenuate cognitive
deficits (Verbois et al., 2003a).

Interestingly, chronic intermittent nicotine

treatment did not restore α7 binding, suggesting that stimulation of the remaining
receptors could be sufficient to improve cognitive function. However, despite the
benefits of nicotine there are some limitations to these studies. Firstly, nicotine is
not a selective agonist and therefore has numerous effects.

By binding to

receptors in the adrenal medulla it can stimulate the release of epinephrine and
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norepinephrine, which among other effects increase heart rate and blood
pressure. It can also promote the release of the neurotransmitter norepinephrine
via its action on nAChRs in the hippocampus and amygdala (Fu et al., 1998).
Furthermore, nicotine is a psychoactive drug and is well known to lead to
dependence; unwanted qualities in a therapeutic compound. In addition to the
problems with the drug, there is an issue of when is the best time to administer
the drug. In the previous two studies conducted in our laboratory nicotine was
administered beginning immediately after injury. However, heightened levels of
cholinergic activity occurring at this time combined with the nicotine being
administered could have exacerbated excitotoxicity. For these reasons we chose
to explore the use of selective nAChR agonists and antagonists in TBI. Having
demonstrated the neuroprotective capability of an α7 antagonist, we explored the
possibility of improving functional recovery using a selective α7 agonist.
We have previously shown that α7 nAChR agonist choline, when
administered in chow to male rats does not result in any significant phenotypic
differences in terms of MWM performance but does significantly increase [125I]-αBTX binding in the hippocampus and cortex (Guseva et al., 2006). We therefore
hypothesized that dietary choline supplementation would improve functional
outcomes

by

improving

cholinergic

tone

following

a

TBI.

Choline

supplementation in rats subjected to a CCI resulted in significant cortical tissue
sparing, reduced neuroinflammation, and attenuated some TBI-induced deficits
in nAChR expression (Guseva et al., 2008). The results from these experiments,
combined with the positive results garnered from the MLA study prompted us to
test the therapeutic potential of α7 nAChR partial agonists.
5.1.4 Partial agonists of the α7 nAChR
In recent years a number of relatively selective α7 nAChR ligands have
been discovered and developed.

While the emphasis on developing these

ligands is driven by their therapeutic roles in AD and schizophrenia, parallels
between these conditions and TBI led us to test these novel ligands in a CCI
model of TBI. Among these new ligands is DMXB-A, otherwise known as GTS-
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21, which along with its active metabolite 4-OH-GTS-21 have been found to be a
selective partial agonists of the α7 nAChR (Meyer et al., 1998b).

DMXB-A has

been found to enhance cognition (nootrophic effect) in healthy male volunteers
(Kitagawa et al., 2003).

In laboratory studies DMXB-A has demonstrated

neuroprotective effects in a rat model of neocortical atrophy (Meyer et al.,
1998a), ischemia (Shimohama et al., 1998), and ethanol-induced neurotoxicity
(de Fiebre and de Fiebre, 2003; Li et al., 2002). Most importantly, DMXB-A has
shown great potential for the treatment of symptoms of schizophrenia (Freedman
et al., 2008; Martin et al., 2004a; Olincy and Stevens, 2007; Simosky et al.,
2002). In addition, there is evidence to suggest that DMXB-A may also be useful
in treating AD (Kem, 2000) and nicotine dependence (Foulds et al., 2004). We
also tested two other α7 nAChR partial agonists, tropisetron and ondansetron,
which unlike DMXB-A are high affinity antagonists of the 5-HT3 receptor. Both
are approved for clinical use, primarily used to treat chemotherapy induced
vomiting, although they may also be administered to TBI patients as part of their
treatment or following surgery. The established safety of these drugs combined
with their selective partial agonism at α7 nAChRs made them exciting molecules
for investigation in a model of TBI. Furthermore, as partial agonists they have
the potential to be therapeutic regardless of the level of cholinergic activity when
administered.

For instance, a full antagonist might be more efficacious in

attenuating nAChR-mediated excitotoxicity, but could worsen cognitive deficits if
administered outside its therapeutic window. Alternatively, a full agonist could
exacerbate excitotoxicity if administered before, or immediately after injury. A
partial agonist therefore would eliminate the need to carefully time treatment with
a full agonist or antagonist. In our study we administered partial agonists for 4
days following injury and began cognitive testing the day after the last injection.
Tissue sparing results did not demonstrate a significant neuroprotective effect of
any partial agonist, and there was no reduction in neuroinflammation, this is
possibly due to the agonist activity of the drugs. It is also possible we could have
produced a neuroprotective effect had we continued administering the drugs for a
longer time-period after trauma. However, we did find that some of our partial
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agonist treatments attenuated cognitive deficits in the MWM (Chapter 4.3.1).
This finding was most pronounced in animals that received 2 mg/kg of tropisetron
or 10 mg/kg of DMXB-A.

Furthermore, these improvements were observed

subsequent to the cessation of treatment, suggesting they result from
neuroprotective effects of treatment rather than a direct enhancement of
cognition. It would be interesting to test whether accentuated effects can be
achieved with extended treatment with these partial agonists.
As in the antagonist study, it was discovered that the most efficacious
dose of tropisetron was not the highest dose. Neither 1 mg/kg, nor 5 mg/kg of
tropisetron significantly improved MWM performance, or reduced [3H]-PK11195
binding. In addition, there was discrepancy between the effects of the different
drugs. It is possible that the doses we chose in the study are not optimal, and
that a more thorough assessment of their use in TBI could achieve therapeutic
effects. It is also possible that the differences are due to differences in their
pharmacological profiles. For instance, potent antagonism of 5-HT3 receptors is
well documented for ondansetron and tropisetron, while DMXB-A may be less
potent at these sites (Gurley and Lanthorn, 1998). In addition, their affinities for
the α7 nAChR vary significantly, with DMXB-A and tropisetron displaying high
affinity for the α7 nAChR, and ondansetron having much lower affinity. Clearly
there is a lot of difficulty in finding a molecule with good selectivity for the α7
nAChR. The action of 5-HT3 ligands at α7 nAChRs should be expected since
they share a great deal of structural homology (Karlin and Akabas, 1995). There
is still hope for selective ligands though, since the potent α7 agonist α-anatoxin,
the α7 antagonist MLA, and [125I]-α-BTX have been shown to be ineffective at 5HT3 receptors (Gurley and Lanthorn, 1998; Yang et al., 1992).
5.1.5 The role of the 5-HT3 receptor
An important consideration in our third study is the possible role that
antagonism of the 5-HT3 receptor plays in neuroprotection and the recovery of
function that we observed. All three of the compounds tested in this study are
known to be antagonists of the 5-HT3 receptor, and two were specifically
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developed to target these receptors in the CTZ of the brainstem. 5-HT3 receptors
are also found in the amygdala, hippocampus, and entorhinal cortex (Fletcher
and Barnes, 1999; Miquel et al., 2002).

They are known to be located

predominantly presynaptically (similar to α7 nAChRs), where they can regulate
the release of neurotransmitters (Doucet et al., 2000; Turner et al., 2004b).
Indeed, 5-HT3 receptors have been shown to regulate GABA release, which in
turn inhibits ACh release (Bolanos et al., 2002; Ramirez et al., 1996).

This

observation has been used as a rationale for treating AD with 5-HT3 antagonists
to improve cholinergic activity (Gil-Bea et al., 2004). Based on these findings it is
conceivable that α7 nAChR partial agonists with 5-HT3 antagonist activity could
be of higher value than more selective α7 nAChR partial agonists.
5.2

Concluding Remarks
The pharmacological studies described within this dissertation, combined

with other pharmacological studies from our laboratory described in Chapter 1
are summarized in Table 5-1. Initial studies from our laboratory focused on the
administration of the agonist nicotine, with the goal of reversing [125I]-α-BTX
binding deficits and thereby facilitating improved MWM performance. Chronic
nicotine infusions succeeded in reversing [125I]-α-BTX binding deficits, but
resulted in increased post-CCI seizures and did not spare cortical tissue. When
MWM performance was assessed in animals administered a series of chronic
intermittent nicotine injections there was a clear improvement in MWM
performance. However, no reversal of [125I]-α-BTX binding deficits was detected.
A more selective α7 nAChR agonist was next administered in the chow of rats
that underwent CCI. Choline administration improved cognitive function, spared
tissue, and reduced inflammation, but did not reverse [125I]-α-BTX deficits.
Questions remain as to the window of therapeutic opportunity for choline in order
to achieve these results.

As described in detail in this dissertation, MLA

produced significant improvements in MWM performance, spared cortical tissue,
and reduced inflammation, but exacerbated [125I]-α-BTX binding deficits. Partial
agonists of the α7 nAChR improved cognitive function, but failed to significantly
spare tissue, reduce neuroinflammation, or reverse [125I]-α-BTX binding deficits.
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Treatment
Nicotine
infusions
Nicotine
injections
Choline pre/posttreatment
MLA

Partial agonists

X

ND

ND

Inflammation

Reduced

X

X

+

deficits

Reversal of BTX

Cognitive

ND

X

+

Tissue Sparing?

+

+

improvement?

+

XX

X

+

X

+

X

+

+

Table 5-1 - Summary of pharmacological studies from our laboratory

Notes

Caused seizures

Window of

opportunity?

Reduced BTX

binding

Dose? Window?

Specificity?

Experimental brain injury causes cognitive impairment, cortical tissue loss, microglial activation, and BTX binding deficits.
Chronic nicotine infusions following CCI reversed deficits in BTX binding, but did not have any effect on cortical tissue
sparing. Additionally, the nicotine infusions resulted in a higher rate of post-CCI seizures. Chronic intermittent nicotine
injections were found to attenuate cognitive deficits as measured in the MWM, but again did not spare tissue, and no
reversal of BTX deficits was found. Choline, an α7 nAChR agonist, when administered in chow before and after CCI
attenuated cognitive deficits, spared cortical tissue, and reduced inflammation, but no reversal of BTX deficits was found.
There are still questions as to whether pre-treatment is necessary to yield these positive effects. As described in this
dissertation, MLA improves MWM performance, spares tissue, and reduces inflammation, but exacerbates BTX binding
deficits. Finally, partial agonists of the α7 nAChR attenuated MWM deficits, but tissue sparing, inflammation, and BTX
binding data did not show a definitive positive effect. (ND) Not done, (X) No effect, (XX) Exacerbated effect of CCI, (+)
Positive effect.
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Despite a lack of knowledge concerning the precise time-course of
cholinergic

changes,

and

pharmacokinetics/pharmakodynamics

of

the

pharmacological agents chosen for these studies, our results are nevertheless
encouraging and merit further investigation. While a lot of work remains to be
done to characterize TBI related changes following injury, our results have
helped

to

describe

neuroinflammation,

the

binding

PK11195.

profile

We

have

of

a

used

promising

marker

this

to

tool

of

assess

neuroinflammation in two pharmacological studies that aimed to demonstrate that
α7 nAChR modulation improves functional and cellular outcomes from. Overall,
the studies outlined herein have demonstrated that (1) the TSPO ligand PK11195
can measure differences in the timing and magnitude of microglial activation
following injury, making it an excellent translational instrument; (2) antagonism of
the α7 nAChR after TBI is neuroprotective and moderately improves functional
outcomes; (3) partial agonists of the α7 nAChR administered after an
experimental brain injury only marginally improve spatial memory and do not
significantly spare cortical tissue.
Based on our findings, the most promising route for future research in this
area is likely to be in the development of α7 nAChR antagonists with more
favorable pharmacological characteristics. The potential of potent and selective
nicotinic agonists and antagonists is well recognized, and therefore drug
discovery research in the field is progressing quickly (Haydar et al., 2009; LopezHernandez et al., 2009; Smith et al., 2009; Tasso et al., 2009). Further studies
with MLA or a novel α7 nAChR antagonist should firstly seek to dissect the α7
nAChR binding reductions we found by including an appropriate sham +
antagonist control group. Studies could aim to refine the therapeutic window for
α7 nAChR antagonist treatment and further elucidate treatment effects on other
measures of cellular damage such as FJ-B or silver staining (Hall et al., 2008).
Furthermore, an effect of these treatments of neurogenesis cannot be ruled out
since has been shown to occur following CNS injury such as ischemia (Jin et al.,
2006; Jung et al., 2009), alcohol withdrawal (Nixon and Crews, 2004; Nixon et
al., 2008), and TBI (Gao et al., 2009; Lu et al., 2005). It would be very interesting
133

to determine whether neurogenesis is affected by our pharmacological
interventions.

Finally, the disappointing results of our partial agonist study

suggest that there may not be a single ‘silver bullet’ pharmacological agent with
which to treat TBI. The studies outlined in this dissertation, and the results of
other studies from our lab suggest that a combination of α7 nAChR antagonists
and agonists administered at the right times might provide most benefit.

Copyright  Thomas M Woodcock 2009
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APPENDICES
APPENDIX I: list of acronyms and abbreviations
5-HT
ABC
ACh
AChE
AD
ALS
AMPA
ANOVA
AP5
ATP
BBB
BTX
Ca2+
CCI
ChAT
CNS
CPP
CT
CTZ
DAB
DAI
DHβE
DMXB-A
DNA
EAA
FITC
FJ-B
FPI
GCS
GFAP
HSD
IACUC
ICP
IED
LD
LTP
mAChR
MLA
MMSE
MWM
Na+
nAChR

-

5-hydroxytryptamine
Avidin: Biotinylated enzyme complex
Acetylcholine
Acetylcholinesterase
Alzheimer’s disease
Amyotrophic lateral sclerosis
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
Analysis of variance
(2R)-amino-5-phosphonovaleric acid
Adenosine-5'-triphosphate
Blood-brain barrier
Bungarotoxin
Calcium (ion)
Controlled cortical injury
Choline acetyltransferase
Central nervous system
Cerebral perfusion pressure
Computerized tomography
Chemoreceptor trigger zone
3,3' Diaminobenzidine
Diffuse axonal injury
Dihydro-β-erythroidine
3-2,4 dimethoxybenzylidene anabaseine (a.k.a. GTS-21)
Deoxyribonucleic acid
Excitatory amino acid
Fluorescein isothiocyanate
Fluoro-Jade B
Fluid percussion injury
Glasgow coma score
Glial fibrillary acidic protein
Honestly significant difference
Institutional Animal Care and Use Committee
Intracranial pressure
Improvised explosive device
Lateral dorsal
Long-term potentiation
Muscarinic acetylcholine receptor
Methyllycaconitine
Mini mental state exam
Morris water maze
Sodium (ion)
Nicotinic acetylcholine receptor
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NeuN
NMDA
NMJ
PAM
PBR
PBS
PET
pMCAO
PNS
ROS
TBI
TUNEL

-

VPL

-

Neuronal nuclei
N-methyl-D-aspartic acid
Neuromuscular junction
Positive allosteric modulator
Peripheral benzodiazepine receptor
Phosphate-buffered saline
Positron emission tomography
Permanent middle cerebral artery occlusion
Peripheral nervous system
Reactive oxygen species
Traumatic brain injury
Terminal deoxynucleotidyl transferase mediated dUTP nick
end labeling
Ventral posterolateral
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APPENDIX II: supplemental figures

Figure A1 - Molecular structure of six ligands that bind the α7 nAChR
Skeletal diagrams showing the molecular structures of α7 nAChR ligands
Methyllycaconitine
(MLA),
Nicotine,
Acetylcholine
(ACh),
3-(2,4dimethoxybenzylidene)anabaseine (DMXB-A), ondansetron, and tropisetron.
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